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ABSTRACT 
REGULATION OF HEPATIC DEVELOPMENT AND MATURATION  
BY TWO CLASSES OF HETEROCHROMATIN 
Jessica Mae Grindheim 
Kenneth S Zaret 
Liver transplantation is the main treatment for acute liver failure patients; however, 
there is an insufficient supply of donor livers.  Since transplanting hepatocytes, the main 
liver cell type, provides therapeutic effect and can be a bridge to transplant or recovery, 
scientists are working on generating replacement hepatocytes from stem cells and other 
cell types through reprogramming protocols.  Currently, replacement hepatocytes 
recapitulate a subset of natural hepatocyte features, yet are still in an immature state, as 
they have not silenced all immature hepatocyte genes and activated all mature hepatocyte 
genes.  Consequently, replacement hepatocytes do not perform as well as natural 
hepatocytes in transplant experiments.  Despite these shortcomings, relatively little is 
known about how natural hepatic maturation is regulated, particularly at the chromatin 
level. 
We discovered extensive chromatin dynamics during hepatic postnatal maturation, 
including changes in H3K9me3-marked and H3K27me3-marked heterochromatin, and 
transcription.  Heterochromatin is of particular interest, as we found that it guards cell 
identity by repressing lineage-inappropriate or temporally-inappropriate genes.  We further 
classified H3K9me3- and H3K27me3-marked chromatin by compaction state with a novel 
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assay, termed srHC-seq.  In postnatal hepatocyte maturation H3K27me3-marked 
heterochromatin represses early maturation genes, late maturation genes, and alternative 
lineage genes to both regulate timing of hepatic maturation and repress alternate fates.  
Significantly, we identify a euchromatic H3K27me3+ promoter signature that predicts 
which H3K27me3-marked genes will derepress in response ablation of the enzymes that 
deposit H3K27me3.  Disruption of either H3K9me3- or H3K27me3-marked chromatin 
leads to liver damage, and in the case of H3K27me3 this is likely due to the aberrant 
derepression of genes associated with fibrosis that normally have a euchromatic 
H3K27me3+ promoter signature.  Our results emphasize the role of heterochromatin in 
regulating liver development, maturation, and fibrosis, and highlight the need to identify 
factors controlling heterochromatin formation and breakdown, both for the purposes of 
enhancing in vitro hepatic maturation and for understanding factors which predispose 
humans to disease.  
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Chapter 1: Introduction  
1.1.  A clinical need for new sources of human hepatocytes 
Liver failure results in a constellation of complications including impaired blood 
coagulation, increased risk of multiple organ failure, sepsis, and, prior to the advent of liver 
transplantation in 1960s, was often fatal (Durand and Valla, 2005; Hurst, 2012).  While 
initial mortality rates in liver transplant recipients were high, advances in surgical 
techniques, immunosuppressive treatments, and anti-microbial agents have made liver 
transplantation the standard clinical treatment for both acute and chronic liver failure.  
Modern 1 and 5 year survival rates in the US across age groups are above 88% and 67%, 
respectively (Neuberger, 2016; NIDDK, 2017; OPTN, 2019a) (Figure 1).  However, these 
improvements in liver transplantation are tempered by an increasing demand for 
transplants that surpasses the pool of available donors.  The vast majority of transplants 
originate from deceased donors and the median wait time to deceased donor transplant 
has increased 1.5- to 2-fold in adult age groups between 2003 and 2014 with only 46-73% 
of patients receiving deceased donor transplants 2 years post listing (OPTN, 2019c, 
2019b, 2019d) (Figure 1). 
Given the shortage of donor livers, there is ongoing research into alternative 
therapies for treatment or as a bridge until the patient’s liver recovers or a transplant 
becomes available.  One option that has been tested is hepatocyte transplantation, or the 
transplantation of only one of the main resident liver cells types instead of the whole liver 
or liver lobes, which is considered much less surgically invasive than whole liver 
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transplant.  The main source of hepatocytes for hepatocyte transplantation is livers that 
were deemed unsuitable for whole organ transplantation for reasons such as steatosis-
related viability complications or ischemic damage (Donato et al., 2006; Fox et al., 1998; 
Sagias et al., 2010; Strom et al., 1997).  Hepatocyte transplantation has primarily been 
tested in patients with congenital metabolic disorders, as the defects are primarily limited 
to the hepatocyte cell type (Table 1).  In many of these cases, there are variable levels of 
improvement in liver function for a limited time, which is generally attributed to engraftment 
level, persistence, lack of graft expansion, and the inability to track for graft rejection in 
real time, which is needed to adjust the immunosuppressant regimen.  However, these 
methods are being improved, such as in one recent study showing that pre-operative liver 
radiation can increase engraftment and create an environment where transplanted cells 
can expand (Soltys et al., 2017).  While in need of improvements, hepatocyte 
transplantation is a promising cell therapy alternative to liver transplant, for both congenital 
metabolic syndromes and liver failure. 
1.2.  Lack of terminal maturation in artificially generated hepatocytes 
As hepatocyte transplantation proof-of-principle studies have proved useful in providing a 
bridge to transplant time (Table 1) and hepatocyte cell therapy protocols are likely to see 
improvement in engraftment and graft maintenance, there is great interest in generating 
hepatocytes from non-hepatocyte cell types.  Autologously sourced cells avoid both the 
search for a suitable liver and one of the largest barriers to successful transplantation, 
graft rejection due to immunoincompatibility.  In the case of patients with congenital 
metabolic disorders, the defect could be corrected by genome-editing technologies and 
still circumvent immune rejection problems.  Alternatively, replacement hepatocytes could 
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be generated, classified with respect to a pre-assessed or broad acceptability to different 
immune system backgrounds, and banked for future use. 
One source of artificially derived hepatocytes for transplantation is pluripotent stem 
cell-derived hepatocytes, or PSC-hepatocytes.  Pluripotent stem cells can be obtained 
from either embryonic stem cells (Evans and Kaufman, 1981; Martin, 1981) or by direct 
reprogramming of somatic cells to a pluripotent state (Takahashi and Yamanaka, 2006).  
While protocols are constantly evolving, many of details are conserved.  The first step 
involves derivation of definitive endoderm with BMP4 signaling and is highly efficient 
(Gouon-Evans et al., 2006; Yiangou et al., 2018), followed by generation of hepatoblast-
like cells, or embryonic hepatic precursor cells, by blocking Activin and mimicking natural 
cardiac FGF and mesenchymal BMP signals to the endoderm (Jung et al., 1999; Rossi et 
al., 2001).  To further differentiate hepatoblast-like cells to hepatocyte-like cells, many 
protocols treat with hepatic growth factor and oncostatin M and have extended growth of 
up to a month in these conditions to improve maturation (Agarwal et al., 2008; Brolén et 
al., 2010; Cai et al., 2007; Chen et al., 2012c; Hannan et al., 2013; Mallanna and Duncan, 
2013; Siller et al., 2015; Si-Tayeb et al., 2010; Song et al., 2009; Touboul et al., 2010).   A 
related technique involves partial pluripotency reprogramming in combination with 
treatment with small molecules to generate cells with hepatocyte phenotype, which is 
interesting for the capability for cellular expansion while theoretically reducing the tumor 
formation risk from undifferentiated cells  (Zhu et al., 2014).  The resulting hepatocyte-like 
cells can have binucleate morphology, express liver transcription factors and functional 
proteins such as HNF4α, CEBPα, PROX1, HNF6, GATA4, ALB, AAT, and CYP3A4, and 
can perform liver functions such as glycogen synthesis, albumin secretion, urea 
production, LDL uptake, and some limited cytochrome P450 activity.  However, these 
PSC-hepatocytes are not considered equivalent to native adult hepatocytes, as they often 
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still express immature liver genes, such as Afp, and fail to express mature genes to the 
appropriately high levels, such as Alb and CYP P450 enzymes (Agarwal et al., 2008; Chen 
et al., 2012c; Duan et al., 2010; Roelandt et al., 2013; Si-Tayeb et al., 2010; Song et al., 
2009; Zhu et al., 2014).  Additionally, hepatocyte-like cells can express CK19, a marker of 
the related cholangiocyte lineage (Cai et al., 2007) and secrete albumin, a key component 
of blood serum, at much lower levels than native hepatocytes.  These results indicate that 
current PSC-hepatocytes fail to induce terminal differentiation. 
Alternatively, hepatocytes for transplantation can also be generated from direct 
reprogramming of somatic cells to hepatocytes, here referred to as induced hepatocytes 
or iHeps.  The Hui and Deng groups have described generation of human iHeps, either 
by ectopic expression of the transcription factors Hnf4, Hnf1, and Foxa3 (Huang et al., 
2014) or ectopic expression of transcription factors Hnf1, Hnf4, Hnf6  and the 
maturation factors Atf5, Prox1, and Cepb (Du et al., 2014).  In both cases, the iHeps 
perform some liver metabolic functions, such as inducible expression and activity of 
CYP3A4 and have expression profiles similar to freshly isolated adult hepatocytes.  
Additionally, both groups are working on methods to make iHeps expandable, which is 
key for scaling up to clinical useful levels.  However, the iHeps have a broad spectrum of 
genes differentially expressed from primary hepatocytes and in transplant studies cannot 
match primary hepatocytes for albumin secretion, liver colonization, and rescue of liver 
damage (Du et al., 2014; Huang et al., 2014).  Additionally, the Deng study tested in vivo 
engraftment and expansion in cells that had tumorigenic modifications which prevent 
clinical use (Du et al., 2014).  Before clinical use, hiHeps will need to be made more 
expandable and have more mature hepatocyte functionality. 
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In summary, both PSC-hepatocytes and iHeps fail to fully recapitulate features of 
adult hepatocytes including expansion in the liver environment, transcriptomic profiles, 
replacing liver function, and rescuing liver damage.  Fine tuning of these cells to exhibit 
more mature phenotypes will be necessary before use in clinical settings. 
1.3.  Regulation of postnatal hepatic maturation 
Embryonic liver development involves the concerted regulation by various transcription 
factors, such as HNF4α, GATA and FOXA family members, and paracrine signaling 
events (Duncan et al., 2009; Zaret and Grompe, 2008; Zorn, 2008).  Numerous changes 
occur in liver after birth but before fully mature adulthood, including egress of 
hematopoietic cells (Brauner et al., 2001), physiological changes from diet, a dramatic 
increase in liver size (Leibing et al., 2018; Septer et al., 2012; Suzuki et al., 2019), 
hepatocyte polyploidization, microbial colonization and consequential exposure to 
microbial metabolites (Avior et al., 2015; Morelli, 2008), changes in membrane fluidity 
(Devi et al., 1992), and sexual maturation.  Postnatal hepatic maturation is also reflected 
in gene expression changes, where fetal liver-specific genes are silenced and mature liver 
genes are induced (Spear et al., 2006).  Here I discuss some postnatal maturation 
processes and what is known of their regulation.  
Diet dramatically changes from primarily placental glucose, to high lipid content 
breastmilk at birth, and returns to a higher carbohydrate diet post-weaning.  Consequently, 
hepatic carbohydrate and lipid metabolism vary respectively, with postnatal induction of 
gluconeogenesis, fatty acid β-oxidation, and de novo lipogenesis  (Decaux et al., 1988; 
Perez-Castillo et al., 1987; Périchon and Bourre, 1995; Sekine et al., 2007).  Ligands in 
milk are thought to bind and activate PPAR, as it is known that murine neonate fatty acid 
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oxidative function is induced partly through postnatal PPAR-dependent DNA 
demethylation and increased mRNA expression, with the demethylation also shown at β-
oxidation genes during the fetal to adult transition in humans (Ehara et al., 2015).  
However, how these metabolic pathways are activated during maturation remains poorly 
understood. 
Hepatic polyploidization, including both multiple nuclei and polyploid nuclei, occurs 
postnatally.  In humans, late teenagers have a mostly diploid with some tetraploid profile 
that increases from 20-30% polyploid to greater than 50% polyploid in the elderly (Liu et 
al., 2003; Watanabe and Tanaka, 1982).  Similarly, murine polyploidization occurs around 
weaning and increases with age (Duncan et al., 2010).  The co-occurrence of weaning 
and polyploidization from cytokinesis failure in rodents led to studies showing that 
weaning-driven increases in blood glucose leads to increased blood insulin, which 
stimulates hepatic insulin-PI3K-AKT signaling, and in turn AKT signaling is sufficient to 
decrease the frequency of cytokinesis events (Celton-Morizur et al., 2009, 2010; Duncan 
et al., 2010; Margall-Ducos et al., 2007).  Deletion of various cell cycle factors or P53 
perturbations effects postnatal hepatocyte polyploidization in mice (Chen et al., 2012a; 
Chipchase et al., 2003; Hsu et al., 2016; Li et al., 2013, 2013; Mayhew et al., 2005; Pandit 
et al., 2012).  While many studies have found cell cycle-associated factors regulate 
hepatocyte ploidy (Wang et al., 2017), what other upstream hepatic maturation factors 
besides diet and insulin control these cell cycle factors remains unclear. 
The control of liver zonation is one of the better characterized maturation 
phenomena (Perugorria et al., 2019).  Liver zonation involves the unequal distribution of 
function and enzymes in hepatocytes across the liver lobule with respect to the pericentral 
and periportal blood vessels.  Zonated functions include metabolism of carbohydrates, 
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ammonia, bile acids, and drugs, as well as transport and secretion enzymes (Jungermann 
and Kietzmann, 1996, 2000).  While early studies showed that some zonated functions 
were related to oxygen, hormone, or nutrient gradients (Gebhardt and Gaunitz, 1997; 
Oinonen and Lindros, 1998), it was not until 2006 that a transcription factor was identified 
that controlled zonation.  A WNT signaling gradient from liver sinusoidal endothelial cells 
(Leibing et al., 2018) across the portocentral axis leads to differential stabilization of -
catenin and TCF-LEF family transcription factors and consequential transcription of a 
subset of zonated genes, in particular ammonia and glutamine metabolism 
(Benhamouche et al., 2006).  Stabilized TCF/LEF becomes a binding partner of the key 
liver transcription factor HNF4, which changes binding patterns to both activate and 
repress specific zonated genes, independent of CMYC, which is also known to be 
activated by Wnt/-catenin signaling (Burke et al., 2009; Colletti et al., 2009).  Despite 
what is already known about Wnt signaling in the maturing liver, given the complexity of 
Wnt-β-catenin signaling, with 19 Wnt ligands, more than 15 receptors, non-canonical Wnt 
signaling, and pathway crosstalk, and given the failure of clinical trials involving Wnt in 
various liver diseases, a more in-depth understanding of liver Wnt-β-catenin signaling in 
liver maturation would likely prove useful in designing replacement hepatocytes 
There are some known examples of postnatal hepatic maturation regulation that 
occur at the transcriptional and post-transcriptional levels.  ZHX2 and ZBTB20 are direct 
transcriptional repressors in mice of Afp, which encodes a serum protein highly expressed 
in embryos that is repressed postnatally (Morford et al., 2007; Perincheri et al., 2005; Xie 
et al., 2008).  ZHX2 may be used more generally, as it also represses mouse major urinary 
proteins and some sexually dimorphically expressed CYP P450 enzymes (Creasy et al., 
2016; Jiang et al., 2017).  Key liver transcription factor HNF4α binding to some 
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transcriptional start sites of some maturation genes is promoted by TAF4-TAF12 two 
weeks after birth in mice (Alpern et al., 2014).  HNF4α is also one of several liver 
transcription factors that set up and maintain the liver program by creating a cross-
regulatory and auto-regulatory network which increases in complexity between embryonic 
and adult stages, though how the network is refined postnatally is unknown (Kyrmizi et al., 
2006; Odom et al., 2006).  In mice and humans 20% of the neonatal-to-adult splice isoform 
switches are attributed to the induction and consequential function of the conserved 
splicing factor ESRP2, thus facilitating maturation of hepatocytes (Bhate et al., 2015).  The 
scattering of known transcriptional and post-transcriptional repressors that have been 
identified underline how incomplete a picture we have a factors refining hepatocyte cell 
identity postnatally. 
The wealth of knowledge of embryonic liver development and adult liver biology 
has informed protocols that aim to artificially generate hepatocytes for clinical use.  In the 
case of PSC-hepatocytes, progenitor cell-like stages are generated with high efficiency 
but fail to achieve fully mature hepatocyte function.  In the case of iHeps, which jump 
directly from one cell type to the hepatocyte fate, there is a similar failure to obtain a mature 
hepatocyte phenotype.  The coincidence of the failure to obtain fully mature hepatocytes 
and the gaps in the postnatal hepatic maturation field indicate that more attention should 
be paid to hepatic maturation. 
1.4.  Guarding cell identity with Polycomb-marked chromatin  
The 3 billion base pairs of DNA in human genome serves as an instruction manual for the 
development and maintenance of hundreds of different cell types with distinct functions 
and morphologies, which cooperate to form a functioning multicellular organism.  This 
plethora of outcomes from the same DNA sequence is possible through differential 
activation and silencing of genes in each cell type in a temporally- and context-specific 
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manner.  In order to achieve the differential gene regulation necessary, the genome of 
eukaryotic cells is organized into multiple hierarchical levels of chromatin (Probst et al., 
2009).  On the most basic level, DNA is organized into the nucleosome, a repeating unit 
in which approximately 147 bp of DNA is wrapped around a nucleosome, consisting of 
histone proteins, with linker DNA between adjacent nucleosomes.  The series of 
nucleosomes form a chromatin fiber that coils into higher-order states, including 
chromatin loops and topologically associate domains (TADs) (Furlong and Levine, 
2018).  Histones have layers of possible regulation, including variants and 
posttranslational modifications (PTMs) on the tails that extend from the globular domain 
(Sitbon et al., 2017).  PTM reader proteins, histone chaperones, chromatin remodelers 
and modifying enzymes, DNA-modifying enzymes, RNA, and chromatin structure shape 
a versatile chromatin landscape that regulates access of TFs to chromatin and thus allows 
the same DNA sequence to generate diverse cell types that respond to different inputs, 
which consequently defines the ability of a cell to have a particular phenotype and to 
response to development, environmental changes, and aging Ardehali, M.B., Anselmo, 
A., Cochrane, J.C., Kundu, S., Sadreyev, R.I., and Kingston, R.E. (2017). Polycomb 
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Physical compaction of the chromatin fiber is a major mechanism controlling 
transcription.  Chromatin fiber compaction was originally defined cytologically by density 
of dye staining and light or dark appearance on electron micrographs, with light-staining 
open euchromatin and dark-staining compact heterochromatin compact (Brown, 1966; 
Heitz, 1928).  Euchromatin is accessible to transcription factors and the transcriptional 
machinery and is associated with the majority of transcriptional activity (Li et al., 2007; 
Workman and Kingston, 1998).  In comparison, physically compact chromatin, or 
heterochromatin, has more dense packing and is thus less accessible, and is associated 
with much less transcription.  Constitutive heterochromatin is one class of heterochromatin 
that is found in most cell types at repetitive regions of the genome and functions to both 
repress the activity of transposable elements and to repress deleterious recombination 
between repetitive sequences (Becker et al., 2016).  Constitutive heterochromatin is 
marked by the H3K9me3 histone modification, which does not have known inherent 
repressive properties, but instead is bound by several HP1 isoforms in mammals, which 
in turn oligomerize and recruit repressive histone modifiers, leading to chromatin 
compaction and heterochromatin spreading (Bannister et al., 2001; Becker et al., 2016; 
Canzio et al., 2011; Lachner et al., 2001).  While more recent studies show that H3K9me3-
marked heterochromatin can also be “facultative”, or highly dynamic during development, 
with lineage- and temporally-specific patterns and consequential repression of lineage-
appropriate genes, facultative heterochromatin is more commonly associated with 
Polycomb group proteins (Becker et al., 2017; Nicetto et al., 2019; Trojer and Reinberg, 
2007).  Polycomb group (PcG) proteins were discovered in Drosophila melanogaster 
homeotic mutants as repressing Hox cluster genes and in mammals have been shown 
more generally to repress transcription of many developmental and lineage regulators 
(Boyer et al., 2006; Kassis et al., 2017; Lee et al., 2006; Lewis, 1978, 1947; Margueron 
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and Reinberg, 2011; Slifer, 1942).  Of note, perturbation of PcG proteins and derepression 
of transcription factors frequently results in changes of cell fate (Bracken et al., 2006; 
Lewis, 1947; Slifer, 1942; Snitow et al., 2016; Xu et al., 2011), underlining the role of 
Polycomb-marked heterochromatin in cell fate control. 
Biochemical studies show that PcG proteins function to maintain transcriptional 
repression by histone tail modification that promotes facultative heterochromatin 
formation.  PcG proteins form 2 large complexes, Polycomb Repressive Complex 1 and 2 
(PRC1 and 2) (Cao et al., 2002; Margueron and Reinberg, 2011), and the more recently 
identified Pho-repressive complex and Polycomb repressive deubiquitinase complex 
(Klymenko et al., 2006; Scheuermann et al., 2010).  Understanding the complex 
recruitment, enzymatic activity, binding partners, and function in different chromatin 
contexts is required to understand how PcG proteins regulate cell identity 
The core PRC2 complex is comprised of four proteins EED, SUZ12, RBBP46/48, 
and one of the two enhancer of zeste homologs, EZH1 or EZH2, with many additional 
proteins that generally have DNA and/or chromatin binding affinity and can promote 
enzymatic activity (Figure 2) (Holoch and Margueron, 2017).  PRC2 is recruited to 
unmethylated CpG islands referred to as “nucleation sites” by PHF1, JARID2, and MTF2 
(Landeira et al., 2010; Li et al., 2010, 2017; Oksuz et al., 2018; Pasini et al., 2010; Peng 
et al., 2009; Shen et al., 2009; Son et al., 2013) or to the PRC1-catalyzed histone mark, 
histone H2A lysine 119 monoubiquitin (H2AK119ub) (Blackledge et al., 2014; Cooper et 
al., 2014).  Transcription or methylated cytosines can render CpG islands refractory to 
H3K27 trimethylation (Holoch and Margueron, 2017).  After recruitment, the PRC2 
complex catalyzes histone H3 lysine 27 trimethylation (H3K27me3) through the mutually 
exclusive histone methyltransferase subunits EZH1 or EZH2  (Cao et al., 2002; Czermin 
et al., 2002; Müller et al., 2002).  Binding of PRC2 component EED to H3K27me3 through 
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its aromatic cage formed by WD-40 repeats leads to allosteric activation of H3K27me2/3 
histone methyltransferase activity and spreading from nucleation sites (Margueron et al., 
2009; Oksuz et al., 2018).  This feed-forward property of PRC2/H3K27me3 supports 
models where H3K27me3 is a true epigenetic mark that persists through cell cycles and 
would explain at least partially for PRC2’s ability to maintain transcriptional profiles 
(Hansen et al., 2008; Margueron et al., 2009).   
Given the diversity of subunits that have been reported in various complexes, there 
is no agreed upon number of PRC1 complexes, but they have been generally subdivided 
into canonical PRC1 (cPRC1) and non-canonical PRC1 (ncPRC1) (Blackledge et al., 
2015) (Figure 2).  All PRC1 complexes share a core of a RING1A or RING1B and one of 
six Polycomb group ring-finger domain proteins (PCGF1-6).  cPRC1 contains PCGF2/4, 
one CBX protein (CBX2/4/6/7/8) which recruits cPRC1 to the PRC2 mark H3K27me3, and 
a Polyhomeotic homologous protein (PHC1/2/3) (Schuettengruber et al., 2017).  cPRC1 
catalyzes H2A119ub through RING1A/B subunits, can compact chromatin, and is 
generally associated with repression (Aranda et al., 2015; Cao et al., 2002; Ku et al., 
2008).  ncPRC1 contains RYBP or its paralog YAF2, and various PCGFs, and, depending 
on the complex, can have either activating and repressive functions.  PRC1 proteins have 
roles in development, cell identity, senescence, and cancer (Gil and O’Loghlen, 2014).   
PcG proteins repress chromatin by multiple mechanisms.  One of the main 
mechanisms is by chromatin compaction, which makes chromatin inaccessible to some 
TFs, the transcriptional machinery, and chromatin remodelers (Schuettengruber et al., 
2017; Shao et al., 1999) (Figure 3).  Classically, PRC1 is considered the main effector of 
chromatin compaction  (Cohen et al., 2018; Francis et al., 2004; Gil and O’Loghlen, 2014; 
Grau et al., 2011; Simon and Kingston, 2009), though there is also evidence of EZH1-
containing PRC2 compacting in vitro chromatin templates and EZH2-PRC2 compacting 
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chromatin in vivo (Margueron et al., 2008; Terranova et al., 2008).  While evidence 
remains to be seen in mammals, in flies a second mechanism of PcG repression involves 
PRC1 binding to the CBP, inhibiting CPB’s enzymatic acetyltransferase activity, and thus 
inhibiting downstream transcriptional activation (Tie et al., 2016).  A third mechanism of 
PcG repression is the looping of Polycomb domains to maintain chromatin domains in a 
repressed state (Ferrari et al., 2014; Lee et al., 2015).  Another proposed mechanism of 
repression is the widespread distribution of H3K27me2/3, which can suppress chromatin 
opening, enhancer activation, and transcription by directly preventing H3K27 acetylation 
from occurring on the same lysine residue (Ferrari et al., 2014; Lee et al., 2015). 
While the PRC2 complex is classically thought to repress expression by eliciting 
chromatin compaction (Simon and Kingston, 2009), Polycomb-bound or -marked 
chromatin can be accessible to binding by some factors and transcribed, indicating that 
there are functions of Polycomb-regulated euchromatin (Becker et al., 2017; Beisel and 
Paro, 2011; Breiling et al., 2001; Dellino et al., 2004; Hawkins et al., 2010; Ku et al., 2008; 
Trojer and Reinberg, 2007).  It is already known that the PRC2 complex repress various 
steps of transcription at promoters.  The stepwise process of transcription involves 
recruitment of the transcriptional machinery to promoters, short transcription and then 
pausing of RNAPII, pausing release and productive elongation, and termination of 
transcription (Jonkers and Lis, 2015).  The PRC2 histone mark inhibits transcription at 
multiple steps, including by inhibiting RNAPII recruitment by blocking acetylation of the 
same residue to H3K27ac (Chopra et al., 2011), inhibiting RNAPII release from pausing 
(Chen et al., 2012b), and inhibiting proper RNAPII elongation in gene bodies (Seenundun 
et al., 2010).  Additionally, PRC2 can methylate non-histone proteins, including elongation 
factor A (ELOA), which seems to cause impaired ELOA ability to promote RNAPII release 
into the elongation stage (Ardehali et al., 2017).  Despite identification of multiple methods 
19 
 
of PRC2-based repression at promoters, a remaining question in the field is why only a 
fraction of H3K27me3-marked genes derepress in response PRC2/H3K27me3 ablation 
(Bae et al., 2015; Ezhkova et al., 2011; Jadhav et al., 2016). 
 
1.5.  Polycomb repression in endoderm lineage development 
Polycomb group proteins (PcG) are transcriptional repressor proteins that are documented 
as regulating the development and cell identity of many lineages, including endoderm 
(Margueron and Reinberg, 2011).  In the intestine, Polycomb proteins are involved or 
implicated in intestinal stem cell proliferation, differentiation, and renewal, and for 
maintaining the appropriate balance of downstream cell types (Chiacchiera and Pasini, 
2017; Koppens et al., 2016; López-Arribillaga et al., 2015; Vizán et al., 2016).  In the 
pancreas, various PcG proteins are involved in regulating the number of endocrine 
progenitors and beta cells, are required for regeneration of the pancreatic exocrine 
compartment, and are required for beta cell regeneration and proliferation in diabetes 
mellitus (Cervantes et al., 2017; Chen et al., 2009; Fukuda et al., 2012; Mallen-St Clair et 
al., 2012; Xu et al., 2014).  PRC1 proteins BMI1 and MEL18 contribute to colitis-associated 
cancer (Liu et al., 2017).  In thymal epithelial cells, PcG proteins regulate growth (Guo et 
al., 2011; Liu et al., 2013).  These examples of PcG proteins regulating proliferation, 
differentiation, and renewal in endoderm all suggest that PcG proteins may play a role in 
those processes in maturing and regenerating liver. 
PcG proteins play known roles in mutliple stages of liver development and 
homeostasis.  In early liver development, EZH2, one of the two H3K27me3 histone 
methyltransferases, modulates the cell fate choice of embryonic endoderm to become 
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pancreatic or hepatic buds (Xu et al., 2011) and is required for hepatoblast proliferation 
(Koike et al., 2014).  Loss of both EZH1 and EZH2 leads to chronic liver damage in adult 
mice and an inability to regenerate after liver toxin-induced damage (Bae et al., 2015). 
Significantly, genes marked by the PRC2 repressive histone modification H3K27me3 
exhibit activation defects in iHeps, with genes in sonication-resistant heterochromatin 
being the most resistant to activation (Becker et al., 2017).  Additionally, multiple PRC2 
proteins have been implicated in repressing non-hepatocyte lineage genes in iHep 
reprogramming (Rastegar-Pouyani et al., 2016).  These results not only leave open a role 
for Polycomb-based regulation in postnatal hepatic maturation but also suggest that 
manipulation of Polycomb proteins may be useful in the generation of artificial 
hepatocytes. 
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1.6.  Figures 
 
Figure 1: Liver transplant survival and demand in the US  
All data in this figure was accessed from the U.S. Department of Health and Human 
Services Organ Procurement and Transplantation Net 
(https://optn.transplant.hrsa.gov/data/view-data-reports/national-data/). 
A) Liver Kaplan-Meier Patient Survival Rates For Transplants Performed: 2008 – 2015. 
1-year survival based on 2012-2015 transplants, 3-year survival based on 2010-2013 
transplants, 5-year survival based on 2006-2011 transplants.  Based on OPTN data 
as of January 18, 2019.   
B) Transplants by Donor Type.  Based on OPTN data as of January 23, 2019. 
C) Liver Competing Risk Median Waiting Time to Deceased Donor Transplant For 
Registrations Listed: 2003-2014.  Missing data denotes n less than 10 or fewer than 
half of recipients having been transplanted.  Data as of January 18, 2019 
D) Liver Competing Risk Percentage with Deceased Donor Transplant at Specific time 
Points For Registrations Listed: 2003-2014.  Based on OPTN data as of January 18, 
2019 
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Figure 2: PRC1 and 2 complexes 
A) A subset of PRC1 and 2 complexes.  Adapted from (Chittock et al., 2017). 
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Figure 3: Multiple mechanisms of PcG repression 
A) PRC1 can induce chromatin compaction via a positively charged compacting region 
present in mammalian CBX2 or fly Psc. In addition, Pc/CBX (via H3K27me3-binding 
through its chromodomain) and Ph/PHC (via polymerization through its SAM domain) 
can contribute to chromatin compaction, which can interfere with SWI/SNF-mediated 
chromatin remodeling or Pol II recruitment. PRC2 can also contribute to the 
compaction of nucleosomal arrays. 
B) Trimethylation of H3K27 (H3K27me3) can directly block acetylation of H3K27 
(H3K27ac), which is involved in gene activation. Further, Pc/CBX can inhibit the 
acetyltransferase activity of CBP, therefore favoring methylation of H3K27. 
C) (C) Distribution of the H3K27me3 mark over large genomic regions might stabilize 
chromatin-looping interactions between PcG-binding sites and gene regulatory 
regions, thereby contributing to stably locking genes in a repressed state. 
Oligomerization of the SAM domain of Ph/PHC is essential for PcG-mediated 
repression and can mediate long-range interactions between distal Polycomb 
domains. 
D)  Dimethylation of H3K27 (H3K27me2) exerts protective functions by preventing 
acetylation of cis regulatory regions (CRRs), such as enhancers or promoters, thereby 
inhibiting their inappropriate activation. 
This figure comes from a review from the Cavalli group (Schuettengruber et al., 2017). 
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1.7.  Tables 
Table 1. Select reports of hepatocyte transplantation in humans 
Indication 
Number 
of 
patients 
Age of 
patients 
Outcome Reference 
Criggler-Najjar 
TypeⅠ 
1 9 years 
decreased bilirubin ~4 
months, received OLT 
(Ambrosino et al., 
2005) 
Criggler-Najjar 
TypeⅠ 
2 
1 and 9 
years 
decreased bilirubin ~4 and 
~6 months received OLT 
(Lysy et al., 2008) 
Urea cycle 
disorder 
4 
1 day to 3 
years 
4-13 months stability, 
received OLT, 1 death 
(Meyburg et al., 
2009) 
Familial hyper-
cholesterolemia 
5 
7 to 41 
years 
3 patients with reduced 
LDL for ~4 months 
(Grossman et al., 
1995) 
Glycogen storage 
disorders 
1 8 years 
ability to eat a normal diet 
for the 7-month follow-up 
(Lee et al., 2007) 
Glycogen storage 
disorder 
1 47 years 
ability to eat a normal diet 
for the 9-month follow-up 
(Muraca et al., 
2002) 
Refsum disease 1 4 years 
Cholestasis resumed, 
symptoms ameliorated for 
18-month follow-up 
(Sokal et al., 
2003) 
Hemophilia A 2 
3 and 35 
months 
Reduced exogenous 
Factor VII required for 6 
months 
(Dhawan et al., 
2004) 
PKU 1 27 years 
Ability to eat a normal diet 
for 7 months 
(Soltys et al., 
2017) 
OLT: orthotopic liver transplantation 
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Chapter 2: PRC2 proteins EZH1/2 regulate timely postnatal 
hepatocyte maturation and fibrosis by repression of euchromatic 
promoters 
2.1.  Preface 
The manuscript presented in this chapter as originally published in Gastroenterology 
(Grindheim et al., 2019).  It has been reformatted here in accordance with the University 
of Pennsylvania dissertation formatting guidelines.  Extended methods are available in 
Appendices.  All sequencing data is available under GEO accession number GSE119219.  
The references for this chapter are at the end of this chapter. 
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2.3.  Abstract 
BACKGROUND & AIMS: The inability to derive fully functional hepatocytes from stem 
cells for transplantation, disease modeling, and drug testing may emanate from the lack 
of knowledge about mechanisms that underlie postnatal cell maturation. Additionally, the 
chromatin-based regulation of fibrosis genes remains incompletely understood. We 
investigated transcriptional dynamics, the roles of chromatin compaction, and the 
Polycomb Repressive Complex 2 (PRC2) in postnatal hepatocytes and in repression of 
fibrosis genes. METHODS: Mouse hepatocytes from postnatal day 14 (P14) and 2-month-
old (M2) wild-type (Wt) and liver-specific deletion of PRC2 components Ezh1 and Ezh2 
(Ezh1/2) mice were characterized using RNA-seq, H3K27me3 ChIP-seq, and sonication-
resistant heterochromatin-seq, a newly presented method to map heterochromatin. Liver 
damage was characterized by histological analysis. RESULTS: We discovered a resource 
of more than 3000 genes differentially expressed in hepatocytes during P14 to M2 liver 
maturation. Genetic ablation of both PRC2 histone methyltransferases in perinatal livers 
causes hepatocytes to prematurely differentiate, expressing genes at P14 that would 
normally be induced by M2, along with a fibrotic phenotype. Genes with euchromatic 
H3K27me3+/H3K4me3+ promoter marking were found to be sensitive to Ezh1/2 loss, 
which included maturation genes, non-liver lineage genes, and fibrosis genes. 
CONCLUSIONS: Polycomb repression is used to restrain expression of hepatocyte 
maturation, fibrosis, and lineage inappropriate genes at euchromatic promoters, thereby 
promoting liver homeostasis and preventing liver damage. Manipulation of Polycomb 
proteins may be used to improve hepatocyte derivation protocols and be a clinical target 
for liver fibrosis patients. 
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2.5.  Introduction 
Due to the shortage of fully differentiated cells for transplantation and disease modeling 
of various tissue types, there is interest in generating replacement cells. Directed 
differentiation and cell reprogramming can generate early stage cells, but with a failure to 
activate a terminally differentiated transcriptional program and a failure to repress genes 
of the starting cell type (Horisawa and Suzuki, 2015; Ieda, 2013; Johannesson et al., 2015; 
Patel et al., 2016). In directed differentiation of hepatocyte-like cells, many fetal genes can 
be activated, but often there is failure to induce mature CYP P450 enzymes and repress 
fetal markers such as Afp (Chen et al., 2012; Duan et al., 2010; Roelandt et al., 2013; Si-
Tayeb et al., 2010; Song et al., 2009). When fibroblasts are reprogrammed to hepatic 
cells, the cells express liver markers and perform some liver metabolic functions but fail 
to activate various mature liver genes and cannot consistently rescue liver damage 
(Huang et al., 2011, 2014; Sekiya and Suzuki, 2011). The literature on embryonic liver 
development (Duncan et al., 2009; Zaret and Grompe, 2008) rarely covers postnatal 
hepatic maturation (Bhate et al., 2015; Morford et al., 2007; Perincheri et al., 2005), though 
there are major physiological changes in liver size, diet (Shearer et al., 1982), microbiota 
and microbial metabolites (Avior et al., 2015; Morelli, 2008), sexual maturation, and 
polyploidization (Duncan, 2013). Thus, there is a need to understand postnatal hepatic 
maturation. 
 Components of Polycomb Repressive Complexes 1 or 2 (PRC1 or PRC2) regulate 
multiple gastrointestinal cell types. The PRC2 protein EED promotes intestinal stem cell 
proliferation and inhibits differentiation (Koppens et al., 2016), while the PRC1 protein 
BMI1 regulates intestinal stem cell proliferation and renewal (López-Arribillaga et al., 
2015). PRC1 proteins BMI1 and MEL18 contribute to colitis-associated cancer (Liu et al., 
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2017). PRC2 protein JARID2 is needed for late differentiation of pancreatic beta-cells 
(Cervantes et al., 2017). In liver development, EZH2, one of the two H3K27me3 histone 
methytransferases, modulates the cell fate choice of embryonic endoderm to become 
pancreatic or hepatic buds (Xu et al., 2011) and is required for hepatoblast proliferation 
(Koike et al., 2014). Loss of both EZH1 and EZH2 leads to chronic liver damage in adult 
mice (Bae et al., 2015). Genes marked by the PRC2 repressive histone modification 
H3K27me3 exhibit activation defects in human fibroblast-to-hepatocyte reprogramming 
protocols, with genes in heterochromatin being the most resistant to activation (Becker et 
al., 2017; Matoba et al., 2014; Onder et al., 2012; Soufi et al., 2012; Sridharan et al., 2013). 
This leaves open a role for Polycomb-based regulation in postnatal hepatic maturation. 
By genetically ablating both Ezh1 and Ezh2, we investigated the relationship 
between postnatal transcriptional, H3K27me3, and chromatin compaction dynamics in 
postnatal hepatocyte maturation and homeostasis. We found that PRC2 represses three 
main classes of genes in postnatal hepatocytes; hepatic maturation genes, non-liver 
lineage genes, and fibrosis genes. Genes that derepress in response to Ezh1/2 loss have 
a unique chromatin signature. These findings impact our understanding of the means by 
which hepatocytes mature postnatally, how hepatocyte lineage fidelity is maintained, and 
how fibrosis genes are primed for a transcriptional response. 
2.6.  Results 
Postnatal hepatic maturation involves differential expression of thousands 
of genes 
Using RNA-seq on hepatocytes isolated by liver perfusion, we found 1215 upregulated 
and 2011 downregulated genes in hepatic maturation between P14 and M2 (alpha ≥ 0.05, 
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FC ≥ 2) (Figure 1A, Supplementary Figure 1A-D, Supplementary Table 2, 3, 4). 
Upregulated genes include the key liver metabolic enzymes Ces1f and Ces3b, and are 
enriched by Gene Ontology for the Uniprot liver tissue expression category, P450 
enzymes, and genes for metabolism of retinol, xenobiotics, and bile acids (Figure 1AB, 
Supplementary Table 5). As expected, fetal liver genes Afp and Gpc3 are among the top 
downregulated genes (Figure 1A) (Belayew and Tilghman, 1982; Morford et al., 2007). 
Downregulated maturation genes enrich cell cycle, cell adhesion, differentiation, and 
signaling categories (Figure 1B). The cell cycle-associated categories reflect diminished 
proliferation in adult hepatocytes, as assayed by staining for proliferation marker PCNA 
(Supplementary Figure 1E). PubMed searches for a random sampling of genes in the cell 
adhesion and signaling categories and “liver” or “hepatocyte” often return no results, 
indicating that these may be new targets to study in liver maturation. Thus, P14 
hepatocytes are transitioning extensively from a fetal to a mature transcriptional program. 
P14 and M2 H3K27me3 states correlate with postnatal hepatic maturation 
We profiled H3K27me3 in P14 and M2 hepatocytes (Supplementary Table 2, 3). As 
expected, H3K27me3 was absent from the expressed liver gene Alb and present at the 
silent Hoxd cluster, and this anticorrelation of expression and H3K27me3 was observed 
genome-wide (Supplementary Figure 1FG). H3K27me3 genomic coverage increased 
from 608 MB at P14 to 827 MB at M2 (Supplementary Figure 1H).  
We called promoters and gene bodies as “lacking”, “losing”, “gaining”, or “retaining” 
H3K27me3 from P14 to M2. Acquisition of H3K27me3 is characteristic of many genes that 
are downregulated in the maturation transition from P14 to M2, with 44% of such 
promoters gaining (n=179) or retaining (n=909) H3K27me3 and 40% gene bodies gaining 
(n=172) or retaining (n=821) H3K27me3 (Figure 1C). In the case of gene bodies that retain 
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H3K27me3, the percent of coverage increases from a median of 62% at P14 to 78% at 
M2; thus increasing H3K27me3 presence at these “retain H3K27me3 genes” was not 
discernible in categorical lack/lose/gain/retain calls (Figure 1D). This increase was not 
solely due to increased H3K27me3 coverage in M2 (p-value at 0.001, Monte Carlo 
simulation). About 9.4% (140) of promoters and 8.6% (129) of gene bodies belonging to 
maturation upregulated genes lose H3K27me3 during the P14 to M2 transition (Figure 
1C). The H3K27me3 and transcriptional dynamics between P14 and M2 indicate a role 
for PRC2 proteins in regulating maturation gene expression. 
EZH1 and EZH2 restrain premature postnatal hepatic maturation 
To assess the role of PRC2 repression in postnatal hepatocytes, we performed RNA-seq 
on Alb-Cre/Alb-Cre; Ezh1-/-; Ezh2flox/flox (“Ezh1/2”) hepatocytes, in which both histone 
methyltransferases for H3K27me3 are ablated. Loss of Ezh1 or Ezh2 alone does not result 
in H3K27me3 loss (Supplementary Figure 2A). Ezh1 single knockout have transcriptomes 
highly similar to Wt, with only 203 differentially expressed genes (Supplementary Figure 
2B, Supplementary Tables 2, 3). With a homozygous Alb-Cre transgene, whose 
expression starts around birth, P14 is the earliest age we observed quantitative 
H3K27me3 loss in Ezh1/2 hepatocytes; hence this time was used to minimize secondary 
effects (Supplementary Fig 2CD). Notably, P14 Ezh1/2 hepatocytes have expression 
profiles between Wt hepatocytes P14 and M2 hepatocytes (Supplementary Figure 1D). 
Strikingly, of the 1215 genes upregulated during hepatocyte maturation at M2, 263 (22%) 
are prematurely upregulated in P14 Ezh1/2 hepatocytes (Figure 3A, Supplementary Table 
3). Of the 2011 genes downregulated in hepatocyte maturation, 128 (6.3%) are 
prematurely downregulated in P14 Ezh1/2 hepatocytes. Expression changes do not 
preferentially affect zonated genes (Supplementary Figure S2E). Taken together, the 
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results indicate that the PRC2 proteins EZH1/2 normally restrain maturation of postnatal 
hepatocytes until the appropriate postnatal time.  
Non-hepatocyte lineage genes are derepressed in P14 Ezh1/2 hepatocytes 
There are 665 genes upregulated and 90 genes downregulated in P14 Ezh1/2 
hepatocytes that are not normally changed during P14 to M2 maturation (Figure 3A, 
Supplementary Table 3). Upregulated genes include many transcriptional regulators, 
DNA-binding factors, and genes expressed in non-liver tissues, but GO analysis did not 
reveal specific biological pathways that were deregulated (Supplementary Table 5). These 
data are consistent with work from others that Polycomb proteins broadly repress alternate 
lineage-specific identity regulators (Boyer et al., 2006; Ezhkova et al., 2011; Margueron et 
al., 2008; Shen et al., 2008), but are insufficient upon deletion to result in outright 
hepatocyte identity change at this postnatal maturation stage.  
A subset of maturation and alternative lineage genes are repressed by 
EZH1/2 
As expected, given the repressive functions of PRC2, the 263 prematurely upregulated 
“late maturation” genes have high H3K27me3 at promoters and gene bodies at P14, but 
not at M2, as compared to genes only upregulated in maturation (Figure 2B). There are 
148 genes upregulated in P14 Ezh1/2 hepatocytes (Figure 2A), although they are normally 
downregulated in maturation and H3K27me3-marked, indicating that these are “early 
maturation” genes that are downregulated in the course of maturation by PRC2. The 665 
“alternative lineage” genes upregulated in P14 Ezh1/2 mutants have high P14 and M2 
H3K27me3 levels and the majority are lowly expressed in Wt hepatocytes (Supplementary 
Figure 2H). These data support a model where PRC2/H3K27me3 repression is used to 
46 
 
repress early and late maturation genes at the appropriate times and non-hepatocyte 
alternative lineage genes. 
P14 and M2 H3K27me3 was low at liver enhancers, regardless of whether the 
enhancers were centered by DNase hypersensitivity or if windows were varied around 
enhancer centers from 200 bp to 5 kb (Supplementary Figure 2G). Specifically, 
H3K27me3 levels were low at enhancers associated with genes upregulated in P14 
Ezh1/2, except for the early maturation genes, which had only 33 associated enhancers 
(Figure 2B). From this general lack of H3K27me3 at liver enhancers, we conclude that the 
Ezh1/2 premature maturation phenotype is not functioning primarily through altered 
repression of enhancers. 
In contrast, of the 263 prematurely upregulated maturation genes, 99 have P14 
H3K27me3 at promoters and 85 have P14 H3K27me3 on gene bodies, for a total of 117 
genes with at least one type of H3K27me3 marking. These genes include Slc13a5, which 
plays a key role in importing citrate into liver cells (Gopal et al., 2007), Pcsk9, which is 
associated with liver cholesterol (LDL) uptake (Ruscica et al., 2016), and Cyp26a1, a key 
enzyme in the clearance of retinoic acid from the liver (Thatcher et al., 2010) (Figure 2C, 
Supplementary Figure 2F). In comparison, Pax3, a silent muscle gene, retains H3K27me3 
marking at the promoter and was not upregulated in maturation. GO analysis on the 117 
H3K27me3-marked genes did not reveal grouped biological process (data not shown). 
Taken together, we conclude H3K27me3 is used to restrain expression of genes in 
postnatal hepatocytes specifically at promoters and gene bodies, and  minimally so at 
enhancers.  
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srHC-seq reveals that Ezh1/2 sensitive genes have euchromatic and 
bivalently-marked promoters 
To assess whether there are global changes in chromatin compaction in hepatic 
maturation, we characterized P14 and M2 Wt hepatocytes using an enzyme- and 
antibody-independent assay termed sonication-resistant heterochromatin sequencing 
(Supplementary Figure 3A). srHC-seq utilizes the physical property of crosslinked 
chromatin to be differentially sensitive to sonication; that is, structurally compact, 
heterochromatic regions are sonication-resistant while structurally open, euchromatic 
regions are sonication-sensitive (Becker et al., 2017). srHC-seq involves fractionation of 
large and small DNA fragments and analyzes the ratio of the two to identify both 
heterochromatic and euchromatic regions. 
srHC-seq was highly reproducible in replicates (Supplementary Table 2, 
Supplementary Figure 3BC). We plotted srHC data as log2(large fragments/small 
fragments), with heterochromatic regions as y > 0 (Figure 3A, red) and euchromatic 
regions as y < 0 (Figure 3A, green). As expected, the silent, non-hepatocyte gene Zfp936 
has a heterochromatic profile in liver and genes at the highly expressed, hepatocyte-
specific Alb/Afp/Afm locus have euchromatic profiles. Importantly, srHC-seq scores for 
promoters and gene bodies shows the inverse correlation between expression and 
chromatin compaction holds true genomically (Figure 3B). 
In contrast to silent and highly expressed loci, Cux2 expression is temporally- and 
sex-specific (Conforto et al., 2012) and srHC profiles reflect these dynamics (Figure 3A). 
While sex-specific differences were ascertainable, the differences represent only a fraction 
of the genome. We therefore merged male and female srHC data for the remaining 
analyses. 
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Both P14 and M2 Wt hepatocytes have about 1200 Mb of srHC heterochromatin 
and 1100 Mb of euchromatin, with H3K27me3 occurring in both domains (Figure 3CD, 
Supplementary Figure 3DE). We did not observe a global increase of euchromatin in P14 
Ezh1/2 hepatocytes or by confocal microscopy of DAPI staining of 6-week-old Ezh1/2 
samples (data not shown). We conclude that large scale euchromatic and heterochromatic 
domains are generally stable in postnatal hepatic maturation, while a subset of genes are 
dynamic. 
 While the PRC2 complex is classically thought to repress expression by eliciting 
chromatin compaction (Simon and Kingston, 2009), Polycomb-bound or -marked 
chromatin can be accessible to binding by some factors and transcribed (Becker et al., 
2017; Beisel and Paro, 2011; Breiling et al., 2001; Dellino et al., 2004; Hawkins et al., 
2010; Ku et al., 2008; Trojer and Reinberg, 2007). PRC2 loss leads to derepression of 
only a fraction of H3K27me3-marked genes in diverse tissues, with promoter H3K4me2/3 
predicting derepression (Bae et al., 2015; Ezhkova et al., 2011; Jadhav et al., 2016). To 
investigate the basis by which a subset of H3K27me3-marked promoters genetically 
respond to Ezh1/2 loss, we plotted srHC-seq profiles at 8121 silent and 2221 highly 
expressed in P14 and M2 Wt animals (Figure 4A). Significantly, promoters of genes from 
all three classes of genes upregulated in P14 Ezh1/2 hepatocytes are already euchromatic 
in P14 Wt hepatocytes, including those with promoter H3K27me3 signal (Figure 4A, note 
extensive green in P14 Wt). To focus on apparent direct PRC2 targets, we plotted srHC 
signal of genes with H3K27me3-marked promoters in P14 Wt samples (Figure 4B). These 
promoters become further euchromatic in Ezh1/2 hepatocytes and the open regions 
increase in width (Figure 4B). Using published P12 liver ChIP data(Alpern et al., 2014), 
we found that the three classes of P14 Ezh1/2 upregulated genes have promoters with 
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low levels of H3K4me3, RNA Polymerase II, and general transcriptional factors (Figure 
4A, Supplementary Figure 4B).  
By plotting signal at promoters of genes that are not differentially expressed in 
maturation or in P14 Ezh1/2 hepatocytes and do have P14 promoter H3K27me3 (Figure 
4A, “remaining P14 H3K27me3+ promoters”), we found that H3K4me3 does indeed help 
predict genes that become upregulated in Ezh1/2 mutants, as does RNAP2, general TFs, 
and a pre-existing euchromatic chromatin state (Figure 4A, Supplementary Figure 4B). 
Thus, promoters that are open and poised yet restrained by PRC2 are regulated during 
hepatocyte maturation. 
Chronic Ezh1/2 loss leads to liver damage 
It has previously been reported that Ezh1/2 in liver leads to chronic liver damage and 
fibrosis in mice by 8 months and increased sensitivity to liver damaging agents (Bae et al., 
2015). We observe that apoptosis occurs 4.6-fold more in Ezh1/2 hepatocytes by 1 month 
postnatal with very rare ductular reactions (Figure 5A). Yet by M2, but not at M1, liver 
fibrosis can be detected by Sirius Green/Fast Red staining (Figure 5B, Supplementary 
Figure 5A). Additionally, ductular responses can occur by H&E and CK19 staining by M2, 
with some larger diameter, malformed ducts than were reported previously (Figure 5B, 
Supplementary Figure 6A). Macroscopic regenerative nodules occur in nearly half of 
Ezh1/2 livers by M2, visible in H&E sections or in the most severe cases, by the naked 
eye as lumps on the liver (Figure 5C). While the Ezh1/2 model loses H3K27me3 in nearly 
100% of hepatocytes at P14 (Supplementary Figure 2C), by M2 these nodules stain for 
H3K27me3 similar to Wt and also stain for EZH2 (Figure 5DE, Supplementary Figure 
6AC), which was not observed previously in Bae et al. (Bae et al., 2015). As the liver is a 
regenerative organ and nodular hepatocytes in Ezh1/2 livers have increased proliferation 
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(Supplementary Figure 6C), we conclude that the EZH2+ nodules originate by selection 
for rare cells which escape Alb-Cre recombination. Thus, loss of PRC2-based repression 
results in loss of hepatic homeostasis, chronic liver damage, and fibrosis. 
Genes involved in liver fibrosis are primed by euchromatic H3K27me3+ 
promoters 
A 232 gene signature predicting fibrosis before histopathological detection was identified 
using a non-alcoholic steohepatitis (NASH) mouse model, and the relevance to humans 
was confirmed by finding 71 of 123 human NASH genes in the mouse 232 gene datasets 
(van Koppen et al., 2018; Teufel et al., 2016). RNA-seq on liver biopsies from a mixed 
cohort of chronic liver disease patients with Hepatitis C and/or fatty liver disease identified 
121 genes upregulated in advanced human liver fibrosis as compared to early fibrosis 
(Ramnath et al., 2018). We found that genes from both datasets are normally 
downregulated in postnatal hepatic maturation, are upregulated in P14 and M2 Ezh1/2 
hepatocytes, and have the predictive euchromatic H3K27me3+/H3K4me3+ promoter 
chromatin state that we identified as sensitizing genes to Ezh1/2 loss (Figure 6A). Genes 
significantly upregulated in P14 Ezh1/2 samples in mouse and human datasets were each 
2.6-fold more likely to have P14 H3K27me3+ promoters (permutation test, p=0.003 and 
p=0.009). Included in fibrosis gene sets with H3K27me3 promoter-marked genes are 
Fbn1, an inflammation and chemotaxis gene that is also upregulated in response to 
damaging chemicals (Ippolito et al., 2016), Fstl1, which is upregulated in humans with 
HCV-induced fibrosis and steatosis (Murphy et al., 2016), and Col1a1, which is 
upregulated in mice and humans with liver fibrosis (Dattaroy et al., 2015) (Figure 6B, 
Supplementary Figure 7BC). Interestingly, genes proposed to be involved hepatocyte 
epithelial-mesenchymal transition (EMT) in response to liver damage include Tgfb1, Vim, 
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and S100a4 (Choi and Diehl, 2009) also have H3K27me3-marked promoters and may be 
upregulated in M2 Ezh1/2 hepatocytes (Figure 6B, Supplementary Figure 7BC). Together, 
the failure to repress fibrosis-related genes starting at two weeks postnatal is associated 
with the 2-month-old fibrotic phenotype in Ezh1/2 livers.  
2.7.  Discussion 
To be effective therapeutically, newly generated hepatocyte-like cells must perform the 
complex metabolic functions of native hepatocytes that are naturally induced postnatally 
(Cui et al., 2012; Fouts and Adamson, 1959; Treluyer et al., 1996), but these late 
maturational functions are limited in many hepatocyte-like cells (Chen et al., 2012; Duan 
et al., 2010; Roelandt et al., 2013; Si-Tayeb et al., 2010; Song et al., 2009). Here we define 
a P14 to M2 transitional hepatocyte profile with more than 3000 transcripts exhibiting 
differential expression. The RNA maturation dataset can be a useful resource for 
assessing the stage of hepatocytes generated from stem cells or by directed 
reprogramming. Perinatal loss of EZH1/2 in hepatocytes leads to premature 
differentiation, suggesting that modulation of Polycomb components may enhance 
maturation in protocols for generating new hepatocytes. 
In our study, altering PRC2 repression led to impaired liver function and fibrosis, 
and previous reports have shown impaired ability to respond to liver damaging agents 
(Bae et al., 2015). Interfering with splicing factors alters liver maturation in mice and also 
leads to susceptibility to liver damage (Bhate et al., 2015). Considering the rising 
worldwide prevalence of NASH and hepatitis B (Wong and Huang, 2018) and that fibrosis 
is a key indicator of chronic liver injury of any etiology (Jung and Yim, 2017), the common 
thread of impaired maturation predisposing the adult liver to damage suggests that 
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studying mechanisms of hepatic maturation may help us identify environmental factors 
that alter maturation in humans and predispose them to liver diseases. Here we have 
identified a H3K27me3+/H3K4me3+ euchromatic promoter signature that primes many 
genes to be upregulated in response to maturation or other signaling events, and we 
propose that this is a chromatin-level mechanism leading to liver fibrosis in the Ezh1/2 
model. Given the euchromatic state of these promoters, it may be that compaction-
independent repressive activities of Polycomb proteins, such as PRC2 inhibiting 
elongation (Ardehali et al., 2017) and PRC1 interfering with RNAPII recruitment (Chopra 
et al., 2009; Tie et al., 2016), are key to regulating transcription in postnatal hepatocytes, 
though a full catalog of precise mechanisms by which Polycomb proteins repress 
transcription is still being worked out. It will be interesting to see how agonists or 
antagonists of different aspects of Polycomb Protein function may help reverse fibrosis, 
considering that there is growing evidence of fibrotic reversal after treatment for hepatitis 
B, C, and autoimmune hepatitis (Jung and Yim, 2017). 
There is conflicting evidence suggesting that hepatocytes can acquire a fibroblastic 
phenotype and expression of mesenchymal markers through EMT during liver fibrosis or 
in response to TGBβ treatment (Choi and Diehl, 2009; Dooley et al., 2008; Nitta et al., 
2008; Taura et al., 2010). We find that expression of these mesenchymal markers is 
slightly upregulated in M2 Ezh1/2 hepatocytes, but expression is highly variable 
(Supplementary Figure 6). This may reflect variability of multiple different sources, 
including variable levels of liver damage and fibrosis, variable contributions of 
H3K27me3+ nodular hepatocytes, and variable numbers of cells undergoing EMT at 
possibly different stages of EMT. The mesenchymal genes tend to be marked by 
H3K27me3 and have euchromatic promoters (Figure 6, Supplementary Figure 7). While 
we cannot conclude from these results whether EMT is occurring, it will be interesting to 
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assess whether PRC2 repression maintains an epithelial state in hepatocytes by 
repressing mesenchymal genes and whether liver damage elicits their derepression.  
Our results emphasize the role of PRC2 proteins in regulating maturation and how 
that may affect fibrosis, but not all maturation genes in our dataset are prematurely up- or 
downregulated in P14 Ezh1/2 mutants. There must be other mechanisms that regulation 
maturation genes in response to changing diet, microbiota, and sexual maturation during 
the two week to two month period. These results highlight the need to identify maturation 
factors, both for the purposes of enhancing in vitro hepatic maturation and for 
understanding factors which predispose humans to disease.  
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2.8.  Main Figures 
 
Figure 1. Postnatal hepatic maturation during the P14 to M2 transition involves 
differential expression of thousands of genes and H3K27me3 dynamics.  
A) log2(M2/P14 fold change) for genes differentially expressed in maturing hepatocytes. 
B) Gene Ontology for genes up and downregulated from P14 to M2 in Wt hepatocytes. 
C) H3K27me3 dynamics at genes up- (top, grey shading) and downregulated (bottom, 
orange shading) in maturation  
D) Percent H3K27me3 gene body coverage of “retain” H3K27me3 genes. Monte Carlo 
simulation and estimated p-value. Whiskers: 5th-95th percentiles. 
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Figure 2. PRC2 proteins EZH1/2 restrain postnatal hepatic maturation.  
A) Relative expression of genes differentially expressed in maturation or in P14 Ezh1/2 
hepatocytes. 
B) P14 and M2 H3K27me3 density at promoters, genes, or enhancers. Whiskers: 5th-95th 
percentiles. Wilcoxon rank-sum test. 
C) srHC-seq (heterochromatic-enriched in red, euchromatic-enriched in green), 
H3K27me3, and RNA signal at genes prematurely upregulated in P14 Ezh1/2 
hepatocytes (Slc15a5, Cyp26a) and a control gene (Pax3). 
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Figure 3. Stable global chromatin compaction in maturation and P14 Ezh1/2 
A) srHC-seq and RNA signal for positive controls sites for heterochromatin, Zfp936, 
euchromatin, Alb locus, or a dynamic gene, Cux2. 
B) srHC-seq scores at promoters and gene bodies for genes binned into expression 
quantiles. 0-30 represents genes without any RNA signal. Note the with increasing 
expression, srHC scores become more euchromatic. Whiskers: 5th-95th percentiles. 
C) Megabases of the genome called as heterochromatic, intermediate, or euchromatic 
and the overlap with H3K27me3 domains. 
D) srHC-seq domains and signal, H3K27me3, and RNA. Note that H3K27me3 occurs in 
both heterochromatic (red) and euchromatic (green) regions. 
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Figure 4. srHC-seq reveals that Ezh1/2 sensitive genes have euchromatic and 
bivalently-marked promoters  
A) ChIP and srHC-Seq signal around transcriptional start sites (-/+ 5kb) for silent genes, 
genes highly expressed in P14 and M2 (top 10% in expression in P14 and M2), three 
classes genes upregulated in P14 Ezh1/2, and the remaining P14 H3K27me3+ 
promoters. Note that the three classes of genes upregulated in P14 Ezh1/2 
hepatocytes have euchromatic promoters (green srHC signal) in P14 Wt hepatocytes. 
In comparison promoters that have H3K27me3 but are not upregulated (bottom, 
orange) have heterochromatic signals (red srHC signal) in P14 Wt hepatocytes. 
B) srHC-seq metaplots for panel (A) groups except highly expressed genes. Filtered for 
genes with P14 H3K27me3-marked promoters. Note that late maturation genes, early 
maturation genes, and alternative lineage genes (green, purple, and red lines) have 
more euchromatic signal in P14 Wt hepatocytes than the genes which are not 
upregulated in P14 Ezh1/2 and have H3K27me3+ promoters (orange line). 
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Figure 5. Ezh1/2 loss leads to chronic liver damage.  
A) Apoptosis as assayed by TUNEL staining. 
B) Fibrosis as assayed Sirius Green (total protein) and Fast Red (collagen) staining. 
C) Examples of a normal Wt liver and 2 Ezh1/2 livers with macroscopic liver nodules. 
Quantification of animals with liver nodules as assessed by histology.  
D) H3K27me3 immunohistochemistry in M2 livers. Regions inside and outside of 
regenerative nodules are outlined by the dotted circle. Wt: 2034 hepatocytes counted. 
Ezh1/2: 2440 hepatocytes counted. Ezh1/2 nodule: 1056 cells counted in 7 nodules.  
Two-sided student’s t-test with standard error. 
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Figure 6. PRC2 represses liver fibrosis signature genes  
A) Genes upregulated in a murine model of NASH-related fibrosis (top) and genes 
upregulated in human advanced fibrosis patients as compared to low level fibrosis 
(bottom). Murine hepatocyte expression, H3K27me3 and srHC-seq, and H3K4me3 
signal around transcriptional start sites -/+ 5 kb. Note that many fibrosis genes have 
H3K27me3+ promoters that are also euchromatic (green srHC signal) and have 
promoter H3K4me3. M2 Ezh1/2 RNA-seq represents a mix of hepatocytes from inside 
and outside of nodules. 
B) srHC-seq, H3K27me3, and RNA signal at fibrosis-related or EMT-related genes. 
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2.9.  Supplementary Figures 
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Supplementary Figure 1: Hepatocyte enrichment strategy and RNA-seq and ChIP-
seq quality control 
A) Hepatocyte enrichment strategy.  The liver ECM is digested in situ by perfusion, the 
liver is dissociated, filtered through a 100 μM filter, and hepatocytes pelleted by 
centrifugation.  Remaining cells are pelleted from the supernatant. 
B) Expression of markers of hepatocytes (Hnf4a, Foxa1), biliary cells (Krt19), blood 
(Ptprc, not red blood cells or platelets), stellate cells (Gfap, Desmin), and endothelial 
cells (Pecam1, Acta2) by RTqPCR from whole perfused liver, pelleted hepatocytes, or 
pelleted supernatant.   
C) Cells from the hepatocyte enrichment strategy have hepatocyte morphology when 
plated on collagen-coated plates in William’s E with penn/strep, 10% FBS, 2 mM L-
glutamine at 37°C. 
D) Spearman correlation for DESeq2-normalized genic expression.  
E) Proliferation as assayed PCNA staining.  Error bars with standard error.  
F) P14 and M2 hepatocyte H3K27me3 at negative (Alb/Afp/Afp) and positive (Hoxd 
cluster) control sites compared to ENCODE consortium P0 and M2 H3K27me3 liver 
ChIP data and expression in hepatocytes  
G) P14 and M2 hepatocyte H3K27me3 density at promoters and gene bodies, and 
expression for genes binned into expression quantiles (female). 0-30th represent silent 
genes. Whiskers: 5th-95th percentiles. 
H) Genomic coverage of H3K27me3 domains 
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Supplementary Figure 2.  Confirmation of H3K27me3 loss in hepatocytes, 
confirmation of minimal Ezh1 germline knockout effect, and RNA expression 
analysis of zonated and alternative lineage genes 
A) H3 and H3K27me3 Western on M2 hepatic nuclear extracts.  Note that single KO of 
Ezh1 or Ezh2 does not cause H3K27me3 loss. 
B) Spearman correlation for DESeq2-normalized genic expression comparing P14 Wt 
and Ezh1 single knockout hepatocytes.   
C) H3K27me3 staining in P14 Wt and Ezh1/2 hepatocytes.  1/500 AM39155 
D) Screening for H3K27me3 loss by Western on P14 hepatocyte whole cell extracts for 
H3 (Millipore 05-928) and H3K27me3 (Active Motif 39155). Samples used for RNA-
seq and srHC-seq are starred.  
E) Zonated genes and expression in layers 1-7 from Halpern et al., 2017 (left).  
Expression of the same genes in the same order in P14 hepatocytes (right). 
F) srHC-seq (heterochromatic-enriched in red, euchromatic-enriched in green), 
H3K27me3, and RNA signal at genes prematurely upregulated in P14 Ezh1/2 
hepatocytes (Pcsk9). 
G) Hepatocyte H3K27me3 density at liver enhancers, liver enhancers centered on a 
DNase hypersensitive site, and heart enhancers.  The defined size of an enhancer 
from its center is varied from 200 bp to 1 kb to show that the results are reproducible.  
Whiskers: 5th-95th percentiles.  
H) Percentage of the 665 alternative lineage genes in each expression quintile.  Note that 
they are mostly silent or very lowly expressed. 
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Supplementary Figure 3.  srHC-seq overview and method validation 
A) High cell number srHC-seq overview. Total DNA isolated from crosslinked, sonicated 
hepatocyte chromatin is shown on an agarose gel for comparison to Total DNA on a 
Bioanalyzer DNA 1000 chip. Representative profiles for Large, Medium, or Small DNA 
fractions and Large DNA that has been sonicated to a smaller size for library prep 
considerations.  
B) srHC-seq (heterochromatic-enriched in red, euchromatic-enriched in green) for all 
biological replicates. 
C) Spearman correlation of srHC-seq signal for non-overlapping 10kb windows across 
the genome. 
D) Compaction domain calling overview.  Conceptually, calling srHC-seq domains 
involved scoring the average large/small fragment score for 10 kb windows with a two 
kb slide, then using high and low score cutoffs to get heterochromatic- and 
euchromatic-enriched windows, merging windows and pruning steps.  With 
increasingly lax enriched window cutoffs, an increasing portion of the genome is called 
as heterochromatic or euchromatic, until the 50% cutoff, where het+/euch+ double 
positive regions that are reclassified as intermediate takeover. 
69 
 
 
Supplementary Figure 4.  Analysis of general transcription factors at transcriptional 
start sites at Ezh1/2-sensitive gene classes and control gene classes 
A) P12 liver ChIP signal for general transcription factors around transcriptional start sites 
(-/+ 5kb) for silent genes, genes highly expressed in P14 and M2 (top 10% in 
expression in P14 and M2, male and female), three classes of Ezh1/2 upregulated 
genes, and other P14 H3K27me3+ promoters (have P14 H3K27me3, but not 
significantly differentially expressed in maturation or in P14 Ezh1/2). 
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Supplementary Figure 5.  Histological analysis of fibrosis in M1 and M2 Wt and 
Ezh1/2 livers 
B) Fibrosis as assayed Sirius Green (total protein) and Fast Red (collagen) staining. 
C) HE on Wt and Ezh1/2 livers and adult Wt mouse liver treated with 14 days DDC.  
Regenerative nodules in 40X magnification Ezh1/2 samples present as pink circles. 
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Supplementary Figure 6.  Histological analysis of proliferation, ductal markers, and  
EZH2 in Wt and Ezh1/2 livers 
A) Immunohistochemistry for the proliferation marker PCNA, the biliary marker CK19, and 
H3K27me3 histone methyltransferase EZH2 on M2 Wt and Ezh1/2 livers. Regions 
inside and outside of regenerative nodules are denoted and (C) quantification of 
hepatocyte PCNA staining in Wt (2063 cells counted from 2 animals), Ezh1/2 outside 
of nodules (2624 cells counted from 4 animals), and Ezh1/2 nodular areas (1299 cells 
counted in 7 nodules from 2 animals).  PV=portal vein. BD=bile duct. Error bars: SEM. 
B) Immunohistochemistry for proliferation marker PCNA on ducts and (D) Quantification 
of biliary PCNA staining in Wt (447 cells counted in 65 ducts from 2 animals) and 
Ezh1/2 (1063 cells counted from 68 ducts from 3 animals). 
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Supplementary Figure 7.  Chromatin state analysis of fibrosis- and EMT-related 
genes 
A) Genes upregulated in a murine model of NASH-related fibrosis (top) and genes 
upregulated in human advanced fibrosis patients as compared to low level fibrosis 
(bottom).  P12 liver ChIP signal for general transcription factors around transcriptional 
start sites (-/+ 5kb).   
B) Relative expression of genes involved in putative hepatocyte EMT (Vim, S100a4, 
Tgfb1, Acta2), a marker of mesenchymal cells (Cdh2), Alb, and a maker of epithelial 
cells (Cdh1). 
C) srHC-seq (heterochromatic-enriched in red, euchromatic-enriched in green), 
H3K27me3, and RNA signal at fibrosis-related or EMT-related genes. 
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2.10.  Methods 
Liver perfusion and hepatocyte isolation 
Mice are anesthetized using isoflurane, the abdominal cavity exposed, venae cavae 
cannulated, and the portal vein severed. 37°C liver perfusion media (Invitrogen 17701-
038) and then liver digest media (Invitrogen 17703-034) are perfused (25 mL for P14, 45 
mL for M2). Dissociated livers in William’s E are strained through a 100 μm filter (Figure 
S1A) and pelleted at 50g for 5 min at 4°C. Hepatocyte enrichment was confirmed by 
depletion of RNAs from contaminating cells types by comparing whole perfused liver, 
isolated hepatocytes, and supernatant (pelleted at 500g) fractions.  
RTqPCR 
RNA was isolated from TRIzol, cDNA generated (Biorad 170-8891), and expression 
analyzed with Power SYBR Green (Thermo 4368577). 
Western blotting 
Whole cells or nuclei (isolated by douncing in RSB) were resuspended in Buffer C (200 
mM Tris pH 7.9, 400 mM NaCl, 1 mM EDTA, 1 mM EGTA, 0.8% SDS, PIC (Roche 
#11873580001), 1mM PMSF). Nuclear extracts were sonicated to reduce the viscosity 
from high DNA content. Extracts were denatured for 30 min at 99˚C in 100mM 
DTT/Sample Buffer (Thermo NP0007) and run with the NuPAGE system 
(NP0335,NP0002) at 80V. Wet transfer to PVDF membranes (100V for 3 hr, transfer buffer 
NP0006) and membranes were blocked for an hour in 5% NFDM-TBST. Primary 
antibodies were incubated overnight in 5% NFDM-TBST. Secondary antibodies (Santa 
Cruz Biotechnology sc-2004, sc-2005) were incubated in 5% NFDM-TBST for 1 hour. 
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Blots were developed using Thermo #34080. Primary antibodies: H3: 1/5000 Millipore 05-
928. H3K27me3: 5ug/mL Abcam 6147. H3K27me3: 1/1000 Active Motif 39155. 
Chromatin preparation and immunoprecipitation 
Hepatocytes were fixed in 25 mL 1% formaldehyde in PBS for 10 min at room temperature, 
quenched with 2.3 mL 2.5 M glycine for 5 min, pelleted at 4˚C at 50g for 5 min, 
resuspended in 10 (P14) or 20 mL (M2) ice-cold RSB (10 mM Tris pH7.4, 10 mM NaCl, 3 
mM MgCl2, 0.5% NP40, PIC, 0.1 mM PMSF, 1% Triton-X 100), dounced, pelleted for 10 
min at 4˚C at 100g, and resuspended in 2 mL ice-cold AS sonication-lysis buffer (10 mM 
Tris-HCl, pH8, 100 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 0.1% Na-deoxycholate, 0.5% 
N-lauroylsarcosine, 1 mM DTT, PIC, 0.1 mM PMSF). 
For srHC experiments, samples were sonicated using a Diagenode Biorupter 
UCD-200 (settings: 30 sec on high, 30 sec off for 30 minutes), Triton-X 100 added to 1%, 
debris pelleted for 15min at 4˚C, and supernatant collected. DNA was extracted from 50 
μL chromatin by adding 150 μL TE/1% SDS and decrosslinked overnight at 65˚C. Next, 
200 μL TE and 8 uL 10 mg/mL RNAse A added for 2 hours at 37˚C shaking. Next, 4 μL 
20 mg/mL Proteinase K was added for 2 hours at 55˚C shaking. DNA was extracted by 
phenol:chloroform:isoamyl separation and ethanol precipitation. 
For ChIP experiments, hepatocytes in AS-sonication lysis buffer proceeded to the 
extensive sonication and ChIP protocol in Nicetto et al., (manuscript accepted, Science). 
P14 and M2 hepatocyte H3K27me3 (Millipore 07-449) libraries were then generated using 
the ThruPlex DNA-seq kit (Rubicon #R400428). The M2 H3K27me3 ChIP was previously 
published Nicetto et al. (GSE114198). 
RNA-seq 
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RNA was isolated using TRIzol, polyA-selected I(nvitrogen (dT)25-61002), libraries 
prepped (NEB 7420), and sequenced with 75 bp single-end reads. For P14 Wt versus 
Ezh1 libraries, libraries were prepped with the NEBNext E6110. 
Immunohistochemistry 
Mice were prepped as for liver cannulation as described above and blood blanched from 
the liver with liver perfusion media. Livers were rinsed in PBS, fixed in 4% PFA-PBS for 1 
hour at 4˚C, washed in PBS, dehydrated, embedded in paraffin, 12 μm sections taken, 
dried, rehydrated in H2O, and washed. Antigen retrieval was performed in citrate buffer 
(10 mM Na Citrate, 0.05% Tween20, pH 6) by microwaving for 15 min. Slides were rinsed 
in water and PBS, quenched in 3% H2O2 in PBS for 15 min, washed, blocked for 15 min 
in avidin, washed, blocked for 15 min with biotin, washed, and serum blocked (10% FBS 
in PBS) for 30 min at room temperature. Primary antibodies were incubated in 10% FBS 
in PBS overnight at 4˚C, washed in PBST (PBS, 0.1% Tween 20). Secondary antibodies 
(1/200 Santa Cruz-2004, -2005) were incubated in 10% FBS in PBS for 45 min at 37˚C. 
Slides were washed in PBST and developed with DAB. Slides were then dehydrated and 
mounted with Cytoseal. PCNA antibody: 1/50 Santa Cruz 7907 Lot0402. H3K27me3 
antibody: 1/500 Active Motif 39155 Lot 01613015. CK19 antibody: 1/100 from Ben 
Stanger’s Lab. For statistics, the two-sided student’s ttest with ftest were used on the 
average percent staining per animal. 
TUNEL staining: Trevigen TACS TdT-DAB kit (Cat #4801-30-K) after avidin/biotin 
blocking. 
H3K27me3 gene body coverage increase statistical analysis 
Monte Carlo simulation was employed to assess the significance of the gene body 
coverage by H3K27me3 domains (Figure 1D): the selected genes were measured for a 
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median P14-M2 increase in gene body domain coverage, a random set of genes of equal 
size was sampled, and the median difference in gene body domain coverage was 
measured 1,000 times, with the p-value estimated as the number of samples in which the 
median difference met or exceeded the observed difference divided by 1,000. 
srHC 
10 μg DNA from sonicated chromatin were resuspended in 50 μL TE. For large fragments: 
25 μL beads (0.5 volumes) (Beckman Coulter A63881) were added to the 50uL of DNA, 
incubated, and beads were removed and large DNA isolated from them as described by 
the manufacturer. For medium fragments: 10 μL beads (0.2 volumes) were added to the 
supernatant from the large beads/DNA slurry, incubated, and beads were removed and 
medium DNA isolated from the beads. For small fragments: 35 μL beads (0.7 volumes) 
were added to the supernatant from the medium beads/DNA slurry, incubated, and beads 
were removed and small DNA isolated from the beads. Size selection efficacy was 
confirmed (Agilent 5067-4626) (Figure S3a). 
For library preparation considerations, large DNA was sonicated after size 
selection with a Covaris S220 with the following settings PP-175 W, DF-10, CB-200, 4-
9˚C, 5 minutes, then ethanol precipitated. 
Libraries were prepped (NEB E7370) per the manufacturer’s recommendations. 
For size selection of small libraries: 55 μL beads for the first step and 25 μL beads for the 
second step. Libraries were sequenced with 75 bp single-end reads. 
Enhancer-promoter unit and DHS processing 
EPUs were downloaded from Shen et al, 2007(Shen et al., 2012). 1 bp was added to 
enhancers that loop to multiple genes. Enhancers were centered by intersecting with 
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concatenated liver DHS sites (GSM1014195 replicates 1-14)(Yue et al., 2014). The first 
DHS event in each enhancer was used.  
Domain calling 
We adapted a previously described algorithm(Becker et al., 2017) to call domains.  
H3K27me3 parameters: 2kb windows, 1kb slide, top 30% cutoff.  srHC parameters: 10kb 
windows, 2kb slide, and 40% cutoff. Intermediate domains include regions not called as 
hetero/euchromatic and heterochromatin/euchromatin double positive regions. 50% or 
75% coverage by domains were used for marked gene and promoter calls, respectively. 
DNA-sequencing and processing 
Reads were aligned to the NCBI v37/mm9 genome using STAR2.4.2a with the following 
arguments: --outFilterMultimapNmax 20, --alignIntronMax 1, then filtered for unique 
alignments to avoid PCR duplication artifacts. RPM-normalized bedgraphs of alignments 
were generated, then values log2(large/small) or ChIP minus Input subtracted calculated 
for every block. To avoid dividing by zero, a small addend was added to every block. 
Biological replicate values were merged using bedtools unionbedg and averaged. 
Read density (or srHC-seq scores) were calculated using the Bioconductor 
Genomation v1.6.0 package using ChIP minus Input (negative values converted to 0) or 
log2(large/small) bigwigs. The resulting values were quantile-normalized across all P14 
and M2 individual biological replicates. On box and whisker plots, whiskers indicate 5 th 
and 95th percentiles and Wilcoxon statistical testing was used. 
RNA-sequencing and processing 
Reads were aligned to the mm9 genome using STAR2.4.2a with the following arguments: 
--outFilterType BySJout, --outFilterMultimapNmax 20, --alignSJoverhangMin 8, --
alignSJDBoverhangMin 1, --outFilterMismatchNmax 999, --alignIntronMin 20, --
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alignIntronMax 1000000. HTSeq version 0.6.1p1 count was used to assign reads to genes 
with the NCBI v37/mm9 genome file (RefSeq genes, refFlat), then normalized and DE 
genes called using DESeq2 (alpha ≤ 0.05, FC ≥ 2). 
For browser views, alignments greater that 75 bp were filtered out to avoid showing 
spurious intronic signal, and converted to RPM-normalized strand-specific bigWigs. 
Replicates were averaged at the RPM-normalized bedGraph stage with the tool bedtools 
unionbedg.  
Zonated genes were kindly provided by Dr. Itzkovitz (Halpern et al., 2017). 
Experimental model and subject details 
All animal studies were performed with the University of Pennsylvania IACUC 
approval. Genetics include the Alb-Cre transgene(Postic et al., 1999), and Ezh1-/- 
(Ezhkova et al., 2011) and Ezh2f/f (Ezh2tm1Tara)(Su et al., 2003) alleles in a mixed 
C57BL/6J and C3H background. 
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2.11.  Supplementary Tables 
The supplementary tables are large files.  They are available online on the 
Gastroenterology journal website, on NCBI GEO, or from the corresponding author. 
Supplementary _Table1:  mus musculus RTqPCR primer sequences 
Supplementary _Table2:  Millions aligned reads for RNA-seq, ChIP-seq, srHC-seq 
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Supplementary_Table3:  Differential expression calls. H3K27me3- and 
heterochromatin/intermediate/euchromatin-marked gene body and promoter calls. 
Supplementary _Table4:  “Liver-enriched” maturation genes.  Genes upregulated in 
maturation that enrich for the UniProt Liver Tissue Expression Category and genes called 
as liver specific in Li et al., Nature 2017 
Supplementary _Table5:  Gene Ontology 
Supplementary _Table6:  Genes differentially expressed in P14 Ezh1 single knockout 
hepatocytes as compared to P14 Wt. 
Supplementary _Table7:  mm9 gene loci, human and mouse orthologs, and H3K27me3-
marking status for fibrosis gene sets 
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Chapter 3:  H39me3-heterochromatin loss at protein-coding genes 
enables developmental lineage specification 
3.1.  Preface 
The manuscript presented in this chapter was originally published on January 3, 2019 
(Nicetto et al., 2019).  It has been reformatted here in accordance with University of 
Pennsylvania dissertation formatting guidelines.  All genomic data are accessible at the 
Gene Expression Omnibus (GEO) database repository GSE114198.  The references for 
this chapter are at the end of this chapter. 
 
One Sentence Summary: H3K9me3-marked heterochromatin is transiently deployed 
during early development and removed later to allow expression of cell type-specific 
genes. 
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3.3.  Abstract 
Gene silencing by chromatin compaction is integral to establishing and maintaining cell 
fates. Trimethylated histone 3 lysine 9 (H3K9me3)–marked heterochromatin is reduced in 
embryonic stem cells compared to differentiated cells. However, the establishment and 
dynamics of closed regions of chromatin at protein-coding genes, in embryologic 
development, remain elusive. We developed an antibody-independent method to isolate 
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and map compacted heterochromatin from low–cell number samples. We discovered high 
levels of compacted heterochromatin, H3K9me3-decorated, at protein-coding genes in 
early, uncommitted cells at the germ-layer stage, undergoing profound rearrangements 
and reduction upon differentiation, concomitant with cell type–specific gene expression. 
Perturbation of the three H3K9me3-related methyltransferases revealed a pivotal role for 
H3K9me3 heterochromatin during lineage commitment at the onset of organogenesis and 
for lineage fidelity maintenance. 
3.4.  Main Text 
The phylotypic period of embryologic development occurs at the onset of organogenesis, 
in which morphological development is most conserved between different species (1–3). 
The “hourglass” model suggests that cell fate decisions are restricted during the phylotypic 
period by evolutionarily conserved transcription factor and signaling activities (1–3). 
Limited assay sensitivity and small numbers cells have made it difficult to investigate 
chromatin dynamics during the phylotypic period, when cell differentiation initiates 
extensively in embryos. Current thinking from the embryonic stem (ES) cell model (4) 
suggests that compacted heterochromatic domains expand as cells mature, helping to 
establish cell identity (5–11). However, these studies did not examine the dynamic events 
occurring during natural lineage commitment.  
 Regions of H3K9me3-marked heterochromatin can have a physically condensed 
structure (12–14) that serves to repress repeat-rich regions of the genome (7, 15–17), 
including centromeric and telomeric regions (18, 19), and silence protein-coding genes at 
facultative heterochromatin (20, 21). The early lethal in vivo developmental phenotypes 
associated with the depletion of H3K9me3-related histone methyltransferases (HMTases) 
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(15, 22, 23) support the idea that H3K9me3 controls genome stability and differentiation. 
Recently, H3K9me3 dynamics at repetitive elements and promoters have been 
characterized at pre-gastrula stages (24). The global heterochromatin reorganization at 
germ layer stages and during lineage commitment in vivo has not been addressed, and 
prior studies did not distinguish H3K9me3-decorated regions that are euchromatic from 
those that are heterochromatic (25). H3K9me3-enriched domains also impede cell 
reprogramming and somatic cell nuclear transfer (17, 25–27), underscoring the 
significance of understanding the natural dynamics by which heterochromatic domains 
restrict cell fates during normal development. 
We globally assessed the dynamics of compacted, sonication-resistant 
heterochromatin (srHC) (25) and H3K9me3 deposition at critical developmental time 
points in the murine endoderm germ layer and in cells along the descendent hepatic and 
pancreatic lineages (Fig. 1A, and fig. S1A and B, fig. S2A to H, fig. S3A to F). Since the 
embryonic starting material has low cell numbers, we developed a sonication-resistant 
heterochromatin sequencing (srHC-seq) method that is sucrose gradient-independent 
(25) to detect regions of srHC (fig. S4 A to E).  We performed srHC-seq in definitive 
endodermal cells, hepatocytes, and mature beta cells, and found similar fractions of the 
genome in srHC in the three cell types (fig. S4 F and G). In all stages, gene expression 
was anti-correlated with sonication resistance (fig. S4H). Analysis of Hi-C-identified closed 
compartments revealed 40% overlap with both adult hepatocytes and mature beta cells 
srHC (fig. S4I), whereas no significant correlation with open compartments was detected. 
We observed extensive dynamics of srHC upon definitive endoderm differentiation (Fig. 
1B, Table S7), including 5,979 and 4,879 genes that lose compaction, whereas 1,630 and 
5,632 genes gain srHC, during hepatocyte and mature beta cell development, 
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respectively. GO analysis revealed that srHC is removed at adult function genes (Table 
S7).  
We mapped H3K9me3 in cells sorted from embryos at different developmental 
stages (fig. S5A to D). Unsupervised hierarchical clustering revealed a high correlation 
between individual replicates, with definitive endoderm cells clustering separately from the 
hepatic and pancreatic lineages (fig. S5E). To compare H3K9me3 landscapes across the 
three germ layers, we included mesoderm progenitors and ectoderm-derived, already 
specified midbrain neuroepithelial cells isolated at e8.25 (fig. S6 A to H) and compared 
their H3K9me3 profiles to definitive endodermal cells, as well as to P0 heart and adult 
nucleus accumbens (Figure 1A). Concordant with the heterochromatin analysis, 
H3K9me3 marked more gene bodies, promoters, and termination transcription sites (TTS) 
in endoderm and mesoderm germ layer than in pregastrula stages or differentiating cells 
(Fig. 1C, fig. S7A-E, Tables S8, S9). A step-wise developmental transition analysis of 
H3K9me3 revealed a substantial loss of H3K9me3 when definitive endodermal cells 
differentiate into hepatic and pancreatic progenitors (Fig. 1D, Tables S10, S11). A similar 
process is detected in the mesoderm lineage, but not upon differentiation of midbrain 
neuroepithelium, which is already past the ectoderm stage, into neurons (fig. S7F, Tables 
S10, S11). 
H3K9me3 and H3K27me3 reside both in srHC and open chromatin, where they 
decorate regions independently or in combination (25) (fig. S8A to C). However, unlike 
H3K9me3, heterochromatin marked by H3K27me3 was similarly distributed over genes 
and intergenic regions in definitive endoderm, hepatocytes, and mature beta cells (fig. 
S9A to E).  
We assessed the acquisition of stage-specific transcriptional signatures along the 
hepatic and pancreatic lineages (fig. S10A to C, Table S12). Combined analysis of srHC, 
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H3K9me3, and transcriptional profiles revealed that gene bodies, TSSs, or TTSs marked 
by H3K9me3 are more repressed when present in srHC than in open chromatin (fig. S11A 
and B). K-means cluster analysis of six developmental stages (fig. S12, Table S13) 
identified 15 patterns of gene expression. Notably, cell type-specific genes that acquire 
expression in terminally differentiated cells showed a net loss of srHC and H3K9me3 along 
both the hepatic and pancreatic lineages (Fig. 2A, C to E, fig. S13A, fig. S14A to D, Table 
S14), whereas constitutively expressed or repressed genes were depleted or decorated 
by the mark, respectively (Fig. 2B and fig. S13B and C). H3K27me3 dynamics at both 
hepatic and pancreatic-specific genes were also detected, showing loss in development 
(fig. S14E).  Of the 1,008 and 1,249 genes in adult hepatocytes and mature beta cells that 
fail to be expressed at a higher level in differentiated versus uncommitted cells, but lose 
H3K9me3, 71% and 74% respectively, showed increased H3K27me3 levels compared to 
definitive endoderm (fig S15A), indicating a compensatory mechanism for maintaining 
heterochromatin at a subset of genes that remain developmentally silent. Overall, the 
results show that H3K9me3-marked heterochromatin is transiently deployed in germ layer 
cells to repress genes associated with mature cell function, and is removed at many sites 
during differentiation to allow tissue-specific gene expression. 
H3K9me3 is established by three main HMTases, Setdb1, Suv39h1, and Suv39h2 
(15, 22, 23). Setdb1 single and Suv39h1/h2 double germ-line knock-outs are associated 
with early lethal phenotypes (15, 17, 22). We used FoxA3-Cre to generate endoderm-
specific (28, 29), conditional knockout (KO) mice for Setdb1 (30) (fig. S16A) and analyzed 
e11.5 livers. H3K9me3 was modestly reduced in mutant embryos (fig. S16B), which 
showed bleeding in different body regions, but no gross morphological differences in the 
liver structure and cell composition (fig. S16C). Single cell RNA-seq on wild-type e11.5 
hepatoblasts revealed three clusters of cell types (cluster 1-3, Table S15), whose 
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differentially expressed genes were associated with developmental processes, hepatic 
metabolism, and hematopoiesis, respectively (Fig. 3A and fig. S17A to E). Expressed 
genes in Setdb1 mutant cells more than doubled in cluster 1 compared to wt cells, but 
were reduced in cluster 2 (Fig. 3A). Setdb1 mutant albumin positive (Alb+) cells from 
cluster 2 fail to induce hepatic markers and separate into a distinct sub-cluster from wt 
Alb+ cells (Fig 3B and Table S15). Adult, conditional Setdb1 mutant livers show occasional 
hypertrophic hepatocytes (fig. S16D and E) that maintain nuclear Setdb1 and H3K9me3 
levels as well as expression of major urinary proteins (MUPs) (fig. S16D). However, the 
bulk of Setdb1-negative cells show lower levels of H3K9me3 and no expression of MUPs, 
in stark contrast to wt livers that uniformly express pericentral MUPs (fig. S16D). Thus, 
Setdb1 modulates hepatocyte differentiation. 
The persistence of low-level H3K9me3 in the conditional Setdb1 mutants and 
Suv39h1 and Suv39h2 double mutants (fig. S16B and S18A), the appearance of escaper 
cells (fig. S16D, arrows), and the expression of H3K9me3-related HMTases being higher 
in definitive endoderm, compared to more specified cells (fig. S18B), prompted us to 
generate an endoderm-specific conditional triple knock-out mutant (TKO) murine strain of 
all 3 H3K9me3-related HMTases (fig. S19A to F). Protein analysis showed a clear 
reduction in Setdb1, Suv39h1 (fig. S20A), and Suv39h2 (fig. S20B), leading to a dramatic 
decrease in H3K9me3, but not in H3K27me3 and H3K9me2 (fig. S20A and C). Single cell 
RNA-seq on E11.5 Liv2+ cells revealed that TKO hepatoblasts clustered into a separate 
group compared to wt and Setdb1 mutant cells (Fig. 4A), with an overlap of only 43 genes, 
of non-liver types, upregulated in common between TKO and Setdb1 mutant cells (Table 
S15).  Indeed, despite expressing albumin (fig. S20D), TKO cells never gained a clear 
hepatic transcriptional profile (fig. S20E and Table S15). One-month old triple mutant 
animals (n=5) appeared smaller in size compared to control littermates (Fig. 4B), showing 
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up to a 3-fold reduction in body weight (fig. S21A). TKO livers display inflammatory 
phenotypes, characterized by a ductular reaction (Fig. 4C). Genomic analysis (fig. S21B 
and C) confirmed a dramatic loss in srHC and H3K9me3 (Fig. 4D), which was validated 
by a global loss of condensed chromatin as seen by electron microscopy (Fig. 4E). RNA-
seq data on 1-month old livers (fig. S21D and E) revealed a marked derepression of non-
hepatic genes in TKO livers and a failure to induce mature hepatocyte genes such as 
MUPs (fig. S22A and B, Table S16). The latter phenotype, seen also in adult Setdb1 KO 
livers (fig. S16D), indicates secondary effects upon depletion of H3K9me3-related 
HMTases. Importantly, markers associated with chromosomal instability were mostly 
unaffected (fig. S22C to E). Thus, failure to establish H3K9me3-marked heterochromatin 
during early development leads to a failure of hepatocyte maturation, even 1 month after 
birth, and results in expression of inappropriate lineage genes.  
Heterochromatin has been defined by biophysical properties more than by 
repressive histone modifications (25). We employed an approach whereby srHC is 
isolated and characterized independently and in correlation to H3K9me3. We found higher 
levels of heterochromatin at gene bodies in early, uncommitted endodermal and 
mesodermal cells, and observed a developmental loss of H3K9me3 and srHC during cell 
differentiation in vivo (fig. S23A). Genetics of H3K9me3-related HMTase mutant mice 
highlighted the importance of proper heterochromatin establishment to promote cell 
differentiation. These findings underscore how epigenetic regulation of chromatin 
structure controls cell identity in embryogenesis. We propose a role for H3K9me3-marked 
heterochromatin as an epigenetic contributor to the hourglass model (1–3), working in 
concert with homeobox proteins (1) and signaling (2) influences, to constrain gene activity 
during the phylotypic period of embryonic development and guarantee establishment of 
cell identity. 
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3.5.  Figures 
 
 
Figure 1: Chromatin compaction and H3K9me3 landscape upon germ-layers 
differentiation.  
(A) Schematic of the cell types and embryonic developmental stages considered in this 
study. Purple, orange and green asterisks aside cell the represented cell types indicate 
samples processed for H3K9me3 ChIP-seq, RNA-seq and srHC-seq, respectively (B) 
Alluvial plot showing dynamics in definitive endoderm srHC (dark grey) and open 
chromatin (light grey) patches upon differentiation into adult hepatocytes and insulin 
producing cells; a-h indicate distinct categories/alluvia, characterized by a specific 
dynamic in srHC and open chromatin; the number of genes in each alluvium is idicated.  
(C) Number of genes marked by H3K9me3 in each indicated stage, along the hepatic and 
pancreatic lineages. ICM, e6.5, and e7.5 data from (25). (D) Number of genes gaining 
(purple) or losing (white) H3K9me3 upon step-wise transition in successive developmental 
stages. Each transition is indicated above the corresponding gene number bar. 
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Figure 2: Loss of srHC and H3K9me3 correlates with gene expression of hepatic-
specific markers upon differentiation.  
(A) Representative UCSC genome browser tracks of srHC-Seq (gray), input-divided 
H3K9me3 (purple) and RNA-Seq profiles (orange) upon definitive endoderm 
differentiation into adult hepatocytes. SrHC and H3K9me3 patches are shown as grey and 
purple bars above each profile, respectively. Cytochrome P450 (Cyp) genes on 
chromosome 5 (A) are shown. The constitutive H3K9me3-undecorated and active Actin b 
and the permanently H3K9me3-enriched and silenced zinc finger protein (Zfp) 936 (B) 
have been included as examples of genes whose expression inversely correlate to 
H3K9me3 presence. Magenta arrows indicate presence of srHC and H3K9me3 and 
absence of expression. Green arrows indicate absence of srHC, H3K9me3, and gene 
expression. (C) Z-score cluster representations for genes expressed in adult hepatocytes. 
(D and E) heatmaps showing levels of srHC (D) and H3K9me3 (E) in the indicated stages. 
For both srHC and H3K9me3 heatmaps, definitive endodermal cells values have been 
ordered in a descendent manner.  
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Figure 3: Setdb1 mutant hepatoblasts upregulate lineage non-specific genes.  
(A) tSNE plots of single cell RNA-Seq data showing wt (cells from n= 7 embryos; left, blue 
squares) and Setdb1 mutant (cells from n=3 embryos; right, red triangles) cells in the three 
identified clusters. (B) tSNE plots of single cell RNA-Seq data showing wt (top, blue 
squared) and Setdb1 mutant (bottom, red triangles) Albumin positive cells from Cluster 2. 
The black arrow indicates transition of Setdb1 mutant cells (red triangles) to a different 
cluster than the wt cells (blue squares).  
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Figure 4: TKO mutant cells lose hepatic identity and show developmental 
phenotypes associated with decreased H3K9me3 and srHC levels.  
(A) tSNE plots of e11.5 single cell RNA-Seq data showing wt, Setdb1 mutant (same as 
Fig.3), and TKO (cells from n=7 embryos; right, dark green circles) cells in the four 
identified clusters. (B) Representative morphological phenotype of 1-month old ctrl (n=3) 
and FoxA3-cre; Setdb1 fl/fl; Suv39h1 fl/fl, Suv39h2 KO/KO triple knockout (TKO) mutants 
(n=5). (C) H&E staining and cytokeratin 7 IHC in 1-month old ctrl and TKO livers. Scale 
bar: 50 um. (D) Percentage of genome covered by H3K9me3 and sr-HC domains in ctrl 
and TKO livers. (E) Representative electron microscopy images for ctrl and TKO one-
month old hepatocytes. Scale bar: 600 nm. The number of cells recorded in the two groups 
is indicated at the bottom. 
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3.6.  Supplementary Figures 
 
 
Fig. S1: Strategy for isolation of 
endoderm-derived cell 
populations.  
(A) Schematic of the cell types, 
embryonic developmental stages 
and cellular surface markers or 
murine strains considered in this 
study. (B) Strategy for cell population 
isolation and downstream analysis. 
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Fig. S2: Sorting strategy of embryonic cells  
(A) Schematic representing the sorting strategy of definitive endodermal ENDM1+ cells 
from e8.25 embryos. (B) Representative sorting pattern of ENDM1+ cells. (C) Schematic 
representing the sorting strategy for Liv2+ hepatoblasts from e10.5 embryos. For this 
experiment Pdx1-GFP transgenic mouse strain have been used to separate pancreatic 
and hepatic cells. Single GFP+ and Liv2+ populations have been used to properly set 
sorting gates (D) Representative sorting pattern of Liv2+ cells. Note that Pdx1-GFP+/Liv2+ 
double positive population can be detected. For the purpose of this paper only Liv2+ and 
Pdx1-GFP+ single positive cells only have been considered. (E) Schematic representing 
the sorting strategy of e18.5 insulin-RFP+ cells. (F) Representative sorting pattern of e18.5 
insulin-RFP+ cells. (G) Bright field (top) and fluorescent image (bottom) of isolated 2-
month old islets from Insulin-RFP+ adult mice. (H) Representative sorting pattern of 2-
month insulin-RFP+ cells. 
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Fig. S3: Validation of sorted cell identities.  
Quantitative PCR (qPCR) of definitive (A) endodermal ENDM1+ cells, (B) Liv2+ 
hepatoblasts and Pdx1-GPF+ pancreatic precursor cells, and (C and E) hepatocytes, (D) 
e18.5 immature and (F) 2-month old mature insulin-RFP+ cells, confirming the identity of 
the isolated cells. Ct values have been normalized to GAPDH and indicated populations 
of isolated cells have been used as reference. Expression is shown as Log2 scale relative 
to reference population. At least three independent biological replicates have been 
considered for each quantification. Taqman probes used for this experiment are indicated 
in Table S1. 
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Fig. S4: srHC-seq strategy and genomic features.  
Sonicated chromatin (A) has been separated in two fractions: sonication-resistant/large 
fragments (B) and sonication-sensitive/small fragments (C). Large fragments have been 
further sonicated to a size usable for sequencing (D). (E) Validation of srHC enrichment 
at MSAT and Eef1a in definitive endoderm and hepatocytes. (F) Percentage of genome 
and (G) genomic features covered by srHC domains in definitive endodermal cells, 
hepatocytes and mature beta cells. (H) Boxplot representation of srHC (large fragments) 
versus open chromatin (small fragments) ratio in relation to gene expression in definitive 
endodermal cells (top), adult hepatocytes (middle) and adult beta cells (bottom). Gene 
expression, indicated as percentile, couples with genes embedded in chromatin-sensitive 
portion of the genome, thus showing smaller large/small fragment ratio. (I) Venn diagrams 
showing overlap between srHC and Hi-C B compartment (A-B compartment data from 
series GSE93431) in adult hepatocytes and mature beta cells. 
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Fig. S5: H3K9me3 antibody validation and sample correlation.  
Peptide competition assay on adult liver (A) and sorted definitive endoderm cells (B) 
protein extracts, testing H3K9me3 antibody specificity. TATA-Binding Protein (TBP) and 
pan-H3 antibodies were used as loading control in (A) and (B), respectively. Ponceau 
staining of histone is indicated at the bottom of the panel (A). (C) Representative 
sonication pattern of sorted cells. Cells have been prepared as indicated in the Material 
and Methods section. (D) Representative H3K9me3 and H3K4me3 ChIP-qPCR for sorted 
cells. The chart shows enrichment of H3K9me3 and H3K4me3 at major satellite repeats 
and Gapdh gene body. (E) Spearman correlation of H3K9me3 ChIP-Seq individual 
replicates considered in this study. 
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Fig. S6: E8.25 mesoderm progenitor and midbrain neuroepithelial cell identification. 
(A) Schematic of the cell types isolated at e8.25. (B) Midbrain neruoepithelial cells were 
isolated dissecting the neural fold from e8.25 embryos. (C) Schematic representing the 
sorting strategy of mesodermal progenitor Flk1+ cells from E8.25 embryos. (D) 
Representative sorting pattern of Flk1+ cells. (E and F) qPCR of mesoderm progenitor 
Flk1+ cells (E) and midbrain neruoepithelial cells (F) confirming the identity of the isolated 
cells. Ct values have been normalized to GAPDH and indicated populations of isolated 
cells have been used as reference. Expression is shown as Log2 scale relative to 
reference population. Three independent biological replicates have been considered for 
each quantification. (G) Representative sonication pattern of mesoderm progenitor Flk1+ 
and midbrain neruoepithelial cells. (H) Spearman correlation of individual replicates of 
samples isolated from e8.25 embryos. 
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Fig. S7: H3K9me3 dynamics at genomic features.  
(A) Percentage of genome and (B) genomic features covered by H3K9me3 domains in 
the cell types and embryonic developmental stages considered in this study. (C) Number 
of genes marked by H3K9me3 in the indicated cell types at the transcriptional start site 
(TSS,  +/- 1kb) and termination site (TTS, +/- 1kb). (D and E) Number of genes gaining or 
losing H3K9me3 at TSS (D) or TTS (E) upon differentiation. Each transition is indicated 
above the corresponding bar indicating the gene number. (F) Number of genes gaining 
(purple) or losing (white) H3K9me3 in mesoderm and midbrain differentiation. Each 
transition is indicated above the corresponding bar indicating the gene number. 
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Fig. S8: Extent of srHC, H3K9me3, and H3K27me3 overlap.  
(A to C) Mb distribution of H3K9me3 and H3K27me3 in srHC and open chromatin in 
definitive endodermal cells (A), adult hepatocytes (B) and mature beta cells (C). 
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Fig. S9: H3K27me3 characterization during development.  
(A) Representative H3K27me3 enrichment detected via ChIP-qPCR, in the indicated cell 
populations, at Arx (positive site) and Eef1a (negative site). (B and C) Percentage of 
genome (B) and genomic features (C) covered by H3K27me3 domains in the indicated 
cell populations. (D) Number of genes marked by H3K27me3 in each indicated stage. (E) 
Number of genes gaining (red) or losing (white) H3K27me3 upon step-wise transition in 
successive developmental stages. Each transition is indicated above the corresponding 
bar indicating the gene number. 
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Fig. S10: Stage-by-stage transcriptome analysis.  
(A) Spearman correlation of individual RNA-Seq replicates for endoderm differentiation 
along the hepatic and pancreatic samples. (B) PCA analysis of RNA-Seq data for the 
endoderm lineage samples considered in the study. (C) Representative GO categories 
and genome browser tracks for genes differentially expressed upon step-wise transition 
along the hepatic and pancreatic lineages. Comparison of e10.5 hepatoblasts vs 
pancreatic precursor cells and 2-month old hepatocytes vs mature beta cells have been 
included. For a comprehensive GO analysis, see Table S12.  
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Fig. S11: srHC and H3K9me3 correlation to gene transcription.  
(A) mRNA expression in definitive endoderm, adult hepatocytes and mature beta cells, for 
genes marked with H3K9me3 and present in srHC or open chromatin. Unmarked genes 
in open chromatin are indicated. (B) Correlation between H3K9me3 enrichment at TSS, 
gene body and TTS, and gene transcription in definitive endodermal cells, adult 
hepatocytes and mature beta cells. 
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Fig. S12: RNA-seq cluster analysis.  
(A) Cluster analysis of Z-score RNA-Seq values for endoderm differentiation along the 
hepatic and pancreatic samples. Each chart shows a profile of gene expression indicated 
as Z-score value. The numbers of cluster considered has been identified as described in 
Materials and methods. Clusters have been organized according to temporal expression 
of genes upon endoderm differentiation along the hepatic and pancreatic lineages. The 
red number beside each chart identifies the cluster number reported on Table S13. 
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Fig. S13: ChIP-qPCR validation of H3K9m3 dynamics at hepatic genes.  
(A to C) Representative UCSC genome browser tracks of input-divided H3K9me3 (purple) 
and RNA-Seq profiles (orange) upon definitive endoderm differentiation into adult 
hepatocytes. H3K9me3 patches are shown as purple bars above each profile. A ChIP-
qPCR validation of candidate genes gaining expression upon H3K9me3 loss along the 
hepatic differentiation pathway is shown: H3K9me3 ChIP-qPCR (n=3) for (A) Cyp3a11, 
Mug1, Cyp3a44, Mug2 and Cyp2u1, Cyp2c37, Cyp3a25 showing progressive loss of 
H3K9me3 (red arrows) associated with gaining in gene expression. (B and C)  show 
H3K9me3 enrichment at the constitutive active actin b gene and the permanently silenced 
zinc finger protein (Zfp) 936 gene. Each chart shows H3K9me3 and IgG enrichment at the 
indicated genic position (green bar). Results are mean. Error bars are SEM. 
Oligonucleotide sequences used for this experiment are indicated in Table S2. 
114 
 
 
Fig. S14: srHC, H3K9me3 and H3K27me3 dynamics at lineage-specific genes.  
(A) Representative UCSC genome browser tracks of srHC-Seq (grey), input-divided 
H3K9me3 (purple) and RNA-Seq profiles (orange) upon definitive endoderm 
differentiation into mature beta cells. SrHC and H3K9me3 patches are shown as grey and 
purple bars above each profile, respectively. Slc30a8  on chromosome 15 (A) is shown. 
Magenta arrows indicate presence of srHC and H3K9me3 and absence of expression. 
Green arrows indicate absence of srHC, H3K9me3 and gene expression. (B) Z-score 
cluster representations for genes expressed in mature beta cells. (C and D) Heatmaps 
showing levels of srHC (C) and H3K9me3 (D) in the indicated stages. (E) Heatmaps 
showing levels of H3K27me3 in the hepatic and pancreatic specific genes identified with 
the K-means clustering. For each heatmaps definitive endodermal cells values have been 
ordered in a descendent manner.    
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Fig. S15: H3K27me3 compensatory effects on genes losing H3K9me3.  
(A) Boxplot showing H3K27me3 compensation on hepatic (top) and pancreatic (bottom) 
genes losing H3K9me3. 
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Fig. S16: E11.5 and adult Setdb1 mutants identification and characterization.  
(A) E11.5 yolk sac genotyping for Cre (top) and SETDB1 (bottom). Note how in SETDB1 
heterozygote and homozygote mutants a ~300bp band indicating rearrangement at the 
SETDB1 locus is detected. “+” and “-“ in the top gel indicate samples positive or negative 
for Cre, respectively. In the bottom gel “wt” indicates Setdb1 wild type samples, “h” and 
“H” indicate samples where Setdb1 is floxed in one allele (heterozygous) or both 
(homozygous) alleles, respectively. Setdb1 homozygous floxed samples are also 
indicated by a red asterisk. (B) Western blot for H3K9me3 and panH3 in FoxA3-Cre; 
SETDB1 +/fl and FoxA3-Cre; SETDB1 fl/fl. (C) Top: representative images of FoxA3-Cre; 
SETDB1 +/fl and FoxA3-Cre; SETDB1 fl/fl e11.5 embryos. Middle: transverse sections 
stained with hematoxylin & eosin (H&E) of e11.5 FoxA3-Cre; SETDB1 +/fl and FoxA3-
Cre; SETDB1 fl/fl embryos at the region indicated by the black, dashed line on top panels. 
Scale bar: 100 um. Bottom: H&E stained zoomed-in images of liver in FoxA3-Cre; 
SETDB1 +/fl and FoxA3-Cre; SETDB1 fl/fl e11.5 embryos. Scale bar: 50 um. (D) H&E 
staining and IHC for SETDB1, H3K9me3 and MUPs in 2-month old FoxA3-Cre; SETDB1 
+/fl and FoxA3-Cre; SETDB1 fl/fl (E) H&E staining in 2-month old Alb-Cre; SETDB1 +/fl 
and Alb-Cre; SETDB1 fl/fl. In both (D) and (E) black arrows indicate overly big hepatocytes 
maintaining SETDB1 expression. Scale bar: 50 um. 
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Fig. S17: Single cell RNA-Seq clustering and GO analysis of e11.5 wt and Setdb1 
mutant hepatoblasts.  
(A) Chart showing the optimal principal component (PC) for the data matrix of single cell 
RNA-Seq samples. (B) Histogram showing the optimal number of clusters for representing 
single cell RNA-Seq data. (C) t-distributed stochastic neighbor embedding (t-SNE) plot 
showing the three identified clusters. Wt and SETDB1 mutant cells are indicated as blue 
squares and red triangles, respectively. (D) t-SNE plot showing cell cycle phases in the 
sequenced cells. (E) Representative gene ontology categories for each of the three 
identified clusters. 
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Fig. S18: Loss of Suv39h enzymes’ effects on H3K9me3, and H3K9me3-related 
HMTase expression.  
(A) IHC of e12.5 wt and two Suv39h double null livers showing a mild reduction in 
H3K9me3 levels. (B) Expression levels of Setdb1, Suv39h1 and Suv39h2 during definitive 
endodermal cell differentiation along the hepatic and pancreatic lineages. 
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Fig S19: Strategy for the generation of Setdb1, Suv39h1, and Suv39h2 triple 
conditional mutant strain.  
(A) Strategy for generating Setdb1, Suv39h1 and Suv39h2 triple conditional mutant mice. 
(B) Schematic of Suv39h1 gene. LoxP sites are indicated as red triangles on Intron 2 and 
Intron 5. DNA sequencing identified proper insertion of loxP sites in mutant mice compared 
to control. (C) Schematic of cre-driven rearrangement on Suv39h1. (D) Genotyping of 
control and mutant DNA from 1-month old liver. Suv39h1 rearrangement can be identified 
as 192 bp band on agarose gel. Asterisk indicates unspecific band. (E) Schematic of 
Suv39h2 gene. DNA sequencing identified 4bp deletion at Exon2. (F) Genotyping of 
control and mutant DNA from 1-month old liver. 4bp deletion leads to a lower band in 18% 
acrylamide gel. 
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Fig. S20: TKO characterization and e11.5 scRNA-seq analysis.  
(A) Western blot for Setdb1, Suv39h1, Vinculin, H3K9me3 and H3 in ctrl and Setdb1, 
Suv39h1 and Suv39h2 triple knock-out (TKO) liver protein extracts. (B) IHC for Suv39h2 
in ctrl and Suv39h2 mutant livers. Scale bar: 50 um. (C) Western blot for H3K9me3, 
H3K9me2, H3K27me3 and panH3 in ctrl and TKO liver protein extracts. Please note that 
western blots in (A) and (C) have been performed using protein extracts from liver. Thus, 
in cells not expressing FoxA3 (e.g. biliary and endothelial cells), floxed alleles of Setdb1 
and Suv39h1 are not recombined. This explains the residual H3K9me3 signal. (D) tSNE 
plots of single cell RNA-Seq data from e11.5 Liv2+ cells, showing wt (top, blue squared) 
Setdb1 mutant (bottom, red triangles) and TKO albumin positive cells distribution. (E) 
Representative gene ontology categories for TKO cells shown in Fig.3A. 
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Fig. S21: One-month TKO characterization.  
(A) Chart indicating body weight (gr) of ctrl (n=5) and TKO (n=5) mice. (B) Spearman 
correlation of srHC-seq individual replicates in ctrl and TKO livers. (C) Spearman 
correlation of H3K9me3 ChIP-seq individual replicates in ctrl and TKO livers. (D) 
Spearman correlation of RNA-seq individual replicates in ctrl and TKO livers. (E) Volcano 
plot showing downregulated (red) and upregulated (green) genes in TKO livers compared 
to ctrl.  
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Fig. S22: TKO livers deregulate cell identity-related genes while chromosomal 
instability-associated markers’ expression is unchanged.  
(A) Western blot for MUPs and Vinculin in ctrl and TKO liver protein extracts. (B) 
IHC for MUPs and osteocalcin in ctrl and TKO mutant livers. Scale bar: 50 um. (C) 
Western blot for chromosome instability associated markers FOXM1 and mcm2 in 
ctrl and TKO livers. Vinculin was used as loading control. (D) IHC for mcm2 and 
H3K9me3 in ctrl and TKO mutant livers. Scale bar: 50 um. (E) Quantification of 
mcm2 positive cells in ctrl and TKO livers per 1,000 hepatocytes. 
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Fig. S23: Summary Model. 
Lineage-specific genes expressed in mature cells are marked by H3K9me3, buried 
into srHC domains, and thereby repressed in early, uncommitted cells. During cell 
differentiation, many cell-appropriate H3K9me3 heterochromatic genes are 
opened up and expressed, while cell-inappropriate genes remain heterochromatic 
and silent. 
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3.7.  Methods 
Mouse Strains 
Three weeks old F1 female progeny of C57BL/6 and CH3 crosses (B6C3F1) were 
regularly purchased from The Jackson Laboratory. Pdx1-eGFP, Ins-RFP, FoxA3Cre (28) 
were used as described. SETDB1fl/fl murine strain was a kind gift from Dr. Shinkai (30) . 
Mice deleted for SETDB1 in foregut endoderm were generated by mating FoxA3Cre; 
SETDB1fl/+ mice to one another. Suv39h1fl/fl and Suv39h2KO/KO mice were generated as 
described below. 
Dissections and cell preparation for sorting 
B6C3F1 females were superovulated by intraperitoneal injection (5 IU pregnant mare 
serum – PMSG, Prospec, cat# hor-272) followed, 48 h later, by a second injection (5 IU 
human chorionic gonadotropin - HCG, Peprotech cat#: 100-39-10UG), and then bred to 
C3H or Pdx1-eGFP or Ins-RFP males. To generate single cells for FACS, embryos at 
different developmental stages (i.e. e8.25, e10.5, e11.5, e18.5) were dissected out of 
decidua and collected in 1.5 ml tubes containing 1X PBS on ice. For e10.5 and e11.5 
embryos, most of the dorsal part (somites) was removed. E18.5 pancreata, clearly visible 
and easy to distinguish, were dissociated from the rest of the organs. Collected samples 
were dissociated with 0.05% Trypsin-EDTA (Life Technologies, #25300-054) for 5 min at 
37°C while gently shaking. The reaction was stopped by adding 0.4X volumes of FBS 
(Hyclone, SH30071). Explants were homogenized by gentle pipetting. Cells were spun 
down at 1500 rpm for 5min at 4°C, and the pellet was resuspended in 320 ul of IMDM (Life 
Technologies, #12440-053) (supplemented with L-glut – Life Technologies #25030-081, 
0.1%BSA - Sigma A9418-50G, 2.5% FBS - Hyclone, SH30071, 1X pen/strep – Life 
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Technologies, #15140-122). Twenty (20) ul were transferred into a new tube and 280 ul 
IMDM were added to it (negative control tube - i.e. samples non incubated with the primary 
antibody). E8.25 definitive endodermal cells were purified using an antibody detecting 
ENDM1 (dilution: 1:50) surface antigen(31–33). Mesoderm progenitor cells were purified 
using anti-Flk1 antibody (dilution1:50). E10.5 hepatoblasts were sorted from Pdx1-GFP 
transgenic embryos, staining the cells for the surface marker Liv2 (MBL, cat# D118-3, 
dilution: 1:100). At the same stage pancreatic precursor Pdx1-GFP positive cells were 
collected. A subpopulation of Liv2+/Pdx1-GFP+ cells was detected at E10.5, as previously 
reported  (33). These cells were not considered for further analysis. E11.5 hepatoblasts 
were sorted from wt embryos using the same antibody and conditions as for e10.5 
embryos. Cells were incubated for 30-40min with primary antibody. Tubes were flicked 
every 5-8min. One (1) ml IMDM (supplemented with L-glut – Life Technologies #25030-
081, 0.1%BSA - Sigma A9418-50G, 2.5% FBS - Hyclone, SH30071, 1X pen/strep – Life 
Technologies, #15140-122) was added to both the sample and negative ctrl tube. Cells 
were spun down at 1500 rpm for 5 min at 4°C and the pellet was resuspended in 300 ul 
of IMDM (supplemented with L-glut – Life Technologies #25030-081, 0.1% BSA - Sigma 
A9418-50G, 2.5% FBS - Hyclone, SH30071, 1X pen/strep – Life Technologies, #15140-
122). PE-conjugated goat anti rat IgG (Biolegend 405406) was added (dilution 1:300). 
Samples were mixed well and incubated for 30min on ice in the dark. Tubes were flicked 
every 5-8 min. One (1) ml IMDM (supplemented with L-glut – Life Technologies #25030-
081, 0.1% BSA - Sigma A9418-50G, 2.5% FBS - Hyclone, SH30071, 1X pen/strep – Life 
Technologies, #15140-122) was added to both the sample and negative ctrl tube. Cells 
were spun down at 1500 rpm for 5 min at 4°C and the pellet was resuspended in 400-800 
ul 1X PBS + 3% BSA (Sigma A9418-50G). Samples were filtered through a cell strainer 
(FALCON 5 ml polystyrene round-bottom tube with cell-strainer cap, #352235). Samples 
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were kept on ice until sorting. Mature beta cells were isolated from Ins-RFP transgenic 
embryos as described (34). 
Isolation of adult hepatocytes and sample preparation for chromatin-related assay 
Two (2) -month old mice were anesthetized using isoflurane (Butler Animal Health Supply, 
#029405) and monitored by paw pinch.  A V-shaped incision was used to reveal the 
abdominal cavity, the intestines moved aside, and a 22 or 24 gauge catheter (Midwest 
Veterinary Supply, #381423) was used to cannulate the venae cavae while liver perfusion 
media pumps into the liver, and the portal vein is immediately severed. 37°C liver perfusion 
media (Invitrogen #17701-038) and then liver digest media (Invitrogen #17703-034) are 
perfused through the liver (45mL each per animal).  Livers are dissociated with a cutting 
motion with cell scrapers in William’s E Medium (Sigma W4128) and strained through a 
100 um filter (BD 352360).   Hepatocytes are loosely pelleted by centrifugation at 50 g for 
5 min at 4°C.  Isolated hepatocytes were resuspended in 1% formaldehyde (Fisher 
Chemical F79-500) William’s E Medium (Sigma W4128) and rocked for 10 min at RT. 
Fixation was stopped by adding 2.5 M glycine (Fisher BioReagents BP381-1) followed by 
5 min incubation at RT. Samples were spun down 50 g for 5 min at 4°C. Cells were 
resuspended in RSB medium (10 mM Tris pH7.4, 10mM NaCl, 3mM MgCl2) freshly 
supplemented with 0.5% NP40, 0.1 mM PMSF and 1 Complete EDTA-free protease 
inhibitor cocktail tablet (Roche, #11873580001). Nuclei were isolated by douncing the 
samples for 25 strokes. Isolated nuclei were washed with Np40-free RSB medium and 
counted using a hemocytometer. Nuclei were aliquoted in 106 nuclei aliquots and 
resuspended in 2 ml ice-cold sonication buffer (10 mM Tris-HCL pH8, 100 mM NaCl, 1 
mM EDTA, 0.5 mM EGTA) freshly supplemented with 0.1% Na-deoxycholate (Sigma 
Aldrich, cat #D6750), 0.5% N-lauroylsarcosine (TEKnova, cat #S3379), 1 mM DTT, 0.1 
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mM PMSF and 1 Complete EDTA-free protease inhibitor cocktail tablet (Roche, 
#11873580001). Thirty thousand (30,000) cell aliquots were snap-frozen and stored at -
80 C. Sample sonication was performed using COVARIS (S22 Focused Ultrasonicator) 
and the following conditions: Incident peak power: 200; Duty Cycle: 10%; Burst/Cycle: 
200; Time: 10-12min. Chromatin immunoprecipitation on adult hepatocytes was 
performed as described in  (25). 
Isolation of one-month old liver cells and sample preparation for chromatin-related 
assay 
One (1) month old control and triple knockout (TKO) mutant liver were dissected and cut 
in pieces. A small piece was transferred to 1.5 ml tube. Samples were minced using 
dissecting scissors. One (1) ml ACK (Life Technologies, #A10492-01) solution was added 
and samples were incubated 5-7 min on ice. Samples were spun down at 1,500 rpm for 5 
min at 4°C; pellet was resuspended in 500 ul 1XPBS and dounced with microcentrifuge 
tubes pellet pestle (DWK Life Sciences – Kimble - #7495150000) for 10-15 sec on ice. 
Samples were spun down at 1,500 rpm for 5 min at 4°C. Pellets were resuspended in RT 
1 ml 1X PBS + 1% formaldehyde (Fisher Chemical F79-500), and incubated for 10 min at 
RT on rocking table. The reaction was stopped by adding 2M glycine (Fisher BioReagents 
BP381-1) and incubating the samples at RT for 5 min on a rocking table. Samples were 
spun down at 2,000 rpm for 10 min at 4°C. Samples were resuspended in 500 ul ice-cold 
washing buffer (1X PBS + 2% FBS - Hyclone, SH30071). Samples were spun down at 
2,000 rpm for 5 min at 4°C, twice. Sampled were resuspended in 1 ml nuclear lysis buffer 
(50mM Tris-Cl pH 8.0, 10mM EDTA, 1% SDS -Lonza, #51213, supplemented with 
protease inhibitors -1 tablet Complete Mini Protease inhibitor cocktail tablets (Roche, 
#04693159001) per 10 ml Buffer). Samples were incubated on ice for 15 minutes, flash 
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frozen and stored at -80°C until used. Samples were sonicated as indicated for adult 
hepatocytes. 
Generation of Suv39h1, Suv39h2 and SETDB1 triple mutant 
Suv39h1 and Suv39h2 loci were targeted using CRISPR-Cas9 technology via zygote 
injection as previously described (35). Specifically, since absence of either of the two 
HMTases can be compensated by the other (13), we decided to obtain a conditional 
mutant for Suv39h1 and a germ-line KO for Suv39h2. Sequences of the oligonucleotides 
used for inserting loxP sites in Suv39h1 intron 2 and 5, or ind/del on Suv39h2 exon2 are 
indicated in Table S5. Zygote injections were performed at the Transgenic and Chimeric 
Mouse Facility (Dept. Genetics) at University of Pennsylvania. Genotyping was performed 
using the primers indicated on Table S5 as indicated in (36). For experiments where triple 
knockout (TKO) mutants were considered, controls were FoxA3-Cre negative; Setdb1 
floxed/floxed; Suv39h1 floxed/floxed; Suv39h2 del/del. 
RT-qPCR sample preparation 
Total RNA was isolated using RNeasy Micro Kit (Qiagen, ID:74004) following 
manufacturers’ instruction. RNA was reverse transcribed using Biorad iScript cDNA 
synthesis kit (bio-Rad #1708891). cDNA was pre-amplified with Taqman probes diluted 
100-fold. Preamplified cDNA was then subjected to qPCR using specific Taqman probes. 
Delta-delta Ct analysis was performed. Taqman probes and primers used in this study are 
listed in Table S1. 
Sample preparation for chromatin-related assays 
We provide here a detailed protocol describing how to prepare low cell number sample for 
chromatin-related experiments. 
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1. Notes 
The following protocol is modified from O’Geen, et al. (37) and recommended for small 
cell number ChIP-seq and is based on successful 3 x 104 cells for ChIP-seq with H3K9me3 
and H3K27me3 antibodies in mouse sorted cells isolated by FACS with cell surface 
markers at different developmental stages (i.e. e8.25, e10.5). Please note for optimal DNA 
recovery when purifying ChIP, use a Phenol Chloroform method. This protocol was 
chosen due to its high specificity and low background.  
2. Buffers 
Cell Lysis Buffer (make 10 ml fresh each time) 
3 mM MgCl2 
10 mM NaCl 
10 mM Tris, pH 7.4 
0.1% Igepal (Sigma Aldrich, cat #I8896) 
Add protease inhibitors (1 tablet Complete Mini Protease inhibitor cocktail tablets 
- Roche, #04693159001-, per 10 ml Buffer).  
Nuclei Lysis Buffer (prepare it fresh each time)  
50 mM Tris-Cl pH 8.0 
10 mM EDTA 
1% SDS (Lonza, #51213) 
Before use, add protease inhibitors (1 tablet Complete Mini Protease inhibitor 
cocktail tablets - Roche, #04693159001- per 10 ml Buffer. Never store at 4C). 
IP Dilution Buffer (RIPA)  
50 mM Tris pH 7.4 
150 mM NaCl 
1% Igepal (Sigma Aldrich, cat #I8896) 
0.25% Sodium Deoxycholate (Sigma Aldrich, cat #D6750) 
1mM EDTA 
Add protease inhibitors (1 tablet Complete Mini Protease inhibitor cocktail tablets 
- Roche, #04693159001- per 10 ml Buffer). 
IP Wash Buffer 1  
(RIPA without protease inhibitors; place it on ice after preparation) 
50 mM Tris pH 7.4 
150 mM NaCl 
1% Igepal (Sigma Aldrich, cat #I8896) 
0.25% Deoxycholic Acid (Sigma Aldrich, cat #D6750) 
1mM EDTA 
IP Wash Buffer 2  
(place it on ice after preparation) 
100 mM Tris-Cl pH 9.0 
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500 mM LiCl 
1% Igepal (Sigma Aldrich, cat #I8896) 
1% Deoxycholic acid (Sigma Aldrich, cat #D6750) 
IP Wash Buffer 3 (IP Wash Buffer 2 plus NaCl; place it on ice after preparation) 
100 mM Tris-Cl pH 9.0 
500 mM LiCl 
1% Igepal (Sigma Aldrich, cat #I8896) 
1% Deoxycholic acid (Sigma Aldrich, cat #D6750) 
150 mM NaCl 
Elution Buffer  
50 mM NaHCO3 
1% SDS (Lonza, #51213) 
3. Cell crosslinking: 
The following has been optimized for crosslinking sorted cells: 
a. Use FACs to sort > 104 cells into 1.5 ml tube, containing 50 ul 1X PBS 
supplemented with 1% BSA (Sigma A9418-50G) and 20% FBS  (Hyclone, 
SH30071). Spin down the cells at 1700 rpm for 12-15 min at 4°C. Resuspend 
the pellet in 200-300ul PBS freshly prepared. Prepare 3 x 104 cells aliquots in 
500ul PBS or alternatively, if you have a lot of cells, prepare 1-3 x 105 cells 
aliquots. 
b. Add 13.5 ul of 37% formaldehyde (Fisher Chemical F79-500) per 500 ul 
sample. Incubate exactly 10 min at room temp. on rotating platform. 
c. Stop crosslinking reaction by adding 36 ul of 2M glycine (Fisher BioReagents 
BP381-1) to the sample. Incubate 5 min at room temp. on rotating platform. 
d. Centrifuge at 2000 rpm for 15 min at 4°C 
e. Wash cells twice in cold PBS supplemented with 2% FBS  (Hyclone, 
SH30071). For each wash, centrifuge at 2000 RPM for 5 min. Slowly aspirate 
supernatant with pipetman, leaving approximately 10 ul of solution behind. Be 
careful to not disturb the pellet.    
4. Preparation of chromatin from crosslinked cells: 
a. If you have > 105 cells, resuspend cells in 300 ul freshly prepared cell lysis 
buffer and incubate on ice for 15 min. Centrifuge at 5000 rpm for 5 min at 4°C. 
Repeat centrifugation if cell lysate is not visible. Remove supernatant with 
pipetman, leaving pellet. Leave approximately 10 ul of supernatant. If starting 
with < 105 cells, proceed to step 2. 
b. Prepare aliquots of 3 x 104 cells in 130 ul Nuclei Lysis Buffer. 
c. Incubate on ice for 15 min, flash freeze (use dry ice or liquid nitrogen), then 
thaw to room temperature to aid in lysis. (You may keep chromatin at -80°C 
until a future day and then thaw to room temperature). 
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d. Sonicate with predetermined conditions so that chromatin is between 200 and 
500 bp in length. If using Covaris (S220 Focused Ultrasonicator) for chromatin 
sonication apply the following parameters (identified after time course 
experiment – see panel below): 
i. Incident peak power: 200 
ii. Duty Cycle: 5% 
iii. Burst/Cycle: 200 
iv. Time: 10-12 min 
e. Centrifuge sonicated chromatin for 10 min at 14K rpm at 4°C, collect 
supernatant and either use immediately in ChIP experiment or freeze at -80°C. 
 
Panel A: COVARIS sonication time course on 30,000 cell aliquots using two different set 
of parameters. Condition B (12 min) is the one used in this paper. 
5. Checking sonicated chromatin: 
a. Collect about 3*103 cells and resuspend them in elution buffer (50 mM Tris-
HCl, pH 8.0; 10 mM EDTA; 1% SDS - Lonza, #51213) 
b. Reverse crosslink at 65°C o/n on heat block 
c. Add 200 ul TE buffer (to dilute SDS - Lonza, #51213) 
d. Add 8 ul of 10 mg/ml RNase A (Roche, #10109169001) and incubate samples 
for 1.5-2 h at 37°C 
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e. Add 4ul Proteinase K (20mg/ml stock) (Roche, #03115828001) and incubate 
1.5-2 h at 55°C 
f. Precipitate DNA with standard phenol-chloroform protocol 
g. Transfer the aqueous phase to a new tube 
h. Add 16 ul of 5 M NaCl, 1.5 ul of 20 mg/ml glycogen (Roche, #10901393001) 
and 800 ul 100% EtOH 
i. Place the samples at -80°C for a couple of hours (you can do this step o/n) 
j. Pellet DNA spinning the samples at 15,000 rpm for 12 min at 4°C (pellet is 
faint!) 
k. Wash with 500 ul 80% EtOH, once 
l. Pellet DNA spinning the samples at 15,000 rpm for 12 min at 4°C 
m. Air dry the pellet and resuspend in 15 ul TE buffer (remove EtOH) 
n. Spin vacuum the samples and resuspend them in 3ul H2O containing 10% 
glycerol 
o. Prepare 1% agarose gel (as thin as possible) without Ethidium Bromide 
p. Load the samples and marker  
q. Run the gel at 90V for 40-45 min 
r. Stain the gel (10 ug/ml final concentration) for 15 min RT while shaking 
s. Wash the gel 5 min RT while shaking in ddH2O 
t. Image the gel. 
u. Note: the sonication can be checked with the Bioanalyzer (Agilent 
Technologies G2939AA) by resuspending the samples from step 14 in water 
(3 ul). 
Chromatin Immunoprecipitation (ChIP) on low cell number samples: 
We provide here a detailed protocol describing how to perform chromatin 
immunoprecipitation and how to obtain samples ready to be used for libraries preparation 
starting from low cell number samples. 
6. Immunoprecipitation 
a. Transfer sonicated chromatin into 0.6 ml Axygen Maxymum Recovery 
microtubes (MCT-060-L-C, #311-03-051). Dilute chromatin with Dilution Buffer 
to a final volume of 500 ul. For input, take 5 ul (1%) from the 500ul containing 
sheared chromatin and transfer to new tube containing 100 ul elution buffer. 
b. Add 1 ug of primary ChIP-grade antibody and incubate overnight on a rotating 
platform at 4°C. 
c. Add 15 ul Cell Signaling ChIP-grade Protein G magnetic Beads (Invitrogen 
#10004D) and incubate 2 h on rotating platform at 4°C. 
d. Transfer chromatin and beads to a pre-chilled 1.5 ml microtubes and allow 
beads to separate in magnetic rack (Thermo Fisher Scientific, #12321D) for > 
30 se. 
e. Remove supernatant with pipetman. Using suction may cause you to lose 
beads and sample.  
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f. Remove tube from rack, resuspend beads in IP Wash Buffer 1, and wash by 
pipetting up and down 12 times. 
g. Place tubes in magnetic rack  (Thermo Fisher Scientific, #12321D) and allow 
beads to separate for > 30 sec. 
h. Repeat steps 5-7 once. 
i. Remove supernatant with pipetman. 
j. Remove tubes from rack, resuspend beads in IP Wash Buffer 2, and wash by 
pipetting up and down 12 times. 
k.  Place tubes in magnetic rack (Thermo Fisher Scientific, #12321D) and allow 
beads to separate for > 30 sec. 
l. Repeat steps 9-11 2 times. 
m.  Remove supernatant with pipetman. 
n.  Remove tubes from rack, resuspend beads in IP Wash Buffer 3, and wash by 
pipetting up and down 12 times. 
o.  Transfer beads and chromatin to a new 1.5 ml microtube. 
p.  Place in magnetic rack (Thermo Fisher Scientific, #12321D) and allow beads 
to separate for > 30 seconds. 
q.  Remove tubes from rack and resuspend in 100 ul Elution Buffer. 
r.  Shake at RT at a setting of 1300 rpm for 1 h. 
s.  Place tubes in magnetic rack (Thermo Fisher Scientific, #12321D) and allow 
beads to separate for > 30 seconds.  
t.  Collect supernatant and add 12 ul 5M NaCl. 
u. Thaw the input and add 12ul 5M NaCl 
v.  Incubate 4 hours to overnight at 65°C. 
w.  Add 3 ul of 10 mg/ml RNase A (Roche, #10109169001) to each sample and 
incubate at 37°C for 30 min. 
7. Phenol Chloroform sample purification 
a. Spin down Phase Lock Gel Light 1.5 ml tube (5 Prime, QuantaBio, #2302820) 
at 14000 rpm for 30 sec. 
b. Add 100 ul TE buffer to each samples (including input) and mix gently (total 
volume 200 ul) 
c. Mix 200 ul ChIP product and 200 ul Phenol/Chloroform/Isoamyl Alcohol by 
pipetting about 10 times and add to Phase Lock Gel Light 1.5 ml tube. Do not 
vortex. 
d. Centrifuge at room temperature for 5 minutes at 14000 rpm. 
e. Optional: Add an additional 200 ul of Phenol/Chloroform/Isoamyl Alcohol and 
mix by pipetting. 
f. Centrifuge at room temperature for 5 min at 14000 rpm. 
g. Collect aqueous solution on top and add to a new tube (should be about 200 
ul). If the volume is less than 200 ul, add Buffer TE to reach 200 ul.  
h. Add 8 ul 5M NaCl, 10 ug glycogen, and 400 ul cold 100% ethanol, and mix. 
i. Precipitate DNA in ethanol at -80°C overnight at least for best recovery.  
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j. Centrifuge at 4°C for 10 min at 11000 rpm. 
k. Aspirate supernatant carefully, without disturbing the very small white pellet. 
To be safe, you may leave 5 ul at the bottom. 
l.  Wash with 500 ul 80% ethanol by pipetting five times. 
m.  Centrifuge at 4°C for 10 min at 11000 rpm. 
n.  Aspirate supernatant carefully, without disturbing the very small white pellet.  
o.  Air dry 5 min, or until ethanol has evaporated, but pellet isn’t completely dry. 
If pellet is too dry, it will be difficult to resuspend. 
p. Resuspend pellet in 30-40 ul Qiagen EB. It is now ready for qPCR. For library 
preparation resuspend the pellet in less volume (e.g. 10 ul).  
srHC isolation and sample preparation for sequencing:  
We provide a detailed protocol describing how to perform isolation of srHC and how to 
obtain samples ready to be used for libraries preparation starting from low cell number 
samples. Related publications at (38–40) 
1. Reagents 
Agencourt® AMPure® XP (Beckman Coulter, cat. no. A63881)  
80% EtOH 
Buffer EB 
10 mM Tris-Cl, pH 8.5) 
Glycine (2M solution) (Fisher BioReagents BP381-1) 
nuclear lysis buffer  
50mM Tris-Cl pH 8.0 
10mM EDTA 
1% SDS - Lonza, #51213, supplemented with protease inhibitors 
TE buffer 
10 mM Tris·Cl, pH 8.0 
1 mM EDTA 
RNase A (Roche, #10109169001) 
Glycogen (Roche, #10901393001) 
2. Equipment 
COVARIS S220 (Focused Ultrasonicator S220) 
microTUBE AFA Fiber Pre-Slit Snap-Cap (COVARIS, cat. #520045) 
DynaMag™-2 Magnet (Thermo Fisher Scientific, #12321D) 
Agilent 2100 Bioanalyzer system (Agilent Technologies, G2939AA) 
Eppendorf Tubes 
3. Cell preparation 
a. Prepare thirty thousand (30,000) cell aliquots in 500 ul PBS from sorted cells. 
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b. Add 13.5 ul of 37% formaldehyde (Fisher Chemical F79-500) per 500 ul 
sample.  
c. Incubate samples 10 min at RT on rotating platform. 
d. Stop crosslinking reaction by adding 36 ul of 2M glycine (Fisher BioReagents 
BP381-1) to each sample. 
e. Incubate samples for 5 min incubation at RT on rotating platform. 
f. Centrifuge samples at 2000 RPM for 15 min at 4°C. 
g. Wash cells twice in cold PBS (use 10 ul of FBS - Hyclone, SH30071, in 500 ul 
of PBS). For each wash, centrifuge samples at 2000 rpm for 5 min at 4°C. 
Slowly aspirate supernatant with pipetman, leaving approximately 10 ul of 
solution behind. 
h. Resuspend the cells in 130 ul nuclear lysis buffer (50mM Tris-Cl pH 8.0, 10mM 
EDTA, 1% SDS - Lonza, #51213, supplemented with protease inhibitors - 1 
tablet Complete Mini Protease inhibitor cocktail tablets - Roche, 
#04693159001-  per 10 ml Buffer). 
4. Chromatin Sonication 
a. Sonicate chromatin using COVARIS S220 following these parameters: 
i. Peak Power  200 
ii. Duty Cycle  5% 
iii. Burst/Cycle  200 
iv. Time   10’ 
5.  DNA purification 
a. Adjust sample volume to 200 ul with nuclear lysis buffer. 
b. Reverse crosslinking by incubating samples at 65°C for 18h on heat block. 
c. Add 200 ul TE buffer (10 mM Tris·Cl, pH 8.0, 1 mM EDTA), 8 ul of 10 mg/ml 
RNase A (Roche, #10109169001) to the samples.  
d. Incubate the samples for 2 h at 37°C. 
e. Add 4 ul, 20 mg/ml Proteinase K (Roche, #03115828001) to the samples.  
f. Incubate the samples for 2 h at 55°C. 
g. Purify DNA using conventional phenol:chloroform:isoamyl extraction. Briefly, 
add 400 ul phenol:chloroform:isoamyl mix to each sample. Mix and quickly 
vortex the samples. 
h. Spin down the samples at max speed for 5 min at RT. 
i. Transfer 350 ul of aqueous phase to a new eppendorf 
j. Add 16 ul 5M NaCl, 1.5 ul 20mg/ml glycogen (Roche, #10901393001) and 800 
ul 100% EtOH to each sample. 
k. Mix the samples thoroughly by inverting the tube 10-15 times. 
l. Incubate the samples are incubated overnight at -80°C. 
m. Centrifuge the samples for 10 min at max speed at 4°C. 
n. Wash the samples with 500 ul 80% EtOH. 
o. Centrifuge the samples for 10 min at max speed at 4°C. 
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p. Air-dry sample pellet at RT 5 min and resuspend it in 21 ul EB buffer. 
q. Save 1 ul purified DNA for checking sonication at the Bioanalyzer (Agilent 
Technologies, G2939AA) in parallel with further processed samples. 
6. Sonication-resistant chromatin selection 
a. Add 0.7X AMPure XP beads (Beckman Coulter, A63881) to the each sample 
(14ul in 20ul initial solution). Please note that the amount of AMPure XP beads 
indicated has been optimized for 3*103 cell samples. Samples of different cell 
number might require adjustment in AMPure XP beads:volume ratio. 
b. Mix samples thoroughly by pipetting 10-12 times. 
c. Incubate samples at RT for 5 min. 
d. Transfer eppendorf tubes to a magnetic rack (Thermo Fisher Scientific, 
#12321D) and beads are allowed to separate for 5 min at RT. 
e. Transfer clear solution to a new eppendorf tube (this fraction is the small, 
sonication-sensitive fragments). 
f. Wash beads (to which large, sonication-resistant fragments are bound) with 
200ul EtOH 80% while tubes are maintained on rack.  
g. Incubate samples for 30 sec with EtOH. 
h. Remove EtOH and wash once more each sample. 
i. Air-dry beads 5 min while tubes are kept on the rack.  
j. Remover tubes from the rack 
k. Elute the beads in 20 ul TE buffer, by pipetting thoroughly. 
l. Save 1 ul purified DNA before further sonication to check samples size at the 
Bioanalyzer (Agilent Technologies, G2939AA) in parallel with further 
processed samples. 
m. Incubate the samples are incubated 5 min at RT.  
n. Place the samples on the magnetic rack (Thermo Fisher Scientific, #12321D). 
o. Incubate the samples for 5 min. 
p. Transfer clear solution to a new tube (this fraction is the large, sonication-
resistant portion of DNA). 
7. Sonication of large DNA fragments 
a. Adjust sample volume to 130 ul adding TE buffer.  
b. Sonicate the samples using COVARIS S220 (Focused Ultrasonicator S220) 
following these parameters: 
i. Peak Power  175 
ii. Duty Cycle  10% 
iii. Burst/Cycle  200 
iv. Time   6’ 
c. Adjust sample volume to 200 ul with TE buffer. DNA precipitation can be 
applied also to small, sonication-sensitive sample. 
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d. Add 1 ul of 20 mg/ml glycogen (Roche, #10901393001), 1/10 volume of sodium 
acetate (3 M, pH 5.2) and 3.0X volume EtOH 100% to each sample 
e. Mix the samples thoroughly by inverting the tube 10-15 times. 
f. Incubate the samples 4 h at -80°C. 
g. Centrifuge the samples for 10 min at max speed at 4°C. 
h. Wash the samples with 500 ul 80% EtOH. 
i. Centrifuge the samples for 10 min at max speed at 4°C. 
j. Air-dry sample pellet at RT 5 min and resuspend it in 11 ul EB buffer. 
k. Save 1 ul of purified DNA for checking sonication at the Bioanalyzer (Agilent 
Technologies, G2939AA) in parallel with further processed samples 
Sample preparation of polyA-selected RNA for sequencing: 
Two replicates were used for each stage. Total RNA was isolated from 3*104 cell aliquots 
using RNeasy Micro Kit (Qiagen, ID:74004) following manufacturers’ instruction. Total 
RNA was resuspended in 50 ul BTE solution (10 mM Bis-tris pH6.7, 1 mM EDTA). RNA 
secondary structures were removed by heating the samples at 65°C for 5 min, followed 
by incubation on ice. Oligo-dT25 dynabeads (Invitrogen #610-02) were used for selecting 
polyA mRNA. Beads were washed 3 times with 2X Oligo-dT binding buffer (OBB: 20 mM 
Tris ph7.5, 1 M LiCl, 2 mM EDTA), resuspended in 50 ul 2X OBB and added to RNA. 
Samples were incubated 5-10 min at RT while gently shaking. Samples were transferred 
to a  (Thermo Fisher Scientific, #12321D) rack, and beads were allowed to separate for 
3-5 min. Beads were washed 3 times with 200 ul Oligo-dT washing buffer (OWB: 10 mM 
Tris Ph7.5, 150 mM LiCl, 1 mM EDTA) and polyA mRNA was eluted into 10 ul BTE. 
Samples were incubated 2 min at 80°C and beads were allowed to separate on the 
magnetic rack (Thermo Fisher Scientific, #12321D). The solution was transferred to a 
fresh tube. Chemical RNA fragmentation was achieved using Mg2+. On ice, for each 10 ul 
sample volume, 4 ul 5X 1st strand buffer from SuperScript III RT kit (Invitrogen #18080-
044) and 2 ul 50 uM random hexamers (Roche) were added. Samples were incubated 16 
min at 94°C in PCR machine and ramped down to 4°C. First strand synthesis was 
139 
 
performed using SuperScript III (Invitrogen #18080-044), following manufacturers’’ 
instructions and adding 1ug actinomycin D (Sigma #A1410) per reaction. Samples were 
incubated in PCR machine according to the following scheme: 10 min at 25°C, 20 min at 
42°C, 30 min at 50°C, 10 min at 55°C. Samples were kept on ice. First strand cDNA was 
purified using conventional phenol:chloroform:isoamyl extraction. cDNA was precipitated 
using 3 M NaAc, 1 ul 20mg/ml glycogen (Roche, #10901393001) and  1 ml 100% EtOH. 
Samples were resuspended in milliQ water. Second strand synthesis incorporating dUTP 
was performed as following: for each sample, 2 ul First Strand bugger (from SuperScript 
III kit; Invitrogen #18080-044), 0.5 ul 0.1 M DTT, 5 ul 10X second strand buffer (dNTPs 
free; NEBnext #B6117S), 2 ul 10 mM dNTPs (with dUPT substituting in place of dTTP), 2 
ul DNApol I (20 U; NEB #M0209), 0.5 ul RNAseH (2.5 U: NEB #M0297) were added. 
Samples were incubated 2-3 h at 16°C. cDNA was purified using MiniElute kit (Qiagen, 
#28004) and samples were eluted in 10 ul RNase-free water.  
Spike-in ChIP-Seq and srHC experiments: 
H2A.v ChIP-seq data were aligned to the Drosophila genome assembly dm6/BDGP R6 
using bwa version 0.7.10 with default parameters. Tags were extended to 200 bp and 
H2A.v peaks were called using SICER-rb (redundancy threshold 1, window size 200 bp, 
fragment size 200 bp, effective genome fraction 0.72, gap size 200 bp, E-value cutoff 0.1). 
The resulting peak regions were used to construct a bwa index and H3K9me3 and input 
data were aligned to this “H2A.v-ome” as well as to the standard mm9/NCBI v37 genome 
using bwa. Aligned tags were extended 200 bp to match the fragment size. Mouse-aligned 
read density was visualized similar to non-spiked-in H3K9me3, except that tracks are also 
scalar adjusted for the ratio of control:mutant spike-in tags as in (41). Because there is no 
logical pairing between mutant (n=2) and control (n=1, two technical repeats) samples, we 
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averaged control samples for each mutant. For srHC spike-in experiments DNA was 
purified from Ctrl (n=1, three technical repeats) and TKO (n=2) samples. 500 ng of purified 
DNA was considered to perform the chromatin fractions separation. Large and small 
fractions were purified and quantified Qubit 3.0 (Invitrogen) and 50 pg of Drospohila DNA 
was spiked-in in each sample, before dilution and librarie preparation. 
Western blotting 
Sample preparation, gel run and signal detection were performed as described in (25), 
with the following modifications: samples were denatured for 5 min at 95°C. Wet transfer 
was performed using in house-made transfer buffer (25 mM of Tris, 192 mM of glycine - 
Fisher BioReagents BP381-1, 20% methanol). Antibodies used in this study are listed on 
Table S3. For Thermo Scientific antibodies, the presented results have been achieved 
using the indicated lot numbers. 
Immunohistochemistry 
Embryos or tissues were fixed in 2% PFA (Electron Microscopy Sciences, #15714-S) o/n 
at 4°C. Samples were washed 3 times in 1X PBS and subjected to dehydration through 
sequential 15 min washes at increasing concentration of methanol in 1X PBS (25% - 50% 
- 75% -100%). Samples were washed twice with 100% EtOH, and stored at -20°C until 
further processed. Samples were equilibrated in 70% EtOH 1X PBS before paraffin 
embedding and sectioning. Sections were deparaffinized through two sequential 5 min 
washes in Xylenes (Fisher Chemical, X3P-1GAL), and reducing concentration of EtOH 
(100%, two washes; 95% EtOH, 75% EtOH, 50% EtOH, one wash). Samples were rinsed 
with water, immersed in sodium citrate buffer (10 mM Na-Citrate, pH6.0) supplemented 
with 0.05% Tween20 (Sigma Aldrich, cat #P1379) and microwaved for 2 min at Power 
Level 10, followed by 13 min microwaving incubation at Power Level 2. Samples were 
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cooled for 20 min at RT and washed 2-3 times in milliQ water for 5 min. Samples were 
washed 3 times in 1X PBS and endogenous peroxidases were quenched immersing the 
samples in 3% H2O2 solution (Sigma H1009-500ml) for 30 min at RT. Samples were 
washed 3 times in 1X PBS and blocking buffer (Thermo Fisher, Pierce Protein-Free T20 
PBS blocking buffer, #37573) for 2-3h at RT. Primary antibodies were diluted in blocking 
buffer and samples were incubated o/n at 4°C. Samples were washed 3 times for 5 min 
with 1X PBS supplemented with 0.1% Tween20 (Sigma Aldrich, cat #P1379) (PBS-T). 
HRP-conjugated secondary antibodies were diluted in 1X PBS-T and samples were 
incubated 1h at 37C. Samples were washed 3 times for 5 min with 1X PBS-T. DAB 
peroxidase staining (Vector, SK-4100) was performed following manufacturers’ 
instructions. Reaction was stopped by immersing the samples in milliQ water. Samples 
were counterstained with Eosin (Millipore, #109844.1000) and dehydrated through 
sequential 2 min washes in 95% and 100% EtOH, followed by two 2 min washes in Xylene. 
Permount (Fisher, #SP15-500) was used as mounting solution. For Thermo Scientific 
Suv39h2 antibody, the presented results have been achieved using the indicated lot 
number. Antibodies used in this study are listed on Table S3. 
Library preparation and next-generation sequencing: 
Libraries were generated using ThruPLEX DNA-seq 48S Kit (Rubicon Genomics, 
#R400427). Libraries were quantified by qPCR using the NEBNext Library quantification 
kit for Illumina (NEB, #E7630L). Libraries were diluted to 8 nM and pooled for multiplexing. 
The diluted concentrations and were quantified a second time using NEBNext kit. Libraries 
were denatured in 0.2 M NaOH and loaded into NextSeq 75-cycles High Output v2 Kit 
(Illumina, FC-404-2005) cartridge at a concentration of 2.5-3 pM. Sequencing runs were 
performed in an Illumina NextSeq 500 machine. 
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Bioinformatics 
H3K9me3 ChIP-seq data for P0 heart and nucleus accumbens were downloaded from 
GSM2192520 and GSE24850, respectively. ChIP-seq data were aligned to mouse 
genome assembly mm9/NCBI v37 using bowtie2, version 2.1.0, using the --very-sensitive 
parameter setting. Read density was visualized using the UCSC Genome Browser to 
display bigWigs created with BEDTools genomeCoverageBed and UCSC Genome 
Browser’s bedGraphToBigWig utility with a normalization step that adjusts each track to 
the library size (RPM) and which takes the fold-change of H3K9me3/Input. RNA-seq data 
were aligned using STAR version 2.5.2 and default parameters, then processed to get 
read counts per gene with HTSeq version 0.6.1. Resulting counts were analyzed for 
significant differential expression using DESeq (standard binomial test with an FDR control 
of 0.1). Spearman correlations were calculated as described in (25) using a 2 kb sliding 
window algorithm, with a sliding step of 1 kb for H3K9me3 and H3K27me3 and 10 kb 
sliding window algorithm, with a sliding step of 1 kb for srHC.  
Calling enriched genomic domains 
Enriched genomic domains (i.e. patches) were called as described in (25), with the 
following modifications. For H3K9me3 and H3K27me3 we used 2 kb sliding window 
algorithm, with a sliding step of 1 kb. For srHC we used 10 kb sliding window algorithm, 
with a sliding step of 1 kb. Fixed percentile enrichment thresholds were applied (to 30% 
for H3K9me3, top 20% for H3K27me3 and top 40% for srHC. A representative example 
of patch calling is indicated on panel B). For spike-in enriched genomic domains calling, 
the threshold value identified upon applied the fixed percentile in the control samples, was 
considered for setting the mutant threshold.  RefSeq genes were considered decorated 
(i.e. patched) if at least 25% of the gene body was covered by called domain(s). For 
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H3K27me3 compensatory effect over H3K9me3, genes not changing expression across 
the indicated time-course (expression ratio of definitive endoderm to hepatocytes or 
mature beta cells < 1.1X) and going from being H3K9me3 patched (> 50% of the gene 
body overlapping the domain class) to unpatched (< 25% of the gene body overlapping 
the domain class) were considered. The area under the curve (AUCs) was computed for 
H3K27me3 and H3K9me3 over those genes. For each experiment, biological replicates 
have been pooled together. Downstream analysis has been performed on pooled 
replicates. 
 
Panel B: Representative example of H3K9me3 patch calling for three indicated cell types. 
Top row shows histograms of Chip over input normalized reads per bin (2kb) and the cutoff 
threshold considered to call patches in the top 30% values. Bottom row shows two 
representative genome track examples showing three different thresholds considered to 
call patches. 
Random down-sampling and data confirmation 
Difference in the number of aligned reads might lead to artifact upon normalization. To 
assess the effect of genomic coverage on H3K9me3 patch definitions, we randomly down-
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sampled the H3K9me3 and input tag counts (after pooling replicates) to one of six cutoffs 
(5M-10M-15M-20M-25M-30M). If the number of tags for a given sample was already under 
the cutoff, it was left as-is. Patches were then re-called using the pipeline used in the 
manuscript. The chart below shows the result of our down-sampling analysis. 
 
Panel C: Percentage of original H3K9me3 domain sequence covered upon down-
sampling. 
 
After patch calling, we counted the number of base-pair positions in the mouse 
genome covered by the original patches, then calculated the % bases still covered after 
down-sampling. We found that even at the limit of 5 million tags, the percentage of patch 
sequence called does not drop below half the original called, and even at the 10 million 
tag limit we are still calling between 70-80% of the original sequence for all samples but 
hepatoblasts. The table below shows the number of genes marked by H3K9me3 in the 
indicated stages after processing random down-sampled from initial reads to 10M and 
30M. No matter how many reads were considered, the number of genes marked by 
H3K9me3 is highest in definitive endoderm and mesoderm progenitors and lower in the 
other developmental stages, confirming the data presented in this manuscript. 
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Panel D: Number of genes marked by H3K9me3 upon down-sampling in the indicated 
samples 
 
We also regenerated fig. S13 using randomly down-sampled data. Down-sampling 
of the data at 30M and 10M recapitulate accurately the figure originally presented in the 
manuscript. 
 
Panel E: fig. S13 recreated using randomly down-sampled data. Tracks have been 
generated using 10M down-sampled data; H3K9me3 domains have been identified using 
10M and 30M down-sampled data. 
Alluvial Plot generation 
Patches of preferential heterochromatin were divided into 1 kb windows, and all windows 
in at least one patch in any of definitive endoderm, hepatocytes, or mature beta cells were 
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scored for patch membership in each stage. A histogram of all windows was made and a 
table of window frequencies (e.g., patched in Def. Endo., unpatched in hepatocytes, 
patched in mature beta cells maps to N windows) was passed as input to the alluvial library 
in R. Alluvia passing through a patched state in definitive endoderm were colored dark 
gray, and those passing through an unpatched state in definitive endoderm were colored 
light gray.  
Assessing overlap between srHC and Hi-C data 
A-B compartment data from series GSE93431 were downloaded from NCBI GEO. Briefly, 
dominant eigenvector assignments from the untreated 20 kb cis contact map were 
downloaded and positive scoring, contiguous regions were treated as A compartments 
and negative scoring, contiguous regions were treated as B compartments. To assess the 
significance of overlap between A or B compartments and large srHC-seq domains, a 
circular shuffling approach was employed. First, the number of srHC-seq domains with at 
least 50% overlap by nucleotide with one or more compartments of a specified type was 
calculated. Next, a background overlap distribution was estimated by circular shuffling the 
SRHC-domains 1,000 times, in each iteration testing whether the overlap at 50% was 
greater than or equal to the observed overlap. The p-value was estimated at the number 
of iterations over 1,000 in which the shuffled overlap met or exceeded the observed 
overlap. 
RNA-Seq data clustering analysis 
From the DESeq value adjusted table, non-expressed genes and genes expressed in 1 
single developmental stage were removed (total discarded gene = 6,665). Unique values 
were considered by removing duplicates. The final total number of genes considered for 
the clustering analysis was 17,570. Automated fuzzy c-means clustering was obtained 
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using the following software (http://computproteomics.bmb.sdu.dk) (42). Gene ontology 
analysis of individual clusters (Table S14) was performed using David 
(https://david.ncifcrf.gov) (43, 44) or GOrilla (http://cbl-gorilla.cs.technion.ac.il) (45, 46). 
Single cell RNA-Seq sample preparation and data analysis 
E11.5 Liv2+ sorted cells from wt (n=7) and FoxA3-Cre;SETDB1fl/fl (n=3) embryos were 
fixed with methanol and stored at -80°C (47). For rehydration, cells were moved from -
80°C to 4°C and kept on ice throughout the procedure. Cells were pelleted at 3000 x g, 
resuspended in PBS + 0.01% BSA (Sigma A9418-50G), centrifuged again, resuspended 
in PBS + 0.01% BSA (Sigma A9418-50G), passed through a 40 μm cell strainer, counted, 
and diluted for Drop-seq in PBS + 0.01% BSA (Sigma A9418-50G). To assess the single-
cell resolution of the procedure we spiked in 10% of 293T cells in the mouse embryo single 
cell suspension. The final concentration of cells was 100 cells/ul and approximately 1.5 ml 
of cell suspension was loaded for each Drop-seq run. Barcoded beads were resuspended 
in lysis buffer (200 mM Tris-HCl pH 8.0RT, 20 mM EDTA, 6% Ficoll PM-400 - GE 
Healthcare/Fisher Scientific -, 0.2% Sarkosyl - Sigma-Aldrich -, and 50 mM DTT - 
Fermentas; freshly made on the day of run) at a concentration of 120 beads/ml. The flow 
rate for cells and beads were set to 4,000 ml/h, while droplet generation oil (Bio-rad) was 
run at 15,000 ml/h. The droplets were then generated and collected in a 50 ml falcon tube 
for a run time of 15 min. Droplet breakage with Perfluoro-1-octanol (Sigma-Aldrich), 
reverse transcription, exonuclease I treatment, and amplification of cDNA were performed, 
following the Drop-seq protocol of the McCarroll lab (http://mccarrolllab.com/dropseq/) 
with minor modifications. After two rounds of purification with 0.6x SPRISelect beads, we 
tagmented 600 pg cDNA using the Nextera XT DNA sample preparation kit (Illumina, cat# 
FC-131-1096). Following cDNA tagmentation, we further amplified the libraries with 12 
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PCR cycles using custom P5-TSO hybrid and custom Nextera-compatible RB70X primers 
with different indexes.  After quality control analysis by Qubit 3.0 (Invitrogen) and a 
Bioanalyzer (Agilent), libraries were sequenced on an Illumina Nextseq500 instrument 
using the 75-cycles High Output v2 Kit (Illumina, FC-404-2005). We loaded the library at 
1.8 pM and used custom read 1 and index 2 primers. The sequencing configuration was 
20 bp (Read1), 8 bp (Index1), 8 bp (Index2) and 56 bp (Read2). Primers used for sc-RNA-
seq libraries preparation are listed in Table S4. 
Upon sequencing the UMI (Unique Molecular Identifiers) count matrices of cells 
were extracted following the Drop-seq Core Computational Protocol from Steve 
McCarroll’s lab at Harvard Medical School (See the details http://mccarrolllab.com/wp-
content/uploads/2016/03/Drop-seqAlignmentCookbookv1.2Jan2016.pdf). As comparing 
wt cells and setdb1 mutant cells, UMIs of 14,154 genes across all cells were obtained. We 
disregarded the cells with the total UMIs of those 14,154 genes less than 2,000. We also 
excluded out the outliers of cells with high proportions of UMIs of genes in the 
mitochondrial genome using MAD-based definition of outliers. After filtering, our data set 
included 1,919 cells including 952 wild type cells and 967 mutant cells. Data were 
normalized to the size of the library of each cell and then the normalized data were 
obtained by taking their logarithm with the base of 2, which were the input of the following 
analysis. We calculated the PCA of the data matrix and determined that 4 was the optimal 
number of optimal principle components since it was the elbow point of the cumulative of 
the percentage of the explained variance (Figure S17A). Next, we computed the two 
components of t-SNE using the first four principle components of PCA of the normalized 
data. The optimal number of clusters of cells is 3, which was determined from the different 
results obtained by varying all combinations of number of clusters and clustering methods 
under Euclidean distance (Figure S17B).  There are 1,260 cells in the cluster 1 (the light 
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green shadow), 500 cells in cluster 2 (in the light orange shadow), and 159 cells in cluster 
3 (the light magenta shadow) (Figure S17C). Then we identified the cell cycle stages of 
cells using the expression levels of cell cycle gens implemented by R package named 
“scater”. Fig. S17D shows that the cells in the same cell cycle states were distributed in 
the different clusters and it means that the cell cycle has no effects on the clustering. 
Based on the clustering information, we performed the differential expression analysis 
using the non-parametric Kruskal-Wallis test. A significant pvalue means that the gene 
expression levels in at least one cluster dominate the ones in one other cluster 
stochastically. The DE genes were selected with the threshold of the pvalue 0.1. Next, we 
calculated the fold changes of the DE genes between the wild type cells and the mutant 
cells. The up-regulated DE genes were chosen with the fold change greater than 1 and 
the down-regulated ED genes were determined by the fold changes less than 1. To show 
the expression patterns of DE genes in the three clusters, we use blue squares to denote 
the wild type cells and red triangles to denote the mutant cells. The marker genes in each 
cluster are the ones only expressing significantly in the corresponding clusters. Based on 
the marker gene list GO analysis was performed for each cluster and the representative 
GO analysis results are shown in Figure S17E. All cells in the cluster 2 with the expression 
of Alb greater than 0 (n= 1,257 single cells) were selected as Alb+ cells in the relevant 
analysis. tSNE plots were generated based on the first two principle components for the 
Alb+ cells (Figure 3B) and p-Value was calculated based on the non-parametric Kruskal-
Wallis test comparing the gene expression in the wt Alb+ cells (n= 732) and the one in the 
mut Alb+ cells (n= 525). To compare wt cells, setdb1 mutant cells, and TKO cells with the 
total UMIs less than 1500 were disregarded and 1,323 wt cells, 1,366 setdb1 mutant cells, 
and 598 TKO cells were left to do the following analysis. Then 4 clusters were identified 
based on the first two components of tSNE, which were shown as four shadows with 
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different colors (Figure 4A). Then all cells with expression levels of Alb greater than 0 were 
chosen as Alb+ cells in the following analysis. Three clusters represented by three 
different shadows with different colors were classified based from the second component 
and the third component of tSNE (Figure 20D). Differentially expressed genes were 
detected by selecting expression with pval < 0.01. Upregulated genes between samples 
were identified considering log2(fold change) >0.5, while downregulated genes were 
identified by selecting log2(fold change) < -0.5. 
Statistics 
A two-tailed t-test has been used for fig. S13. The Wilcoxon rank sum test was used for 
figure S11A and S15A. Spearman correlation coefficient was computed between all 
replicates and shown in figure S5E, S6H, S10A, S21B to D. Unless otherwise indicated, 
error bars indicate standard error mean (SEM). 
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3.8.  Tables 
Table S1. ThemoFisher Taqman probes and primers used in this study 
Probe Source Identifier Catalog # 
Taqman mouse FoxA2 probe and primers Thermo Mm01976556_s1 4331182 
Taqman mouse PYY probe and primers Thermo Mm00520716_g1 4331182 
Taqman mouse Gata4 probe and primers Thermo Mm00484689_m1 4331182 
Taqman mouse Afp probe and primers Thermo Mm00431715_m1 4331182 
Taqman mouse Sox17 probe and primers Thermo Mm00488363_m1 4331182 
Taqman mouse Cdx2 probe and primers Thermo Mm01212280_m1 4331182 
Taqman mouse Sox2 probe and primers Thermo Mm03053810_s1 4331182 
Taqman mouse Alb probe and primers Thermo Mm00802090_m1 4331182 
Taqman mouse Ttr probe and primers Thermo Mm00443267_m1 4331182 
Taqman mouse Pdx1 probe and primers Thermo Mm00435565_m1 4331182 
Taqman mouse Ptf1a probe and primers Thermo Mm00479622_m1 4331182 
Taqman mouse Nkx6.1 probe and primers Thermo Mm00454961_m1 4331182 
Taqman mouse Onecut1 probe and primers Thermo Mm00839394_m1 4331182 
Taqman mouse Sox9 probe and primers Thermo Mm00448840_m1 4331182 
Taqman mouse Amy1 probe and primers Thermo Mm00651524_m1 4331182 
Taqman mouse Cpa1 probe and primers Thermo Mm00465942_m1 4331182 
Taqman mouse Ins1 probe and primers Thermo Mm01950294_s1 4331182 
Taqman mouse Ins2 probe and primers Thermo Mm00731595_gH 4331182 
Taqman mouse MafA probe and primers Thermo Mm00845206_s1 4331182 
Taqman mouse Gcg probe and primers Thermo Mm00801714_m1 4331182 
Taqman mouse Arx probe and primers Thermo Mm00545903_m1 4331182 
Taqman mouse Kr19  probe and primers Thermo Mm00492980_m1 4331182 
Taqman mouse Pax6 probe and primers Thermo Mm00443081_m1 4331182 
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Taqman mouse Six3 probe and primers Thermo Mm01237639_m1 4331182 
Taqman mouse Otx2 probe and primers Thermo Mm00446859_m1 4331182 
Taqman mouse Tal1 probe and primers Thermo Mm01187033_m1 4331182 
Taqman mouse Tbx20 probe and primers Thermo Mm00451515_m1 4331182 
Taqman mouse Nkx2.5 probe and primers Thermo Mm01309813_s1 4331182 
Taqman mouse Pecam1 probe and primers Thermo Mm01242576_m1 4331182 
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Table S2. Primers used in ChIP-qPCR experiments 
Name Forward sequence (5'->3') Reverse sequence (5"->3') Location 
Arx 
CTTGTTACCGCTTGTCCTGA
G 
TGCGATCTTTGTTCCTTTCC gene body 
Cyp2c37 
CTCGAGATGCAGGTAGTGA
GAA 
TGGGACCAATACTGCTGATT
C 
gene body 
Cyp2u1 GTCACAGCCAATGACCCTTT GCTCAACTCTCCCAGCCTTA gene body 
Cyp3a11 CAATAGTCAGCCCGTTTACG CCATTCACCACATCCTTGG gene body 
Cyp3a25 
TGTGTCTCACAATACAATGA
CAC 
CTGAGTCAAGGGTGTAATCC gene body 
Cyp3a44 CTGCAGCATACAAAGCCA CTGTCCTTTTCTCTGCTTTG gene body 
Eef1a 
GCTATGCAAGCAACATTTCC
TAT 
CCTCCACTTGGTAAGCCTGA gene body 
Gapdh 
TATAGGGCCTGGGTCAGTG
C 
AGCTGAGTCATGGTGGTTCT
G 
gene body 
MSAT 
GACGACTTGAAAAATGACGA
AATC 
CATATTCCAGGTCCTTCAGT
GTGC 
repeats 
Mug1 
ATAAGCCAGAGTATGTGAGG
G 
TGGAATACAAGGATTTGGGT
G 
gene body 
Mug2 
GATAGTTAAAATTATTCAGG
ATCACC 
CTTCTATAGTTTACTGCATGT
CGC 
gene body 
Zfp936 
CAACATAGTAAAGTGCTTGC
ATGT 
CGAAGATAGCTGGGTTTGTA
GG 
gene body 
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Table S3. List of antibodies used in this study 
Antibody name Source Identifier Application 
anti-histone H3 (tri methyl K9) 
validated fig.S5A,B; S20A,C 
Abcam ab8898 ChIP, WB, IHC 
anti-histone H3 (di methyl K9) Abcam ab1220 WB 
anti-histone H3K27me3 Active Motif #39155 WB, IHC 
anti-histone H3K27me3 Millipore 07-449 ChIP 
anti-histone H3 (tri methyl K4) Abcam ab8580 Chip 
anti-histone H3 Abcam ab1791 WB 
anti-TBP Abcam ab51841 WB 
anti-MUPs 
validated fig.S22A,B 
Santa Cruz 
Biotechnology 
sc-66976 IHC 
anti-Cytokeratin 7 
validated Fig.4C 
Abcam ab181598 IHC 
anti-FLK1 BD Pharmingen #550549 cell sorting 
anti-ENDM1 
In-house 
(Gadue et al., 
2009) 
 cell sorting 
anti-LIV2 MBL D118-3 cell sorting 
anti-Osteocalcin 
validated fig.S22B 
Abcam Ab93876 IHC 
anti-FOXM1 
Santa Cruz 
Biotechnology 
sc-376471 WB 
anti-mcm2 Cell Signaling  4007S WB, IHC 
anti-Setdb1 
validated fig.S20A 
Thermo 
Scientific 
MA5-15722 
Lot #RI2264653 
WB, IHC 
anti-Suv39h1 
validated fig.S20A 
Thermo 
Scientific 
MA1-25505 
Lot #SL2492781 
WB 
anti-Suv39h2 
validated fig.S20B 
Thermo 
Scientific 
PA5-11366 
Lot #SI2420746A 
IHC 
anti-Vinculin Sigma v9131 WB 
goat anti-rabbit IgG-HRP 
Santa Cruz 
Biotechnology 
sc-2004 WB, IHC 
goat anti-mouse IgG-HRP 
Santa Cruz 
Biotechnology 
sc-2005 WB, IHC 
PE-conjugated goat anti-rat IgG Biolegend #405406 cell sorting 
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Table S4. List of primers used for single cell RNA-Seq 
Primer Sequence (5’->3’) 
Template Switch 
Oligo 
AAGCAGTGGTATCAACGCAGAGTGAATrGrGrG 
TSO-PCR AAGCAGTGGTATCAACGCAGAGT 
P5-TSO-
Hybrid(RB519) 
AATGATACGGCGACCACCGAGATCTACACACGAGTGAGCCTGTCCGC
GGAAGCAGTGGTATCAACGCAGAGT*A*C 
P5-TSO-
Hybrid(RB520) 
AATGATACGGCGACCACCGAGATCTACACCGTGTCTAGCCTGTCCG
CGGAAGCAGTGGTATCAACGCAGAGT*A*C  
Nextera RB701 
CAAGCAGAAGACGGCATACGAGAT CGATAACC 
GTCTCGTGGGCTCGG AGATG 
Nextera RB702 
CAAGCAGAAGACGGCATACGAGAT CTAGCGTA 
GTCTCGTGGGCTCGG AGATG 
Nextera RB703 
CAAGCAGAAGACGGCATACGAGAT AATGGCCT 
GTCTCGTGGGCTCGG AGATG 
Nextera RB704 
CAAGCAGAAGACGGCATACGAGAT GTTACCTC 
GTCTCGTGGGCTCGG AGATG 
Nextera RB705 
CAAGCAGAAGACGGCATACGAGAT ACACGTGT 
GTCTCGTGGGCTCGG AGATG 
Nextera RB706 
CAAGCAGAAGACGGCATACGAGAT CGTCATGA 
GTCTCGTGGGCTCGG AGATG 
Read1 primer GCCTGTCCGCGGAAGCAGTGGTATCAACGCAGAGTAC 
DropSeqIndex2 GTTGATACCACTGCTTCCGCGGACAGGC 
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Table S5. Oligonucleotide sequences for zygote injection to generate Suv39h1 and Suv39h2 
mutant alleles and for genotyping 
Oligonucleotide name  Sequence (5'->3') 
Suv39h1 intron 2 gRNA GAGGGGCTGGCCGAGTATGGTGG 
Suv39h1 intron 5 gRNA GAAGGAGGATTACAGTCAGGAGG 
Suv39h2 exon 2 gRNA AAGCTCACATGTAAATCGATTGG 
Suv39h1 intron 2 loxP 
site 
GATATCATAACTTCGTATAATGTATGCTATACGAAGTTAT 
Suv39h1 intron 5 loxP 
site 
GGATCCATAACTTCGTATAATGTATGCTATACGAAGTTAT 
Suv39h1 intron 2 HDR 
oligo 
GCAGGATAGTTAGAGGAGCCCACTGAAAGTAGCATGCTTAGT
TTAAATGTAGCCTTCATTTTCTGTCTATAAAATGGGAGGGGCT
GGCCGAGTGATATCATAACTTCGTATAATGTATGCTATACGAA
GTTATATGGTGGCCCAAGCCTTTAATCTCAGCACTGGGGAGG
CAGAGGCAGGTTGATTTCTGAGTTTGAGGC 
Suv39h1 intron 5 HDR 
oligo 
TGTGGGAGAGGATGTTTGGCTGAAGAGTTAAATATACTCACT
TCCATCTTAAATCACCTACCCCCTGCCCCTCCTGGATCCATAA
CTTCGTATAATGTATGCTATACGAAGTTATGACTGTAATCCTC
CTTCACCTTCCTTGTTCTGAGCCTCTGGATACCCTTGTGTTTT
CTAGCCTGACCTCTTCTTG 
Suv39h1 intron 2 oligo for 
mRNA synthesis 
GAGGGGCTGGCCGAGTATGGGTTTTAGAGCTAGAAATAGCA
AGTTAAAATAAGGCTAGTCCGTTATCAACTTGAAAAAGTGGCA
CCGAGTCGGTGCTTTTTT 
Suv39h1 intron 5 oligo for 
mRNA synthesis 
GAAGGAGGATTACAGTCAGGGTTTTAGAGCTAGAAATAGCAA
GTTAAAATAAGGCTAGTCCGTTATCAACTTGAAAAAGTGGCAC
CGAGTCGGTGCTTTTTT 
Suv39h2 exon 2 oligo for 
mRNA synthesis 
AAGCTCACATGTAAATCGATGTTTTAGAGCTAGAAATAGCAAG
TTAAAATAAGGCTAGTCCGTTATCAACTTGAAAAAGTGGCACC
GAGTCGGTGCTTTTTT 
Suv39h1 intron 2 T7-
sgRNA_primer_F 
GAAATTAATACGACTCACTATAGGGAGAGAGGGGCTGGCCG
AGTATGGGTTTTAGA 
Suv39h1 intron 5 T7-
sgRNA_primer_F 
GAAATTAATACGACTCACTATAGGGAGAGAAGGAGGATTACA
GTCAGGGTTTTAGA 
Suv39h2 exon 2 T7-
sgRNA_primer_F 
GAAATTAATACGACTCACTATAGGGAGAAAGCTCACATGTAAA
TCGATGTTTTAGA 
T7-sgRNA_primer_R AAAAAAGCACCGACTCGGTG 
Suv39h1 intron 2 
genotyping primer F 
GGAGCCCACTGAAAGTAGCA  
Suv39h1 intron 2 
genotyping primer R 
ACTCCAGCCCCTCCTTTTT 
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Suv39h1 intron 5 
genotyping primer F 
TCACTTCCATCTTAAATCACCTACC  
Suv39h1 intron 5 
genotyping primer R 
GGTCAGGCTAGAAAACACAAGG 
Suv39h2 exon 2 
genotyping primer F 
GCCTTGCCTAGTTTCACTTGAT  
Suv39h2 exon 2 
genotyping primer R 
GGACATTGCCTTACCTTTGC 
 
Other Supplementary Materials for this manuscript include the following:  
Table S6. mm9_reads_alignment_summary.xlsx 
Table S7. srHC_Seq_genes_in_alluvia.xlsx 
Table S8. Genes_decorated_with_H3K9me3.xlsx 
Table S9. H3K9me3_at_TSS_and_TTS.xlsx 
Table S10. H3K9me3_dynamics_at_stage_transitions.xlsx 
Table S11. H3K9me3_Patch_Gene_coverage.xlsx 
Table S12. RNA-seq_differentially_expressed_genes_GO_analysis.xlsx 
Table S13. RNA_seq_clustering.xlsx 
Table S14. Quantile_normalized_AUCs_Z_score_hepatic_and_pancreatic_genes.xlsx 
Table S15. scRNA_seq_genes_and_differentially_expressed_genes_analysis.xlsx 
Table S16. Differentially_expressed_genes_1mo_Ctrl_vs_TKO_livers.xlsx 
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Chapter 4: Perspectives and Future Directions  
4.1.  Sonication-resistant heterochromatin sequencing as a method to map 
compacted heterochromatin and open euchromatin  
There are hundreds of cell types that cooperate to perform the necessary physiologies of 
complex multicellular organisms such as mammals and, remarkably, each of these cell 
types have the same complement of chromosomes with essentially the same sequence.  
Packaging DNA into heterochromatin, a compact and repressive structure, is key for 
locking down cellular identity in development and maintenance (Becker et al., 2016; 
Fadloun et al., 2013), reprogramming (Becker et al., 2017; Mansour et al., 2012; Soufi et 
al., 2012), and is perturbed in disease settings (Rao et al., 2017; Schuettengruber et al., 
2017).  Classically, heterochromatin has been defined by physical compaction as seen 
through a microscope (Brown, 1966; Heitz, 1928), but more recently heterochromatin has 
been defined by the histone marks H3K9me3 or H3K27me3.  H3K9me3-marked 
chromatin is often defined as constitutive heterochromatin that represses pericentromeric 
repeat elements to maintain genome stability (Fukagawa et al., 2004; Lehnertz et al., 
2003), but more recent studies have shown cell type-specific repression of genes as well 
(Becker et al., 2017; Hawkins et al., 2010; Nicetto et al., 2019; Zhu et al., 2013).  
H3K27me3-marked chromatin is classically defined as facultative heterochromatin, as it 
has lineage- and temporally-specific patterns and represses many lineage-determining 
genes (Margueron and Reinberg, 2011; Xu et al., 2014; Zhu et al., 2013).  However, 
definitions of heterochromatin based on histone marks are limited, as the these H3K9me3- 
or H3K27me3-marked chromatin can be physically heterochromatic or euchromatic with 
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compaction state predicting gene activity and accessibility to binding by transcription 
factors (Becker et al., 2016; Beisel and Paro, 2011; Blahnik et al., 2011; Breiling et al., 
2001; Grindheim et al., 2019; Hawkins et al., 2010; Nicetto et al., 2019; Piacentini et al., 
2003; Riddle et al., 2012; Trojer and Reinberg, 2007; Vakoc et al., 2005). 
Heterochromatic and euchromatic regions can be mapped genome-wide with a 
new technique termed gradient-seq (Becker et al., 2017).  Gradient-seq was inspired by 
an initial observation that input sequencing tracks from ChIP-sequencing experiments are 
depleted for signal in H3K9me3-marked heterochromatin domains, suggesting that 
heterochromatin is sonication-resistant and thus underrepresented in most sequencing 
protocols as they involve size selection or bias for small fragments (Becker et al., 2017; 
Soufi et al., 2012).  Supporting this hypothesis, heterochromatin is resistant to mechanical 
shearing (Frenster et al., 1963) and promoters of highly active genes are sonication-
sensitive (Auerbach et al., 2009).  The gradient-based method was chosen based on 
previous studies using centrifugation to analyze chromatin structure (Ghirlando and 
Felsenfeld, 2008; Gilbert et al., 2004; Ishihara et al., 2010) and involves fractionation of 
crosslinked, sonicated heterochromatin on a sucrose gradient, a setup in which 
heterochromatin is fast migrating and euchromatin is slow migrating (Appendix B, Figure 
1).  Crosslinking with formaldehyde, which creates linkages between closely-spaced 
molecules, about 2 Å, aids in making heterochromatin more sonication-resistant, 
(Quievryn and Zhitkovich, 2000; Solomon and Varshavsky, 1985).  While Gradient-seq 
has the advantage of being able to isolate RNA, DNA, and protein from heterochromatin 
and euchromatin, it is also laborious, requiring tens of millions of cells and characterization 
of many fractions of the sucrose gradient.  
To map euchromatin and heterochromatin while circumventing high cell numbers, 
laborious sucrose gradients, and fraction analysis, Dario Nicetto and I developed a novel 
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technique termed srHC-seq.  srHC-seq was inspired by the observation from gradient-seq 
data (before sequencing) that DNA from heterochromatin is enriched for high molecular 
weight fragments, while DNA from euchromatin is enriched for low molecular weight 
fragments (Appendix B, Figure 1).  My version of the srHC-seq protocol involved isolation 
of 10 μg DNA from crosslinked, sonicated chromatin, followed by size fractionation with 
SPRI beads of large, medium, and small fragments of DNA fragments.  In contrast, the 
Nicetto version (Chapter 3, (Nicetto et al., 2019)) is aimed at lower amounts in input cells 
(30,000 cells) and to accommodate this, does not involve isolation of the medium fragment 
size population.  Given that the medium fragment size population overlaps with both small 
and large fragment size populations, we believe that the tripartite separation will create a 
clearer separation between heterochromatin and euchromatin when mapped.  
Significantly however, results from both protocols on adult mouse hepatocytes show highly 
similar results, despite being performed by two different people, on two different sonication 
instruments, with two related but distinct size selection protocols, and with two different 
library prep protocols (Appendix B, Figure 2).   
Robust calling of promoter and gene srHC chromatin compaction state is also 
possible with srHC-seq.  With increasingly lax enriched window cutoffs from 10-40%, an 
increasing portion of the genome is called as heterochromatic or euchromatic, from 
approximately 500 MB of each at 10% to approximately 1100 MB at 40% (Appendix B, 
Figure 3AB).  Despite the increasing fraction of the genome which is called as 
heterochromatic or euchromatic with 10% to 40% enriched window cutoffs, there is 
relatively mild change in the number of genes or promoters called as heterochromatic, 
euchromatic, or intermediate  and, reflecting the robustness of this technique, euchromatic 
genes have high expression and heterochromatic genes have relatively low expression 
(Appendix B, Figure 3CD).  Contrary to the term “Polycomb-marked heterochromatin”, we 
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find that there are genes and promoters called both as euchromatic and H3K27me3+ 
(Appendix B, Figure 3CD) and are expressed, albeit at lower levels that genes that are 
called as euchromatic and H3K27me3- at their gene bodies or promoters.  We also note 
that promoter srHC chromatin state is a better predictor of expression than coding 
sequence srHC chromatin state, likely due to the large size of genes and the extreme 
openness of the promoters of expressed genes.  Curiously, genes called as having 
heterochromatic gene bodies or promoters at P14 have higher levels of expression than 
genes called as having heterochromatic gene bodies or promoters at M2, suggesting 
cellular heterogeneity or incomplete “lockdown” of the genome occurs at the relatively 
immature P14 timepoint. 
We find that srHC-seq data agrees strongly with observations that the higher-order 
Type A and B chromatin compartments associated with active and inactive chromatin 
(Boettiger et al., 2016; Lieberman-Aiden et al., 2009; Lin et al., 2012; Rao et al., 2014; 
Vieux-Rochas et al., 2015; Wang et al., 2016) (Appendix B, Figure 4).  Interestingly, we 
find that a quarter of Type A compartments were called as heterochromatic and 70% of 
those regions are marked by H3K27me3 domains, suggesting that A heterochromatin 
compartments are particularly dependent on Polycomb-related compaction.  Future work 
could investigate whether A compartment H3K27me3 domains represent the Polycomb-
repressed aggregates termed “Polycomb Bodies” that localize to the nuclear interior and 
are dependent on nucleoplasmic LAMIN A/C to maintain transcriptional repression and 
aggregation (Marullo et al., 2016) and whether methods of PRC2/H3K27me3 repression 
sorts with A/B compartment.  
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4.2.  PRC2/H3K27me3 function at euchromatic promoters 
The factors that determine which H3K27me3-marked or PRC2-bound genes that respond 
to Ezh1/2 loss with subsequent gene activation has been an ongoing question in the field.  
Several groups have noted that genes with promoter H3K4me2/3 (Bae et al., 2015; 
Ezhkova et al., 2011; Jadhav et al., 2016) and genes marked by tissue-specific H3K27me3 
are also more likely to derepress in response to H3K27me3 loss (Jadhav et al., 2016).  
We also find low levels of pre-existing H3K4me3 at Ezh1/2-sensitive promoters and by 
plotting srHC-seq signal at the transcriptional start sites of genes with promoter 
H3K27me3 which do and do not upregulate in response to Ezh1/2 loss, we additionally 
find that euchromatic promoter signal is a predictor of Ezh1/2 sensitivity (Chapter 2, Figure 
4).   
The conflicting repression-associated and activation-associated features at the 
promoters of H3K27me3+ Ezh1/2-sensitive genes suggests that there is a fine balance 
being maintained at these promoters.  On the pro-activation side, a transcription factor 
may be binding, hence the open promoter state and H3K4me3 presence.  The open state 
may be preventing the spread of H3K27me3, since compact chromatin templates are 
better substrates for the PRC2 complex (Jiao and Liu, 2015; Yuan et al., 2012).  H3K4me3 
can inhibit PRC2 methyltransferase activity and may be preventing H3K27me3 spread 
(Schmitges et al., 2011).  On the pro-repression side, PRC2 is recruited to unmethylated 
CpG islands and H3K27me3 at the promoter blocks acetylation of H3K27, which is 
involved in gene activation  (Tie et al., 2016).  Additionally, while PRC2 at promoters 
seemingly is not functioning through chromatin compaction, it may be able to methylate 
elongation factor A, which leads to reduced transcription (Ardehali et al., 2017).  We 
additionally found that the open promoters become further euchromatic with wider open 
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regions in Ezh1/2 cells, suggesting that SWI/SNF remodeling may be inhibited by PRC2 
(Schuettengruber et al., 2017).  Our finding that Ezh1/2-sensitive promoters are 
euchromatic underline the importance of compaction-independent repressive activities of 
PRC2. 
4.3.  PRC2/H3K27me3 involvement in postnatal hepatocyte identity  
In postnatal liver maturation, we found that PRC2 is used extensively to repress 
multiple functional classes of genes with pre-existing euchromatic promoters, including 
late and early maturation genes.  In the case of late maturation genes with promoter 
H3K27me3, the fact that these genes have euchromatic promoters and derepress, once 
PRC2 repression is relieved, suggests that Polycomb repression was the “last line of 
defense” holding these genes from being activated by transcription factors already present 
in the nuclear milieu.  Many key liver transcription factors are expressed in the embryo 
and form an increasingly complex and self-reinforcing transcriptional network that persists 
in adults (Kyrmizi et al., 2006; Odom et al., 2006).  This leaves open the question of what 
upstream cues signal through transcription factors to tip the balance between repression 
and activation in the context of maturation.  Sexual maturation is one obvious potential 
candidate, with known growth hormone, estrogen, and androgen signaling differences in 
liver between males and females, and even sex-specific transcription factors (Ma et al., 
2014; Torre et al., 2017), though we did not observe obvious differences.  Weaning and 
the consequential switch from a high fat milk diet to a high carbohydrate diet with additional 
metabolites is another possible cue for maturation (Hashimoto and Ogawa, 2018).  These 
same upstream hormone and metabolic cues may also cause the initial repression of early 
maturation genes, for which PRC2/H3K27me3 can then maintain repression.  A 
167 
 
hypothesis-generating experiment to identify factors which affect PRC2-repressed 
maturation genes could be done by comparing the list of PRC2-maturation genes with the 
wealth of liver expression data in mutants that is publicly available. 
As PRC2 represses maturation genes in a time-appropriate manner and loss of 
Ezh1/2 lead to premature maturation at the transcriptional level, Polycomb repression may 
be impacting physiological maturation changes such as liver lobule zonation and 
hepatocyte polyploidization.  While we did not see preferences for periportal or pericentral 
zonated genes to change expression as a group (Chapter 2, Supplemental Figure 2), this 
does not rule out the possibility that individual zonated genes are regulated by PRC2.  This 
could be addressed in future studies using H3K27me3 ChIP-seq in periportal and 
pericentral hepatocytes to identify PRC2 targets and histology or single cell RNA-seq to 
assess gene expression in periportal and pericentral hepatocytes.  Hepatocyte 
polyploidization is also possibly regulated by PRC2, as polyploidization is affected by 
expression of cell cycle factors (Chen et al., 2012a; Chipchase et al., 2003; Hsu et al., 
2016; Li et al., 2013, 2013; Mayhew et al., 2005; Pandit et al., 2012), which we find 
downregulated prematurely in P14 Ezh1/2 hepatocytes (Chapter 2, Figure 1), and P14 
Ezh1/2 hepatocytes stain for a proliferation marker less frequently than P14 Wt 
hepatocytes (data not shown).  While pinpointing which of the many differentially 
expressed cell cycle or other genes are regulated by PRC2 may be complicated, overall 
polyploidization could be assessed with propidium iodide staining and cell sorting.  Overall, 
finer characterization of discrete hepatocyte physiological changes that are regulated by 
PRC2 is an exciting new research area. 
PcG proteins are noted for their roles in repressing transcription factors to influence 
cell fate (Bracken et al., 2006; Lewis, 1947; Slifer, 1942; Snitow et al., 2016; Xu et al., 
2011), and consistent with this, we find that PRC2 represses the expression of alternative 
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lineage genes specifically with a euchromatic H3K27me3+/H3K4me3+ promoter state in 
postnatal hepatocytes.  While euchromatic H3K27me3+/H3K4me3+ promoter state 
explains at the chromatin-level, why some alternative lineage genes are activated in 
response to Ezh1/2 loss, it does not explain the physiological benefits.  One hypothesis 
could be that Ezh1/2-sensitive alternative lineage genes are primed to respond to some 
unidentified stimulus to aid in liver function.  Another hypothesis could be that these genes 
are simply “leftovers” from development that do not have a second redundant layer of 
repression.  Future studies may keep in mind whether these derepressed alternative 
lineage genes are used in physiological responses such as hepatocyte to cholangiocyte 
transdifferentiation or response to acute liver injury (Yanger et al., 2013). 
Future work might also investigate whether certain transcription factors or classes 
of transcription factors maintain the open state of sensitive promoters, what physiological 
functions these primed or restrained genes have, and what non-histone targets of Ezh1/2 
are involved in liver maturation.  Work relative to the clinic could investigate whether 
human hepatocytes maturation genes are similarly regulated by PRC2/H3K27me3, 
whether artificially derived hepatocytes have defects in maturation gene repression or 
activation at genes that should or should not be repressed by PRC2, and whether 
manipulation of Polycomb proteins affects the maturation state of artificially derived 
hepatocytes. 
4.4.  Implications for artificially derived hepatocytes  
Artificially derived hepatocytes are currently benchmarked by comparison to gene 
expression profiles of the starting cell type and mature hepatocytes, some metabolic tests, 
and transplantation assays.  We propose that benchmarking could be improved by 
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inclusion of immature and mature transcriptional, H3K27me3, and chromatin compaction 
profiles.  A comparison of artificially derived, immature, and mature hepatocyte 
transcriptional profiles could identify the extent of hepatocyte maturity and lineage fidelity 
by identifying three gene classes and to what extent they are expressed: 1) immature liver 
genes have been silenced, 2) mature liver genes have been upregulated, and 3) 
“hepatocyte-inappropriate”, or genes that should not be expressed in hepatocytes at all, 
are aberrantly expressed.  Further benchmarking of correct H3K27me3 and chromatin 
compaction profiles would not only benchmark artificially derived hepatocytes, but also 
suggest why transcriptional regulation is not occurring as it does in mature hepatocytes.  
In the cases of immature liver genes and hepatocyte-inappropriate genes that are 
expressed in artificially derived hepatocytes, follow-up could determine whether these 
genes are failing to be repressed by PRC2 as assessed by H3K27me3 and euchromatic 
signal as assessed by srHC-seq at promoters, gene bodies, and possibly enhancers.  
Repression of immature liver genes and hepatocyte-inappropriate genes could be key for 
clinical efficacy because as seen in the Ezh1/2 mouse model (Chapter 2), liver fibrosis 
may stem or fail to be resolved because of derepression of either or both of these gene 
sets.  In the case of mature liver genes that fail to activate or fail to activate to the sufficient 
levels, a follow-up would be to ask whether these genes are inappropriately repressed by 
PRC2 with either heterochromatic or euchromatic H3K27me3.  Mismatches in chromatin 
state between artificially derived hepatocytes and mature hepatocytes as defined by 
benchmarking could further be used to design and test methods to improve protocols. 
As perturbation of PRC2 repression results in premature maturation of postnatal 
day 14 immature mouse hepatocytes and represses maturation genes in a time-
appropriate manner, manipulation of PRC2 repression should be tested as a method to 
improve artificially derived hepatocytes.  A first-order experiment would be to see if 
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transient knockdown or inhibition of Ezh1/2 would cause a further maturation of artificially 
derived hepatocytes.  Theoretically, transient relief of PRC2 repression could allow for 
transcriptional activation of inappropriately repressed liver factors and hepatocyte 
transcriptional network stabilization that would remain after PRC2 repression is restored.  
One drawback of removing all PRC2 repression is that there may be sustained expression 
of hepatocyte-inappropriate genes even after restoration of PRC2 activity.  Further 
experiments would seek to determine which discrete genes or gene sets are preferentially 
affected by activation or inhibition of different Polycomb proteins, as it is likely that PRC2 
variant complexes, PRC2 accessory proteins, and H3K27me3 histone demethylases 
differentially affect genes in heterochromatin or euchromatin, with or without nearby 
transcription, with or without transcription factor binding, and from methods that are 
H3K27me3-dependent or non-histone target-dependent.  Inhibition of PRC2 variant 
complexes, PRC2.1 and PRC2.2 (Chittock et al., 2017), or Polycomb accessory proteins 
PHF1, JARID2, and MTF2, which affect PRC2 recruitment and enzymatic activity 
(Landeira et al., 2010; Li et al., 2010, 2017; Oksuz et al., 2018; Pasini et al., 2010; Peng 
et al., 2009; Shen et al., 2009; Son et al., 2013), may allow for derepression of liver genes.  
Overexpression of H3K27me3 histone demethylases JMJD3 and UTX (Hong et al., 2007) 
may be desirable if H3K27me3 is used to repress liver genes, while inhibition may be 
desired if they remove H3K27me3 from hepatocyte-inappropriate genes.  Thus, 
perturbation of one or a combination of Polycomb factors might be used to cause 
repression or derepression of discrete gene sets to generate artificially derived 
hepatocytes more similar to native mature hepatocytes. 
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4.5.  PRC2/H3K27me3 involvement in liver fibrosis 
Liver cirrhosis, the end stage of liver fibrosis, is a complicated disease involving multiple 
cell types and signaling pathways with underlying mechanisms remaining incompletely 
understood.  The most common causes in Western countries include alcoholism, hepatitis 
C virus infection, and nonalcoholic fatty liver disease (Di Bisceglie, 2000; Innes et al., 
2013; Naveau et al., 2005).  Hepatocytes, the main liver parenchymal cell type, are one 
of the key cell types injured by hepatotoxic agents and, when damaged, release reactive 
oxygen species and fibrogenic mediators.  These paracrine factors then activate hepatic 
stellate cells to become the main recognized collagen-secreting cells in liver damage 
(Zhou et al., 2014).  With chronic activation, the extracellular matrix builds up and 
compresses the sinusoids, causing portal hypertension.  Portal hypertension from fibrosis 
causes systemwide problems with blood flow to the kidneys and kidney failure, and in the 
liver there is a reduction in the functional number of functional portal triads.  Less liver 
function leads to buildup in ammonia, which is particularly toxic for the brain, decreased 
bilirubin conjugation leading to jaundice, hypoalbuminemia, and decreased clotting factor 
production which leads to coagulation deficiencies. 
We observed that Ezh1/2 hepatocytes exhibit increased apoptosis in animals as 
young as 1-month-old, which progresses to chronic liver damage and liver fibrosis by 2-
months (Chapter 2, Figure 5), results which suggest that PRC2 is involved in repression 
of fibrosis-driving or fibrosis-response genes.  To investigate this, we utilized two 
published datasets; a 232 gene signature predicting fibrosis before histopathological 
detection from a non-alcoholic steatohepatitis (NASH) mouse model (van Koppen et al., 
2018; Teufel et al., 2016) and 121 genes upregulated in advanced human liver fibrosis as 
compared to early fibrosis from a mixed cohort of chronic liver disease patients with 
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Hepatitis C and/or fatty liver disease (Ramnath et al., 2018) (Chapter 2, Figure 6).  
Strinkingly, a third to a half of genes from both datasets have, the predictive euchromatic 
H3K27me3+/H3K4me3+ promoter chromatin state that we identified as sensitizing genes 
to Ezh1/2 loss and are normally downregulated in postnatal hepatic maturation.  We found 
it curious that these fibrosis genes were not previously seen in the classes of genes 
aberrantly upregulated in P14 Ezh1/2 hepatocytes, ie, prematurely upregulated late 
maturation genes at P14, early maturation gene that failed to be repressed at P14, and 
alternative lineage genes that are aberrantly upregulated at P14.  Further analysis led to 
the observation that a striking 79 of 232 (34%) mouse nonalcoholic steatohepatitis-related 
fibrosis genes and 35 of 121 (29%) human advanced fibrosis genes are significantly 
downregulated in maturation and not significantly upregulated by P14 in Ezh1/2 animals; 
thus PRC2 is used to repress these fibrosis genes at a later timepoint than P14.  The 
temporal delay in both the liver damage phenotype and liver fibrosis gene upregulation 
data support a model where PRC2 is used to repress and prime fibrosis-response genes. 
Of the liver fibrosis genes that are repressed by PRC2, Tgfb1 and Pdgfa are of 
particular interest (while the Pdgfa promoter is not called as marked by H3K27me3 in Wt 
M2 hepatocytes, visual inspection of track views reveals significant upstream H3K27me3 
signal in Wt M2 hepatocytes).  TGF-β1 is the among the most potent inducers of liver 
fibrogenesis (Kirmaz et al., 2004; Matsuoka and Tsukamoto, 1990; Nakatsukasa et al., 
1990; Schuppan et al., 2003), PDGF-A is a strong HSC mitogen and activator, and levels 
of both increase with the severity of fibrosis and cirrhosis (Borkham-Kamphorst et al., 
2004; Cao et al., 2010; Jeong et al., 2004; Thieringer et al., 2008).  TGF-β1 can be 
secreted by hepatocytes in response to liver damage and primarily targets hepatic stellate 
cells, where it stimulates expression of matrix-producing genes (Wells et al., 2004; Zhou 
et al., 2014), and can also can inhibit hepatocyte DNA synthesis and induce apoptosis 
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(Kirmaz et al., 2004).  Mice overexpressing PDGF-A in hepatocytes develop spontaneous 
fibrosis (Thieringer et al., 2008) and dominant negative PDGF receptor treatment can 
inhibit hepatic stellate cell activation and attenuate fibrosis (Borkham-Kamphorst et al., 
2004).  The chronic liver damage experienced by livers with Ezh1/2 hepatocytes may 
come from an inability to silence Tgfb1 and Pdgfa transcription, and thus are unable to 
stop a feed forward liver damage response.   
While further experiments are needed to confirm PRC2 repression of fibrosis 
genes in human liver samples, there are impactful clinical implications.  Fibrosis was 
previously thought to be irreversible but there is growing evidence that treatment of the 
underlying cause of damage, such as hepatitis B, C, and autoimmune hepatitis, can lead 
to fibrotic reversal (Jung and Yim, 2017).  In non-liver fibrosis models inhibition of an 
H3K27me3 demethylase with a small molecule inhibitor leads to accumulation of 
H3K27me3 and reduced expression at key fibrosis genes (Bergmann et al., 2018).  If re-
establishment of PRC2 repression at fibrosis genes in hepatocytes is part of the process 
of fibrotic reversal, then inhibition of H3K27me3 demethylases could be a therapeutic 
target.   
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Appendix A: Murine hepatocyte isolation by liver perfusion 
This appendix describes how to isolate mouse hepatocytes from liver from animals using 
a two-step collagenase perfusion protocol.  It is designed for mice at least two weeks old 
or at least 6-7 g in total body weight.  Also included are protocols for confirming enrichment 
of hepatocytes with RTqPCR and isolating hepatocyte nuclei. 
Key to this protocol are the perfusion and digest medias, which are manufactured 
by Invitrogen.  Invitrogen appears to have developed their perfusion and digest medias 
from a 1987 Ichihara Lab protocol (Nakatani et al., 2002; Shimaoka et al., 1987).  While 
the constituents of these medias are proprietary, it is likely that, per the 1987 protocol, 
perfusion media is Ca++-free Hanks’ solution containing 5 mM EGTA at 37°C. Per the 
catalog, “Liver Perfusion Medium is a buffered, balanced salt solution formulated to 
cleanse the liver of blood, prevent clotting, and initiate loosening of cell-to-cell contact”.  
Invitrogen describes digest media as containing collagenase and dispase, which digest 
the extracellular matrix. 
I.  Objective 
Enrichment of hepatocytes from other liver cell types is preferred for studies in which 
contaminating cell types muddy data interpretation, such as in transcript or chromatin 
studies.  Additionally, isolated and cultured hepatocytes can be used for other studies, 
albeit the technology maintaining hepatocyte function and identity in culture is currently 
limited.   
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II.  Key Reagents 
Isoflurane (Butler Animal Health Supply, Cat# 029405) 
Or other IACUC-approved anesthesia method 
22- or 24-gauge catheters (Midwest Veterinary Supply, 381423) 
22-gauge for 2-month-old mice (M2), 24-gauge for postnatal day 14 (P14) mice.  
These catheters have an auto-eject feature, which means that the needle retracts 
from the catheter when a button is pushed, which is useful because manually 
retracting the needle can be shaky and can tear the blood vessel. 
This protocol is designed for P14 mice or older, which have a total body weight of 
6-7 grams on the lower end.  Animals younger than P14 are sometimes too small 
for cannulation with a 24-gauge catheter 
37°C liver perfusion media (Invitrogen 17701-038) 
25 mL for each P14 animal, 50 mL for each M2 or other adult animal.  
Store at 4°C. 
37°C liver digest media (Invitrogen 17703-034) 
22 mL for each P14 animal, 45 mL for each M2 or other adult animal.   
Store at -20°C in 45 mL aliquots.  Digest media comes with white particulate.  Avoid 
adding particulate to the aliquots or the tubing because it clogs the bubble trap and 
can function as a blood clot in the liver. 
cell scrapers 
swivel head scrapers are easier to work with 
70% EtOH 
in squirt bottle 
PBS 
for rinsing tubing 
H2O 
for rinsing tubing 
William’s E Medium (Sigma W4128) 
Given the short time in media, the exact media is probably not key unless the 
hepatocytes are destined for culture. 
100 μm cell filter (BD 352360) 
Dissecting scissors 
curved tip scissors are easier to use 
Serrated tweezers 
serrated tweezers are better at gripping 
Peristaltic pump setup 
From input to output:  42°C water bath with media, tubing from media to bubble 
trap, tubing from bubble trap to threaded adaptor (threaded to screw onto 
catheter).  Peristaltic pump is set up somewhere along the tubing. 
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The water bath is set at 42°C to mitigate the cooling effects from the media flowing 
through the tubing.  
Bubble trap function:  The bubble trap is meant to ensure media but not bubbles 
reach the catheter since bubbles can act like blood clots.  When media is coming 
into the bubble trap, have it facing input-side down.  Gravity creates a reservoir of 
media inside of the bubble trap.  Later, flip the bubble trap to output-side down so 
that the media falls because of gravity and air rises because of gravity and no 
bubbles come through the output side of the tube and into the mouse.  
10 cm petri dish 
Cotton applicators 
Surgical qtips 
Anesthesia chamber 
Surgical setup 
Wrap a Styrofoam board, approximately 18 inches by 12 inches, in cellophane for 
easy cleanup.  Prop up the back the Styrofoam on a roll of lab tape or the lid of a 
tip box.  The angled work surface makes it easier to perform surgery and predict 
where excess liquid will flow.  Have a layer of paper towels under the mouse and 
taller stacks of paper towels framing the left, right, and bottom of the surgical table 
to soak up excess media. 
Perform the perfusion in a chemical hood to avoid exposure to mouse dander and 
isoflurane. 
TRIzol Reagent (Thermo 15596026) 
iScript cDNA synthesis kit (BioRad 1708891) 
or other cDNA synthesis kit 
Power SYBR Green PCR Master Mix Set (Thermo 4367659) 
RSB  
A hypotonic cytoplasmic membrane lysis buffer used in the isolation of hepatic 
nuclei. 
10 mM Tris-HCl, pH 7.4 
10 mM NaCl 
3 mM MgCl2 
0.5% NP40 
Add fresh:  
cOmplete Protease Inhibitor Cocktail to a final concentration of 2X (Roche 
04693116001) 
5 mM PMSF 
  
183 
 
III.  Protocol 
Liver perfusion, hepatocyte isolation, and nuclei isolation 
See Figure 1 for schematic. 
1. Prepare workspace 
a. Warm perfusion and digest media to 42C in the water bath 
b. Sterilize dissecting scissors and tweezers in EtOH 
c. Rinse tubing in PBS, then EtOH, then PBS. 
d. Turn on peristaltic pump.  The tubing has been squished together and may be  
stuck closed, but ten minutes running without media usually massages out any 
stuck kinks. 
2. Anesthetize the mouse 
a. Per lab IACUC guidelines. 
b. Monitor anesthesia paw pinch.  The mouse should continue visibly breathing 
until sometime after cannulation and blood loss. 
3. Cannulation and perfusion 
a. Apply 70% EtOH on the abdomen to keep hair out of the abdominal cavity. 
b. Start the peristaltic pump at ~8 mL/min, with the tubing in perfusion media.  The 
bubble trap should be input-side down. 
c. Using tweezers, grasp the skin of the abdomen, and make a midline incision 
just above the urethra.  Open to the left and right to make a U-shaped incision 
that exposes the abdominal cavity.  Make sure not to cut abdominal organs, 
like the liver, which often suctions to the diaphragm and body wall. 
d. Push the viscera to the right (left side of the mouse) out of the abdominal cavity 
with a qtip to reveal the inferior vena cavae (IVC), which runs near the spine.   
i. Sometimes the bladder will obstruct the IVC but squeezing the bladder 
with blunt tweezers forces urine out and reduces bladder size. 
ii. If the lower portion of IVC (near the kidneys) is hidden by fat or connective 
tissue, as happens often in fat or old mice, gently rub the IVC down 
towards the tail with the qtip in long strokes, then the connective tissue 
will rub off, leaving a more exposed IVC. 
e. Flip the liver up and back towards the head to reveal the blood vessels 
beneath. 
f. Flip the bubble trap to output-side down so media but not air moves through 
the output tube. 
g. For right-handed people: Have a qtip in the left and the cannula in the right.   
Block blood flow by using the qtip to apply gentle pressure to the IVC close to 
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the liver, preferably above the connection of the IVC and the aorta abdominalis.  
This expands the diameter of the IVC. 
h. Cannulate the IVC with the needle bevel side up.   
i. For mice weighing 7 grams or more (adult mice and most P14), cannulate 
the IVC below the connection to the aorta abdominalis  
ii. For mice weighing less than 7 grams, cannulate the IVC above the 
connection to the aorta abdominalis because it has a wider diameter 
iii. Come in at an angle almost parallel to the IVC so as not to poke through 
the other side of the vein.  This step needs to be smooth and sure, 
because if the needle is shaking, it can tear through the vein. 
i. Press the auto-retract button to retract the needle and leave the cannula in 
place.   
i. There should be “flashback”, or blood traveling back up the cannula.  
Sometimes when this does not happen the perfusion still works.   
j. When the perfusion media is coming out the output side the tubing (and 
attached adaptor), screw the end onto the cannula.   
i. The blood vessels should immediately start swelling because media is 
being pumped into a closed system. 
k. Immediately sever the portal vein.  
i. The liver should immediately blanch (change color from red to beige) and 
over the next minutes will slightly swell.  If the liver does not blanch, a 
qtip can be used to gently massage the liver a little to dislodge a clot.  Do 
not over-massage. 
l. After perfusion media switch to digest media.   
4. Liver dissociation 
a. Dissect out the liver, transfer to a Petri dish with ~20 mL William's E media. 
b. For “total perfused liver” samples, cut off a small chuck of liver. 
c. Dissociate with a cutting motion, not a scraping motion.  Release of cells makes 
the media cloudy.  When all the cells possible have been removed by the 
cutting motion, then scrape the “husk” of the liver for remaining cells.   
d. Filter dissociated cells through a 100 μM cell strainer. 
e. Spin at 50 x g at 4C for 5 min in a swinging bucket centrifuge to form a loose 
hepatocyte pellet.  Hepatocytes are very large and pellet at this slow speed. 
f. For “supernatant” samples, which represents non-hepatocyte liver cell types, 
pellet remaining cells from the supernatant at 500 x g at 4C for 10 min.  
g. Resuspend hepatocytes in 10 mL William’s E and pellet again.  This is the 
hepatocyte fraction 
h. Count hepatocytes with a hemocytometer.  Automated cell counters have 
trouble with hepatocytes because they look granular. 
185 
 
i. Rinse tubing with PBS, then 70% EtOH, then PBS, then H2O. 
5. Nuclei isolation 
a. Resuspend hepatic pellet in 10 mL RSB.   
i. Too much contaminating media will change the tonicity of the solution 
and the hepatocytes will not swell as needed for efficient cytoplasmic 
membrane lysis. 
b. Immediately dounce 13 times with a tight-fitting Wheaton dounce attached to 
spinning drill press. 
c. Check for nuclei. 
d. Count nuclei with a hemocytometer.  Automated cell counters have trouble with 
all the debris. 
e. Pellet nuclei at 100 x g at 4C for 5 min 
 
Assessing hepatocyte enrichment 
This describes a standard RTqPCR analysis of total perfused liver, isolated hepatocytes, 
and pelleted supernatant from the hepatocyte perfusion protocol.  Total perfused liver 
represents total liver minus cell types lost to perfusion, such as red blood cells.  Pelleted 
supernatant represents non-hepatocyte cell types that were not pelleted with hepatocytes.  
In this protocol, hepatocyte enrichment is assessed by expression of different liver cell 
type marker genes in the perfused liver, hepatocyte, and pelleted supernatant fractions.  
See Figure 1 for results. 
 
Target Forward, Reverse Sequences 
Hnf4a 
 variants 1,2,3  
ggcaatgacacgtccccatc 
cacagatggcgcacaggg 
Foxa1 
tggctccaggatgttaggga 
acagggacagaggagtaggc 
Krt19 
ccctcccgagattacaacca 
ggcgagcattgtcaatctgt 
Gfap 
ctttgcacaggacctcggca 
acgcagccaggttgttctct 
Des 
gtggagcgtgacaacctgat 
tcggaaggcagccaagttgt 
Pecam1 
variant 1 
aggattcagctgaggtgggc 
tggatgctgttgatggtgaagg 
Acta2 
ggagaagcccagccagtcg 
ccagagccattgtcgcacac 
Ptprc 
IDT primer assay: 
Mm.PT.58.7583849 
Gapdh 
atggtgaaggtcggtgtgaac 
gccttgactgtgccgttgaat 
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1. Isolate RNA from hepatocytes, perfused liver, and pelleted supernatant from 
TRIzol per manufacturer’s protocol. 
2. Generate cDNA per manufacturer’s protocol. 
3. Run qPCR on the equivalent of 20 ng RNA that has been converted into double-
stranded DNA. 
a. Primers for markers hepatic cell populations.   
i. hepatocyte: Hnf4a, Foxa1 
ii. cholangiocytes: Krt19 
iii. stellate cells:  Gfap, Des 
iv. endothelial cells: Pecam1, Acta2 
v. immune cells, not including red blood cells or platelets: Ptprc  
vi. Internal control: Gapdh 
4. Calculate Relative Expression 
a. Relative expression: 2(Ct:target – Ct:Gapdh) 
b. Relative to supernatant: (relative expression supernatant)/(relative expression 
liver or total perfused liver) 
IV.  Results 
RTqPCR results on total perfused liver, hepatocytes, and pelleted supernatant show that 
markers of non-hepatocyte liver cell types, including cholangiocytes (Krt19), stellate cells 
(Gfap, Des), endothelial cells (Pecam1, Acta2), and immune cells (Ptprc) overwhelmingly 
fractionate into the pelleted supernatant fraction, with some signal in total perfused liver.  
Additionally, hepatocyte makers (Hnf4a, Foxa1) are enriched in the hepatocyte fraction.  
Supernatant shows variable signal for hepatocyte markers because the hepatocyte pellet 
is very loose and a variable quantity of hepatocytes are taken when supernatant is taken.  
This could probably be rectified by “clearing” the supernatant with a 50 x g spin to pellet 
contaminating hepatocytes before pelleting supernatant at 500 x g.  We conclude that 
hepatocytes have been dramatically enriched and non-hepatocyte cell types have been 
depleted in the hepatocyte fraction. 
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V.  Figures 
 
Figure 1: Isolation of murine hepatocytes 
A) Hepatocyte enrichment strategy.  The liver ECM is digested in situ by perfusion, the 
liver is dissociated, filtered through a 100 μM filter, and hepatocytes pelleted by 
centrifugation.  Remaining cells are pelleted from the supernatant. 
B) Expression of markers of hepatocytes (Hnf4a, Foxa1), biliary cells (Krt19), blood 
(Ptprc, not red blood cells or platelets), stellate cells (Gfap, Desmin), and endothelial 
cells (Pecam1, Acta2) by RTqPCR from perfused liver (after perfusion and before 
dissociation), pelleted hepatocytes, or pelleted supernatant.  Adapted from (Grindheim 
et al., 2019). 
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Appendix B: Sonication Resistant Heterochromatin Sequencing, a 
method for mapping sonication-resistant heterochromatin 
This appendix provides a detailed explanation of the sonication-resistant heterochromatin 
and high-throughput sequencing protocol.  Dario Nicetto, PhD and I developed protocols 
in parallel, with my protocol designed for high cell number experiments corresponding to 
10 μg isolated DNA (in Chapter 2, (Grindheim et al., 2019)) and Dario’s designed for low 
cell number experiments (30,000 cells) (in Chapter 3, (Nicetto et al., 2019)).  The high cell 
number version isolates large, medium, and small fragments of DNA to increase 
separation and resolution between small and large populations, while the low cell number 
version isolates large and small fragments.   
This appendix also describes some observations about the relationship of srHC, 
H3K27me3, transcription, and Type AB compartments.  srHC-seq, H3K27me3 ChIP-seq, 
and RNA-seq data was aligned and processed as described in (Chapter 4, (Grindheim et 
al., 2019)).  
I.  Objective 
To use the differential sonication sensitivity of crosslinked chromatin to genomically 
identify euchromatic and heterochromatic loci. 
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II.  Background 
It has been observed that heterochromatin is resistant to mechanical shearing (Frenster 
et al., 1963) and promoters of highly active genes are sonication-sensitive (Auerbach et 
al., 2009).  Genome-wide, the differential sensitivity of crosslinked chromatin to shearing 
by sonication was confirmed with a technique termed gradient-seq (Becker et al., 2017).  
The gradient-seq protocol involves fractionation of crosslinked, sonicated heterochromatin 
via a sucrose gradient, a setup in which heterochromatin is fast migrating and euchromatin 
is slow migrating (Figure 1).  Reflecting the relative crosslinking efficiency and sonication 
sensitivity of euchromatin and heterochromatin, isolation of DNA fragments from different 
fractions of the sucrose gradient reveals that DNA from euchromatin corresponds to low 
molecular weight fragments while DNA from heterochromatin corresponds to higher 
molecular weight fragments. 
While the gradient-seq protocol has already been developed, there are some 
drawbacks to this method, as is true with any experimental method.  Fractionation on a 
sucrose gradient is laborious and requires analysis of many gradient fractions in each 
experiment.  Additionally, it is likely that a portion of euchromatin fractionates rapidly with 
heterochromatin because they are crosslinked together (Figure 1).  Given that my studies 
did not include proteomics or transcriptomics of species in euchromatin or 
heterochromatin, advantages allowed for by gradient-seq, I opted to develop a related 
technique, srHC-seq, which involves fractionation of low and high molecular weight DNA 
isolated from crosslinked and sonicated chromatin, corresponding to euchromatin and 
heterochromatin, respectively.   
191 
 
III.  Key Reagents 
Crosslinked and sonicated chromatin 
This chromatin should be sonicated sufficiently so that the majority of DNA 
fragments are small molecular weight (≤ 500 bp) (Figure 1).  Data in this Appendix 
and Chapter 2 was from chromatin sonicated on a Diagenode Biorupter for 30 min 
(30 sec on Hi, 30 sec Off).  The tail of larger molecular weight DNA may or may 
not be visible an 1% agarose gel with ethidium bromide, depending on gel 
thickness, quantity of DNA, ethidium bromide concentration, etc.  See Figure 1. 
Agencourt AMPure XP beads (Beckman Coulter A63881) 
SPRI (Solid Phase Reversible Immobilization) beads were developed by the 
Whitehead Institute (DeAngelis et al., 1995)  The paramagnetic property, or 
magnetic only in a magnetic field, of SPRI beads prevents the beads from clumping 
and falling out of solution.  The beads are coated with carboxyl molecules which 
reversibly bind to DNA in the presence of the “crowding agent” polyethylene glycol 
and NaCl.  Here “bead slurry” refers to beads in PEG/NaCl buffer. 
With an increasing bead slurry to DNA in water or 0.1X TE ratio, progressively 
more DNA is “crowded” out of solution, with large molecular weight DNA fragments 
crowding out first.  After crowding out of solution, DNA can bind reversibly to the 
beads.  As AMPure XP beads have a high binding capacity (1 μL beads can bind 
3 μg of DNA, it is unclear whether that is 1 μL of beads or 1 μL of bead slurry), the 
volumetric ratio of bead slurry to DNA in water or 0.1X TE is usually the most 
important factor for size selection. 
magnetic Eppendorf rack 
for separation of beads from supernatant 
Covaris S220 or other sonicator 
for sonication of large DNA fragments to a size sufficiently small enough to be 
compatible with Illumina library prep sequencing protocols.  As of 2018, many high-
throughput library preparation protocols involve size selection of small fragments 
and PCR amplification, which also selects for smaller fragments.  Additionally, 
sequencing on an instrument such as Illumina Nextseq 500/550 models involves 
a DNA amplification step termed “cluster generation”, which also selects for small 
molecular weight fragments.   
TES buffer 
10 mM Tris-HCl, pH 8 
10 mM EDTA 
1% SDS 
TE buffer 
10 mM Tris-HCl, pH 8 
10 mM EDTA 
RNase A 
DNase-free.  Temperature quoted in the protocol below is based on the 
manufacturer’s recommendations. 
Proteinase K 
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DNase-free. Temperature quoted in the protocol below is based on the 
manufacturer’s recommendations. 
Glycogen (Roche 10 901 393 001) 
NEBNext Ultra DNA Library Prep Kit (NEB 7370) 
Likely many other commercial kits will also work.  This NEB kit has size selection 
steps for different sized inserts.  The variability between small and large-sonicated-
to-small fragments is not huge and the goal in the size selection step in the library 
prep protocol is to select for everything. 
NEBNext Multiplex Oligos for Illumina (Index Primers Set 1-4, NEB E7335S, E7500S, 
E7710S, E7730S) 
Agilent Bioanalyzer 
The size of srHC size-selected fragments and resulting libraries need to be 
measured.  
NEBNext Library Quantification Kit (NEB E7630) 
Libraries need to be quantified prior to sequencing.  This is done with information 
about average library size (from a Bioanalyzer run) and qPCR with this or other 
kits against standards of known size and concentration.  The NEBNext library 
quantification kit is compatible with the NEBNext Ultra Library prep kit (the qPCR 
primers will amplify the libraries). 
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IV.  Protocol 
Isolation of DNA fragments from crosslinked and sonicated chromatin 
This may be scaled up or down as necessary. 
1. Decrosslinking 
a. 200 μL chromatin + 200 μL TES 
b. 65°C/overnight/shaking 
2. RNA and protein degradation 
a. + 200 μL TE (to dilute the SDS present for enzymatic activity) 
b. + 4 μL 10 mg/mL RNAse A for 2 hours/37°C/shaking 
c. + 4 μL 20 mg/mL Proteinase K 2 hours/55°C/shaking 
3. Phenol:chloroform:isoamyl alcohol fractionation of DNA 
a. + 400 μL PCI 
b. vortex 
c. Spin ≥ 12,000 x g for 15 min at room temperature 
d. Take 350 μL of aqueous phase 
4. Ethanol precipitation 
a. 350 μL of aqueous phase + 1.5 μL 10 glycogen + 32 μL 2.5 M NaCl + 1 mL 
100% EtOH 
b. Precipitate at -20°C overnight 
c. Pellet DNA: 20,000 x g for 10 min at 4°C 
d. Wash with 500 μL ice cold 80% EtOH 
e. Air dry pellet 
f. Resuspend in 50 μL 0.1X TE 
g. Check DNA molecular weight fragment distribution on a 1% agarose gel with 
1 μL ethidium bromide per 100 mL gel or a Bioanalyzer DNA 1000 ChIP (Figure 
1) 
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DNA size selection of small, medium, and large fragments 
Start with 10 μg DNA in 50 μL 0.1X TE or water.  This quantity of DNA in the stated volume 
is important because of the volumetric crowding properties of PEG/NaCl.  If this exact 
amount of DNA in the exact volume of buffer is not available, start with a pilot scaling down 
the volumes to a minimum of 25 μL because pipetting small amounts is difficult. 
1. Let the beads come to room temperature and vortex beads to resuspend 
2. 10 μg DNA in 50 μL 0.1X TE + 25 μL beads 
a. Pipette 10X, incubate 5 min at room temp, incubate 5 min at room temp on a 
magnetic rack. 
b. Take the supernatant to Step 3 
c. Wash the beads twice with 200 μL freshly prepared 80% EtOH 
d. Air dry 5 min at room temp 
e. Elute in 20 μL 0.1X TE.  Pipette 10X, incubate 5 min at room temp, incubate 5 
min at room temp on a magnetic rack. 
f. Expected: 1400 ng large MW DNA fragments 
3. Supernatant + 10 μL beads 
a. Pipette 10X, incubate 5 min at room temp, incubate 5 min at room temp on a 
magnetic rack. 
b. Take the supernatant to Step 4 
c. Wash the beads twice with 200 μL freshly prepared 80% EtOH 
d. Air dry 5 min at room temp 
e. Elute in 10 μL 0.1X TE.  Pipette 10X, incubate 5 min at room temp, incubate 5 
min at room temp on a magnetic rack. 
f. Expected: 400 ng medium MW DNA fragments 
4. Supernatant + 35 μL beads 
a. Pipette 10X, incubate 5 min at room temp, incubate 5 min at room temp on a 
magnetic rack. 
b. Discard the supernatant 
c. Wash the beads twice with 200 μL freshly prepared 80% EtOH 
d. Air dry 5 min at room temp 
e. Elute in 20 μL 0.1X TE.  Pipette 10X, incubate 5 min at room temp, incubate 5 
min at room temp on a magnetic rack. 
f. Expected: 1 ug small MW DNA fragments 
5. Check DNA molecular weight fragment distribution on a Bioanalyzer DNA 1000 
ChIP (Figure 1) 
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Sonication of large molecular weight fraction DNA 
Most library prep protocols cannot accommodate large MW fragments because of a size 
selection step and a PCR amplification step, nor can the Illumina NextSeq 500/550 
sequencer.  
1. Sample prep 
a. Dilute large DNA to 130 μL in 0.1X TE and transfer to a Covaris S220 microtube 
b. Sonication with Covaris S220 
i. PP: 175 W 
ii. DF: 10 
iii. CB: 200 
iv. 4-9°C 
v. 5 min 
2. Ethanol precipitation 
a. 130 μL sample  
b. + 70 μL H20  
c. + 17.4 μL 2.5 M NaCl  
d. + 875 μL 100% EtOH 
e. Precipitate at -20°C overnight 
f. Pellet DNA: 20,000 x g for 10 min at 4°C 
g. Wash with 500 μL ice cold 80% EtOH 
h. Air dry pellet 
i. Resuspend in 19 μL 0.1X TE.   
j. For the rest of the protocol, these large-sonicated-to-small size fragments 
continue to be referred to as “large” fragments 
3. Check DNA molecular weight fragment distribution on a Bioanalyzer DNA 1000 
ChIP (Figure 1) 
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Library Prep 
With NEBNext Ultra DNA Library Prep Kit E7370  
1. End Prep 
a. Blunts ends and adds an A overhang.  This step is per the manufacturer’s 
protocol 
b. Dilute DNA to 55.5 μL with H2O 
c.  
DNA 55.5 μL 
End Prep Enzyme Mix 3 μL 
10X End Repair Rxn Buff 6.5 μL 
d. Incubate 
e. 30 min @ 20°C 
f. 30 min @ 65°C 
g. Hold @ 4°C (but proceed asap) 
h. With heated lid 
2. Adaptor ligation 
a. Adds a stem-loop adaptor with a T overhang.  The stem loop prevents 
concatenatation.  This step is per the manufacturer’s protocol. 
b.  
End Prep Rxn 65 μL 
Blunt/TA Ligase MM 15 μL 
15 μM NEBNext Adaptor 2.5 μL 
Ligation Enhancer 1 uL 
c. Incubate 
i. 15 min @ 20°C 
ii. 30 min @ 65°C 
iii. 30°C heated lid because high temperatures can interfere with the ligation 
reaction 
d. Add 3 μL USER enzyme (cuts at U’s in the adaptor) 
e. Incubate 15 min 37°C 
3. Size selection of small fraction inserts with AMPure XP beads 
a. This step is adapted to the size of small fragments. 
b. Let the beads come to room temperature and vortex beads to resuspend 
c. 86.5 μL Adaptor Rxn + 13.5 μL H2O + 55 μL beads 
i. Pipette 10X 
ii. incubate 5 min @ room temp 
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iii. incubate 5 min @ room temp on a magnetic rack. 
iv. Transfer the supernatant to a new tube 
v. Supernatant + 25 μL beads 
vi. Pipette 10X 
vii. incubate 5 min @ room temp 
viii. incubate 5 min @ room temp on a magnetic rack. 
d. Transfer the supernatant to a new tube 
i. Wash the beads twice with 200 μL freshly prepared 80% EtOH 
ii. Air dry 5 min at room temp 
iii. + 17 μL 0.1X TE to elute 
iv. Pipette 10X 
v. incubate 5 min @ room temp 
vi. incubate 5 min @ room temp on a magnetic rack 
vii. Take 15 μL eluate 
4. Size selection of large-sonicated-to-small fraction inserts with AMPure XP 
beads 
a. This step is adapted to the size of large-sonicated-to-small fragments. 
b. Let the beads come to room temperature and vortex beads to resuspend 
c. 86.5 μL Adaptor Rxn + 13.5 μL H2O + 35 μL beads 
i. Pipette 10X 
ii. incubate 5 min @ room temp 
iii. incubate 5 min @ room temp on a magnetic rack. 
iv. Transfer the supernatant to a new tube 
d. Supernatant + 45 μL beads 
i. Pipette 10X 
ii. incubate 5 min @ room temp 
iii. incubate 5 min @ room temp on a magnetic rack. 
iv. Transfer the supernatant to a new tube 
v. Wash the beads twice with 200 μL freshly prepared 80% EtOH 
vi. Air dry 5 min at room temp 
vii. + 17 μL 0.1X TE to elute 
viii. Pipette 10X 
ix. incubate 5 min @ room temp 
x. incubate 5 min @ room temp on a magnetic rack 
xi. Take 15 μL eluate 
5. PCR enrichment of adaptor-ligated DNA 
a. Per the manufacturer’s suggestions for the quantity input DNA, the small 
fraction has 8 cycles amplification and the large fraction has 7 cycles 
amplification. 
b. Vortex MM to resuspend 
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DNA from steps 3 and 4 15 μL 
NEBNext Q5 HotStart HiFi PCR MM 25 μL 
NEBNext Index Primer 5 μL 
Universal PCR Primer 5 uL 
c. PCR amplification and barcoding 
Hot Start and Initial Denaturation 30 sec @ 98°C 1 cycle 
Denature 10 sec @ 98°C small: 8 cycles 
large: 7 cycles Anneal/Extend 75 sec @ 65°C 
Final extension 5min @ 65°C 1 cycle 
Hold 4°C  
d. During the 4°C hold, run 1 μL of samples a Bioanalyzer HS DNA ChIP to check 
for amplification.  If no broad hump of amplification is seen around 300 bp, 
more cycles can be added. 
6. PCR cleanup with AMPure XP beads 
a. This step is per the manufacturer’s protocol. 
b. Let the beads come to room temperature and vortex beads to resuspend 
c. 50 μL PCR rxn + 45 μL beads 
d. Pipette 10X 
e. incubate 5 min @ room temp 
f. incubate 5 min @ room temp on a magnetic rack. 
g. Wash the beads twice with 200 μL freshly prepared 80% EtOH 
h. Air dry 5 min at room temp 
i. + 22 μL 0.1X TE to elute 
j. Pipette 10X 
k. incubate 5 min @ room temp 
l. incubate 5 min @ room temp on a magnetic rack 
m. Take 20 μL eluate 
7. Check library molecular weight fragment distribution 
a. on a Bioanalyzer DNA 1000 ChIP (Figure 1) 
b. Possible contaminating factors include: 
i. 127 bp peak is contaminating adaptor 
ii. < 85 bp peaks are contaminating primers 
iii. > 1 kb fragments can be over-amplification 
c. If the area under the curve of these contaminations is small compared to the 
area under the curve of the library, then that is acceptable. 
d. Note the average fragment size of each library for the library quantification 
step. 
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Library quantification, dilution, and sequencing 
With the NEBNext Library Quantification Kit (NEB E7630) and the NextSeq 500/550 
sequencer. 
1. Quantify library concentration  
a. per the manufacturer’s protocol (1 in 30,000 and 1 in 60,000 dilutions are a 
good starting point to use for staying inside the standard curve). 
2. Dilute libraries to 2 nM 
3. Quantify the 2 nM libraries concentration per the manufacturer’s protocol (1 in 
10,000) 
4. Pool libraries in a 1:1 ratio of molecules to get equal sequencing depth 
a. Example 1: if all the libraries really were diluted to 2 nM, that would be equal 
volumes of each library.  
b. Example 2: 4 diluted libraries are actually 1 nM, 2 nM , 2 nM, and 4 nM.  To 
get equal representation, pool 10 μL of the 1 nM library, 5 μL each of the 2 nM 
libraries, and 2.5 μL of the 4 nM library. 
5. Quantify the 2 nM pooled library concentration per the manufacturer’s protocol 
(1 in 10,000) 
6. Denature and dilute pools  
a. per the current version of the NextSeq 500/550 protocol (or whatever 
sequencer is currently in use).  With the NextSeq, the manufacturer 
recommends a final concentration of 1.8 pM.  The Zaret Lab typically uses 
more than that without overclustering.  1.5X (2.7 pM) this amount often works 
well with srHC-seq. 
7. Sequence single-end, 75 bp reads 
a. Paired-end might give more information about small fragment size locations, 
but we have not investigated this.  
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Alignment and processing of srHC-seq data 
Since alignment and analysis software are often updated, the general step is described 
and particular parameters that are useful.  See (Grindheim et al., 2019) for exact 
parameters. 
1. Alignment and processing 
a. Align FASTQs 
b. Convert SAMs to BAMs 
c. Sort BAMs by location 
d. Convert BAMs to BEDs 
e. Get unique alignments to minimize PCR duplication artifacts. 
f. Convert to BAMs 
g. Sort BAMs by location 
h. Convert to BEDs 
2. Track creation 
a. Get RPM 
b. Split BEDs into individual chromosomes for computational memory purposes 
c. Make RPM-normalized BGRs 
d. Perform log2( (large fragment RPM-normalized BGR) / (small fragment RPM-
normalized BGR) ) 
i. log2(large/small) translates into large-/heterochromatic-enriched regions 
being y > 0 and small-/euchromatic-enriched regions y < 0.  This is easy 
to interpret with the human eye on a genome browser. 
e. Concatenate chromosomal BGRs 
f. Sort by location 
g. Average biological replicates 
i. bedtools unionbedg -filler "N/A" 
h. Convert to BW 
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Domain calling 
Call domains with the published Zaret Lab algorithm (Becker et al., 2017) plus additional 
steps.  In short, for euchromatic domains, the Becker/Zaret algorithm will perform 
small/large fragments analysis, and for heterochromatic domains, the algorithm will 
perform large/small fragment analysis before further processing.  See Figure 3 for a 
simplified schematic.   
1. Compute large/small or small/large enrichments for windows and bins:   
a. Script:  computeEnrichments_sliding.mouse.basicChrsNoM.py (written by 
Justin Becker, edited by Jessica Grindheim for the mouse genome) 
b. Settings: 10 kb windows, 2 kb bin/slide (“bin” and “slide” used somewhat 
interchangeably) 
i. With these settings, the script splits the genome into 10 kb windows with 
a 2 kb slide between and calculates window and bin division scores for 
each window and bin, depending on the input files.   
1. The first few windows on chromosome 1 would be, 0 kb - 10 kb, 
2 kb - 12 kb, 4 kb - 14 kb, etc.   
2. The first few bins on chromosome 1 would be, 0 kb - 2 kb, 2 kb 
- 4 kb, 4 kb - 6 kb, etc. 
c. Input files:  
i. BEDs of sorted, unique alignments for large and small srHC fractions 
1. The script uses “ChIP” and “Input” nomenclature. 
2. For heterochromatic domains, “ChIP” = large fragments BED 
and “Input” = small fragments BED 
3. For euchromatic domains, “ChIP” = small fragments BED and 
“Input” = large fragments BED 
d. Output files: 
i. Windows division scores:  RPM-normalized pileup is calculated for 
large/small or small/large division in each window for every individual 
sample. 
ii. Bins division scores:  The script also splits the genome up into 2 kb bins. 
The bins for chromosome 1 would be 0 - 2 kb, 2 - 4 kb, 4 - 6 kb, etc.  Each 
2 kb bin in the genome is scored for RPM-normalized large/small or 
small/large division for each individual sample.  
2. Get enriched windows with a fixed percentile cutoff 
a. Script: getEnrichedBins_fixedPercentile.r (written by Justin Becker) 
b. Settings: 60% cutoff 
c. Input Files:  Windows division scores 
d. Output files: 
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i. Enriched Windows:  Windows scores for biological replicates are 
averaged.  With a 60% cutoff, the highest 40% scoring windows are 
defined as enriched windows. 
3. Merge neighboring windows 
a. Script:  mergeNeighbors.py (written by Justin Becker) 
b. Input files:  Enriched Windows 
c. Output files:  
i. Merged enriched windows:  enriched windows that are adjacent are 
merged into larger windows.  For example, if chromosome 1, 2 kb – 12 
kb, 4 kb – 14 kb, and 6 kb – 16 kb are all enriched windows, then they 
become one large window from 2 kb – 16 kb.  For another example, if 
chromosome 1, 2 kb – 12 kb and 6 kb – 16 kb are enriched windows (but 
not the intervening 4 kb – 14 kb), then they remain two separate enriched 
windows.  
4. Merge replicate bin scores 
a. Script:  mergeReplicateBinScores.r (written by Justin Becker) 
b. Input files:  Bin division scores 
c. Output files:   
i. Merged bin division scores:  Bins division scores were previously 
calculated per individual samples.  This file has bin scores averaged 
across the biological group.  For example, if three biological replicates 
have bins scores for chromosome 1, 0 kb – 2 kb of 2, 3, and 4 then the 
averaged bin score would be 3.   
5. Prune merged enriched windows 
a. Script:  pruneDomains.py (written by Justin Becker) 
b. Settings: 1X prune 
c. Input files: Merged enriched windows, Merged bin division scores 
d. Output files: 
i. Pruned windows:  The 60% cutoff corresponds to an large/small division 
score.  This script takes merged enriched windows and prunes the 2kb 
edges off if the 2kb edge bins are less than 1X * the 60% large/small 
cutoff value. 
6. Merge overlapping pruned windows 
a. Script:  mergeDomains.py (written by Justin Becker) 
b. Input files: Pruned windows 
c. Output files 
i. Enriched domains:  Adjacent or overlapping pruned windows are merged 
into “enriched domains”.  For example, pruned window 1 is located on 
chromosome 1 from 4 kb – 20 kb, pruned window 2 is located on 
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chromosome 1 from 20 kb – 30 kb, pruned window 3 is located on 
chromosome 1 from 36 kb – 46 kb, and pruned window 4 is on 
chromosome 1 from 150 kb – 170 kb.  Pruned windows 1, 2, and 3 are 
merged into 1 large domain from 4 kb – 46 kb.  Pruned window 4 is 
separate and the intervening space from 46 kb to 150 kb is not an 
enriched domain. 
This is where the Becker/Zaret algorithm is finished. 
7. Determine final heterochromatic, intermediate, and euchromatic domains 
a. Use bedtools to get final domains.   
b. Heterochromatic domains = heterochromatic domains from the Becker/Zaret 
algorithm minus any regions overlapping with the euchromatic domains from 
the Becker/Zaret algorithm 
c. Euchromatic domains = Euchromatic domains from the Becker/Zaret algorithm 
minus any regions overlapping with the heterochromatic domains from the 
Becker/Zaret algorithm 
d. Intermediate domains = Regions called neither heterochromatic nor 
euchromatic with the Becker/Zaret algorithm, and regions that were called both 
heterochromatic and euchromatic with the Becker/Zaret algorithm. 
V.  Conclusions 
srHC-seq is highly reproducible 
srHC-seq is a highly reproducible technique by Spearman correlation of replicates and 
browser views (Chapter 2, Supplemental Figure 3, not reproduced here to avoid 
redundancy). 
The reproducibility of srHC-seq in the hands of different users has not been 
previously assessed.  Dario Nicetto, PhD also performed M2 Wt hepatocyte srHC-seq 
(Nicetto et al., 2019), so I took this opportunity to assess the similarity between his data 
set and the one generated here.  Differences in sample prep include Dario using a Covaris 
S220 to sonicate crosslinked chromatin while I used a Diagenode Bioruptor UCD-200.  
Also, Dario used his small cell number/small DNA input protocol which does not isolate 
medium-size DNA fragments.  Different library prep kits were also used.  To compare 
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these protocols as uniformly as possible, both datasets were processed identically from 
the FASTQ stage on as described in (Grindheim et al., 2019).  M2 Wt hepatocyte srHC-
seq profiles from both datasets are highly similar at the positive controls sites for closed 
an open chromatin (Zfp936 and the Alb/Afp/Afm locus) and at the dynamic Cux2 locus 
(Figure 2). 
We also employed a circular shuffling approach on heterochromatic and 
euchromatic domains to statistically assess similarity (code by Greg Donahue, Zaret Lab). 
Briefly, heterochromatic and euchromatic domains were called as described in (Grindheim 
et al., 2019) for both datasets. Grindheim domains were randomly displaced in a 
downstream direction by X bases on each chromosome, with domains or partial domains 
dropping off the end of the chromosome re-ordered to the beginning of the chromosome 
(called “shuffled domains”), and the number of Nicetto domains with 50% or higher 
sequence overlaps to the shuffled domains was counted. This experiment was repeated 
1,000 times, and the p-value was estimated as the number of experiments in which the 
randomized overlap was greater than or equal to the observed non-randomized overlap, 
divided by 1,000.  Estimated p-values for euchromatic and heterochromatic domains are 
less than 0.001.  These results confirm statistically that Grindheim and Nicetto M2 srHC 
domains are significantly related. 
Robust heterochromatic and euchromatic gene calling with srHC-seq 
With increasingly lax enriched window cutoffs for domain calling, an increasing portion of 
the genome is called as heterochromatic or euchromatic, until the 50% cutoff, where 
heterochromatic +/euchromatic + double positive regions that are reclassified as 
intermediate takeover (Figure 3AB).  Despite the increasing portions of the genome which 
are called as heterochromatic or euchromatic with 10% to 40% enriched window cutoffs, 
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there is relatively mild change in the number of genes or promoters called as 
heterochromatic, euchromatic, or intermediate (Figure 3C), reflecting the robustness of 
this technique for calling gene or promoter compaction states.  Also reflecting the 
robustness of this technique, euchromatic genes have high expression and 
heterochromatic genes have relatively low expression (Figure 3D).  Curiously, genes 
called as having heterochromatic gene bodies or promoters at P14 have higher levels of 
expression than that genes called as having heterochromatic gene bodies or promoters 
at M2, suggesting cellular heterogeneity or incomplete “lockdown” of the genome at the 
relatively immature P14 timepoint. 
srHC-seq reveals a preference for H3K27me3 in Type A compartment 
heterochromatin 
Chromosomal organization is cell-type specific and related to transcriptional control 
(Dekker and Mirny, 2016; Gorkin et al., 2014; de Laat and Duboule, 2013). The highest 
level of topological organization segregates the genome into megabase scale 
compartments termed Type A and B, which are associated with active and inactive 
chromatin, respectively, with the latter enriched at the nuclear lamina (Boettiger et al., 
2016; Lieberman-Aiden et al., 2009; Lin et al., 2012; Rao et al., 2014; Vieux-Rochas et 
al., 2015; Wang et al., 2016).  We found a high concordance between srHC-seq data and 
adult liver Type AB compartments, with Type A compartments being more euchromatic, 
B compartments being more heterochromatic (Schwarzer et al., 2017), and also high 
concordance with lamin-associated domains (Peric-Hupkes et al., 2010) (Figure 4AB).  
Specifically, nearly three quarters of Type A compartments are called as euchromatic by 
srHC-seq, and nearly three quarters of Type B is called as heterochromatic by srHC-seq 
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(Figure 4C).  Thus, srHC-seq reflects compaction predictions based on AB compartment 
calls.   
Interestingly, a quarter of Type A compartments are called as heterochromatic by 
srHC-seq, and nearly a quarter of B compartments are called euchromatic (Figure 4C). 
Supporting this, gene expression more closely tracks with srHC-seq heterochromatin and 
euchromatin calls at gene bodies and promoters than with AB compartment localization 
(Figure 4D).  These results confirm the findings of others (Lieberman-Aiden et al., 2009; 
Rao et al., 2014), that AB compartments are generally transcriptionally active/euchromatic 
and inactive/heterochromatic, respectively, but also show that regions within a 
compartment do not always conform to the general euchromatic or heterochromatic nature 
of the compartment. Interestingly, 70% of heterochromatin in Type A overlapped with M2 
H3K27me3 domains, while only 51% of heterochromatin in B (Figure 4B), suggesting that 
A heterochromatin compartments are more dependent on Polycomb-related compaction.  
With the srHC-seq assay we can accurately identify the heterochromatic/euchromatic 
state of annotated genomic features, such as promoters and genes, which in turns predicts 
the transcriptional states of genes more accurately than AB compartment localization 
(Figure 4D). 
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VI.  Figures 
Figure 1: Fractionation of high and low 
molecular weight DNA for srHC-seq 
A) Gradient-seq schematic with DNA 
from different fractions run on an agarose 
gel.  Adapted from (Becker et al., 2017).  
Note that low MW DNA fragments 
correspond to sonication-sensitive 
euchromatin and high MW DNA fragments 
correspond to sonication-resistant 
heterochromatin. 
B) High cell number srHC-seq overview. 
C) Total DNA from crosslinked, 
sonicated hepatocyte chromatin is shown on 
a 1% agarose gel for comparison to  
D) Total DNA on a Bioanalyzer DNA 
1000 chip. Representative profiles for Large, 
Medium, or Small DNA fractions and Large 
DNA that has been sonicated to a smaller 
size for library prep considerations. 
B-D Adapted from (Grindheim et al., 2019) 
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Figure 2: High reproducibility of srHC-seq data 
A) srHC-seq (top: Grindheim, bottom in light blue: Nicetto) and RNA signal for positive 
controls sites for heterochromatin, Zfp936, euchromatin, Alb locus, or a dynamic gene, 
Cux2. 
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Figure 3: srHC-seq heterochromatin and euchromatin domain, promoter, and gene 
body calling 
A) Compaction domain calling overview.   
B) Portion of the genome called as heterochromatic, euchromatic, or intermediate with 
variable enriched window cutoffs.  Heterochromatic and euchromatic window cutoffs 
are the same.   
C) # of genes or promoters called as heterochromatic, intermediate, euchromatic, or NA 
with variable enriched window cutoffs.  Marked genes  50% of the gene body 
overlapping with a domain.  Marked promoters  75% of the gene body overlapping 
with a domain.  NA refers to genes that do not meet the definition of a marked gene. 
D) Wt gene expression in P14 (left) and M2 (right) hepatocytes. Genes are divided into 
srHC Heterochromatic, Intermediate, or Euchromatic promoters  (>=75% of TSS -
1kb/+500bp marked by a domain) or gene bodies (>=50% of gene body marked by a 
domain) (top 40% enriched window cutoff).  Genes are further divided into H3K27me3-
marked at the promoter (>=50% of TSS -1kb/+500bp marked by an H3K27me3 
domain) or at the gene body (>=25% of gene body marked by a domain) (top 30% 
enriched window cutoff).  Whiskers indicate 5-95 percentiles. 
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Figure 4: AB compartments 
A) Type A (green) and Type B (red) compartments in adult mouse liver at 20 kb or 100 
kb resolution (Schwarzer et al., 2017), srHC-seq signal in M2 Wt hepatocytes, DamID 
of LaminB1 in mouse log2-ratio (Peric-Hupkes et al., 2010), RNA-seq signal M2 Wt 
hepatocytes, and RefSeq genes. 
B) srHC-seq seq signal in non-overlapping 10 kb windows inside of Type A or B 
compartments (100 kb resolution).  Wilcoxon rank sum test with continuity correction, 
all p-values < 2.2e-16. 
C) Left: A and B compartments (100 kb resolution) divided into heterochromatin, 
intermediate, or euchromatic domains.  Right: Heterochromatin and euchromatin in A 
or B compartments further divided into H3K27me3 or H3K9me3 domains. 
D) Female expression for genes and promoters that have been divided into A/B 
compartment (100 kb resolution) location and further divided into 
heterochromatin/euchromatin calls.  
VII.  Bioinformatics methods 
Calling genes in Type AB compartments 
The Spitz Lab provided adult mouse liver AB compartment data (Schwarzer et al., 2017). 
If a gene body or promoter overlapped at least 90% with a Type A compartment, it was 
called as in Type A. If a gene or promoter overlapped at least 90% with a Type B 
compartment, it was called as in Type B.  Given the large size of Type A B compartments, 
this captured the majority of genes. For example, with compartments at a 20kb or 100kb 
resolution, approximately 5% and 2% of genes were unassigned, respectively 
srHC-seq scores in Type AB compartments 
To determine srHC-seq scores in Type AB compartments, the genome was first divided 
into 10 kb windows without overlap.  10 kb windows completely inside of a Type A 
compartment are “Type A windows” and the same for “Type B windows”.  Quantile 
normalized srHC-seq scores for these windows were used.  To test for differences in srHC-
seq scores between A and B compartments, the Wilcoxon rank sum test with continuity 
correction was used. 
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Appendix C: Cut and Run, a method for mapping proteins on 
chromatin  
Cut and Run is a method developed by the laboratory of Steven Henikoff for identifying 
protein-DNA interaction.  This appendix describes how I adapted the Elife 2017 version of 
the Cut and Run protocol (Skene and Henikoff, 2017) to work on fresh hepatic nuclei.  In 
the Cut and Run protocol, a protein A-MNase fusion protein is recruited to chromatin by 
an antibody against a protein of interest, where the MNase portion of the fusion protein 
can then cleave DNA.  In contrast to ChIP, this Cut and Run protocol is performed on non-
crosslinked, unsonicated nuclei.  The protocol should also work on non-hepatic nuclei as 
well.  
I.  Objective 
To determine the genomic location of target, such as transcription factors or histone 
modifications, without crosslinking or sonication. 
II.  Background 
The genomic location of histone modifications or transcription factor binding is key to 
understanding transcriptional regulation or other nuclear processes.  Therefore, genome-
wide chromatin profiles are commonly generated using a technique termed chromatin 
immunoprecipitation (ChIP), first described in 1985 (Solomon and Varshavsky, 1985).  In 
ChIP protocols, cells are crosslinked with formaldehyde to stabilize protein-DNA 
interactions.  Crosslinking is followed by sonication, which is needed to break 
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chromatin/DNA down into soluble and mappable smaller fragments.  Immunoprecipitation 
enriches for fragments of interest and DNA is extracted for analysis by qPCR, microarrays, 
or more recently, high-throughput sequencing.  While ChIP has revolutionized the study 
of chromatin biology and gene regulation, there are some drawbacks, including  masked 
epitopes and false positives from crosslinking (Baranello et al., 2016; Jain et al., 2015; 
Meyer and Liu, 2014; Park et al., 2013; Skene and Henikoff, 2017; Teytelman et al., 2013).  
One alternative is native ChIP, or ChIP without crosslinking in ionic conditions that leave 
electrostatic interactions intact.  Native ChIP required the use enzymatic methods, such 
as MNase treatment, to cleave DNA to smaller, mappable fragments (Kasinathan et al., 
2014).  Native ChIP can avoid epitope masking, epitope degradation, and can be used on 
smaller numbers of cells, but can have its own biases related MNase overdigestion or 
cleavage preferences (Axel, 1975; Iwafuchi-Doi et al., 2016; Rhee et al., 2014; Weiner et 
al., 2010; Xi et al., 2011).   
To circumvent some of these biases, the Henikoff Lab developed Cleavage Under 
Targets and Release Using Nuclease, or Cut and Run (Skene and Henikoff, 2017).  Cut 
and Run does not require crosslinking or sonication, thus avoiding some epitope masking 
and false positive biases.  The version of Cut and Run (Figure 1) described here involves 
incubation of nuclei with an antibody against the target of interest, then incubation with a 
protein A-MNase fusion protein, which is directed to bind the antibody by the bacterially-
derived protein A.  The cleavage reaction is initiated by the addition of calcium and stopped 
with the addition of cation chelating agents.  DNA fragments released by MNase cleavage 
of DNA around the DNA-antigen-antibody-pA-MNase complex are released and can be 
isolated by incubation, nuclei pelleting, and isolation of cleaved DNA fragments from the 
supernatant (Figure 1).  The Henikoff Lab has used their protocol to determine chromatin 
profiles for both TF and histone modifications and claim that this targeted digestion method 
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reduces background as compared to standard ChIP methods, thus reducing the cell 
number and sequencing depth required.  In another version of their protocol, robotic 
automation is possible by the combination of low cell numbers and magnetic beads.  
  
218 
 
III.  Key Reagents 
4-6 million nuclei per reaction 
Here isolated from fresh hepatocytes as described in Appendix A.  We did not test 
Cut and Run on frozen cells or nuclei, because freezing may cause cellular lysis 
or DNA breakage and background signal. 
3-5 μg antibody per reaction 
Likely more antibody should be used in the cases of histone modifications with 
broad genomic coverage.  
Also do a no antibody control to assess endogenous nuclease and background 
pA-MNase cleavage. 
pA-MNase enzyme 
As of 2019, provided directly from the Henikoff Lab. 
Cut and Run Buffer 1 (CR1) 
20 mM HEPES, pH 7.5 
150 mM NaCl 
2 mM EDTA 
Add fresh:  
0.5 mM spermidine (note: short half-life) 
0.1% BSA 
Protease inhibitors, EDTA-free Roche, # 11836170001 
Sterile filter. 
Cut and Run Buffer 2 (CR2) 
20 mM HEPES, pH 7.5 
150 mM NaCl 
Add fresh:  
0.5 mM spermidine (note: short half-life) 
0.1% BSA 
Protease inhibitors, EDTA-free Roche, # 11836170001. (note: EDTA-free is very 
important because it chelates calcium ions, which are needed for MNase cleavage) 
Sterile filter. 
Cut and Run Buffer 3 (CR3) 
CR2 with 2 mM CaCl2   
Calcium ions allow MNase to cleave DNA. 
Stop Solution 
Cation chelating solution to stop MNase cleavage.  Also contains spike-in DNA for 
sequencing normalization. 
150 mM EDTA 
300 mM EGTA 
75 pg/mL mononucleosomal-sized, heterologous spike-in yeast DNA 
0.5 mL Eppendorf tubes 
The small volume reduces sloshing and possible nuclear lysis 
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TES buffer 
10 mM Tris-HCl, pH 8 
10 mM EDTA 
1% SDS 
TE buffer 
10 mM Tris-HCl, pH 8 
10 mM EDTA 
RNase A 
DNase-free.  Temperature quoted in the protocol below is based on the 
manufacturer’s recommendations. 
Proteinase K 
DNase-free. Temperature quoted in the protocol below is based on the 
manufacturer’s recommendations. 
Glycogen (Roche 10 901 393 001) 
NEBNext Ultra DNA Library Prep Kit (NEB 7370) 
Likely many other commercial kits will also work.   
NEBNext Multiplex Oligos for Illumina (Index Primers Set 1-4, NEB E7335S, E7500S, 
E7710S, E7730S) 
Agilent Bioanalyzer 
For fragment size analysis 
NEBNext Library Quantification Kit (NEB E7630) 
For library quantification prior to sequencing.  Library quantification is done with 
information about average library size (from a Bioanalyzer run) and qPCR with this 
or other kits against standards of known size and concentration.  The NEBNext 
library quantification kit is compatible with the NEBNext Ultra Library prep kit (the 
qPCR primers will amplify the libraries). 
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IV.  Protocol 
Cut and Run Reaction 
The hepatocyte nuclei used here were isolated as described in Appendix A. 
1. Wash nuclei 
a. Pellet nuclei 200 x g/4 min/4°C in a swinging-bucket centrifuge. 
i. Faster speeds make nuclei clump together and it becomes difficult to 
resuspend them. 
b. Resuspend in 1.5 mL ice cold CR1.  Mix by gentle pipetting. 
c. Save protein for Western, if desired. 
i. 100 μL TES per 10E6 nuclei 
d. Incubate for 5 min on ice 
e. Pellet nuclei 
f. Resuspend in about 1.5 mL CR2 
g. Count nuclei with a hemocytometer. 
h. Aliquot 4-6 million nuclei per reaction (the same number of nuclei in each 
reaction) in 0.5 mL tubes  
2. Primary antibody incubation 
a. Pellet nuclei  
b. Resuspend in 500 μL CR2. 
c. +3-5 μg Ab 
d. Rotate/2 hours/4°C 
e. Also do a no antibody control! 
3. 3 washes in 500 μL CR2 
4. pA-MNase incubation 
a. Pellet nuclei 
b.  Resuspend in 300 μL CR2 with 180 ng pA-MNase  
i. 180 ng corresponds to a 1/1000 dilution pA-MNase of the 360 ng/μL 
batch of enzyme.  Per Pete Skene’s recommendations. 
c. Rotate/1 hour/4°C 
5. 3 washes in 500 μL CR2 
6. Digestion reaction 
a. Place tubes on wet ice.  Heat can cause over digestion and off-target digestion. 
b. Pellet nuclei 
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c. Resuspend in 300 μL CR3, including the no Ab control. 
d. Mix by inverting, incubate 5-15 min (determine incubation time in a pilot 
experiment) 
e. Stop digestion by adding 20 μL Stop Solution 
f. Mix by inverting 
7. Retain desired fraction of cutting reaction 
a. Leach fragments out of nuclei: rotate/1 hour/4°C 
b. Pellet nuclei 
c. Take 300 μL of leach supernatant.   
i. Taking too much of the supernatant will also take nuclei, which will lead 
to background signal. 
d. + 3 μL 10% SDS 
e. + 5 μL 5M NaCl 
f. Can freeze here. 
8. RNA and protein degradation 
a. + 2 μL 10 mg/mL RNAse A 
b. Incubate for 2 hours/37°C/shaking 
c. + 4 μL 20 mg/mL Proteinase K 
d. Incubate for 2 hours/55°C/shaking 
9. Phenol:chloroform:isoamyl alcohol fractionation of DNA 
a. + 400 μL PCI 
b. Vortex thoroughly 
c. Spin ≥ 12,000 x g for 15 min at room temperature 
d. Take 350 μL of aqueous phase 
10. Ethanol precipitation 
a. 350 μL of aqueous phase + 1.5 μL 10 glycogen + 32 μL 2.5 M NaCl + 1.1 mL 
100% EtOH 
b. Precipitate at -20°C overnight 
c. Pellet DNA: 20,000 x g for 10 min at 4°C 
d. Wash with 500 μL 80% ice cold EtOH 
e. Air dry pellet 
f. Resuspend in 15 μL 0.1X TE 
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Library generation, quantification, dilution, and sequencing 
1. Generate libraries with NEBNext Ultra DNA Library Prep Kit E7370 
2. Check library molecular weight fragment distribution 
a. on a Bioanalyzer DNA High sensitivity ChIP 
b. Possible contaminating factors include: 
i. 127 bp peak is contaminating adaptor 
ii. < 85 bp peaks are contaminating primers 
iii. > 1 kb fragments can be over-amplification 
c. If the area under the curve of these contaminations is small compared to the 
area under the curve of the library, then that is acceptable. 
d. Note the average fragment size of each library for the library quantification 
step. 
3. Quantify library concentration  
a. With the NEBNext Library Quantification Kit (NEB E7630)  
b.  A 1/30,000 dilution is a good starting point to use for staying inside the 
standard curve 
4. Dilute libraries to 2 nM 
5. Quantify the 2 nM libraries concentration per the manufacturer’s protocol (1 in 
10,000) 
6. Pool libraries in a 1:1 ratio of molecules to get equal sequencing depth 
a. Example 1: if all the libraries really were diluted to 2 nM, that would be equal 
volumes of each library.  
b. Example 2: 4 diluted libraries are actually 1 nM, 2 nM , 2 nM, and 4 nM.  To 
get equal representation, pool 10 μL of the 1 nM library, 5 μL each of the 2 nM 
libraries, and 2.5 μL of the 4 nM library. 
c. 5-10 million reads are recommended for proteins with “peaky” profiles, like 
transcription factors. 
7. Quantify the 2 nM pooled library concentration per the manufacturer’s protocol 
(1 in 10,000) 
8. Denature and dilute pools  
a. Per the current version of the NextSeq 500/550 protocol (or whatever 
sequencer is currently in use).  With the NextSeq, the manufacturer 
recommends a final concentration of 1.8 pM.  The Zaret Lab typically uses 
more than that without over-clustering.   
9. Sequence paired-end, 37 bp/37 bp reads 
a. NextSeq 500/550 sequencer. 
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Alignment and processing of Cut and Run data 
As softwares are frequently updated, the steps are described in short.  Specifically, data 
was aligned and processed as described for H3K27me3 ChIP data in Chapter 2 
(Grindheim et al., 2019). 
1. Alignment and processing 
a. Align FASTQs to the target genome, here mouse,  
b. Optional: Align FASTQs to the spike-in control genome, here saccharomyces 
cerevisiae 
c. Convert SAMs to BAMs 
d. Sort BAMs by location 
e. Convert BAMs to BEDs 
f. Filter for unique alignments to avoid PCR duplicates 
g. Convert to BAMs 
h. Sort BAMs by location 
i. Convert to BEDs 
2. Track creation 
a. Get RPM 
b. Split BEDs into individual chromosomes for computational memory purposes 
c. Make RPM-normalized BGRs 
d. For traditional, Henikoff RPM-normalized tracks, with spike-in normalization 
i. Concatenate chromosomal BGRs 
ii. Sort by location 
iii. Average biological replicates 
1. bedtools unionbedg -filler "N/A" 
iv. Convert to BW 
e. For Cut and Run minus no Ab control (recommended to control for endogenous 
nuclease and background pA-MNase cleavage). 
i. Perform (sample RPM-normalized BGR) - (no Ab control RPM-
normalized BGR) ) 
ii. Concatenate chromosomal BGRs 
iii. Sort by location 
iv. Average biological replicates 
1. bedtools unionbedg -filler "N/A" 
v. Convert to BW 
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V.  Conclusions 
Successful transcription factor and histone modification Cut and Run 
reactions 
We performed Cut and Run on a no antibody control sample, H3K4me3, H3K27ac, 
FOXA2, and several Polycomb group proteins (Figure 2).  As positive controls binding 
profiles in hepatocytes, we compared Cut and Run results to published ENCODE adult 
liver H3K4me3 and H3K27ac, adult FOXA2 hepatocyte ChIP-exo (Iwafuchi-Doi et al., 
2016), and M2 H3K27me3 hepatocyte ChIP (Grindheim et al., 2019).  As compared to 
published ENCODE data, there is robust Cut and Run H3K4me3 and H3K27ac signal over 
no antibody control background signal.  Similarly, FOXA2 signal was robust at FOXA2 
binding sites as assessed by adult hepatocyte FOXA2 ChIP-exo.  In the case of Cut and 
Run for the Polycomb components, there is signal at open regions, such as the promoters 
of expressed genes or FOXA2 binding sites, that disappears when the Cut and Run no 
antibody control signal is subtracted indicating that Cut and Run was not successful with 
these antibodies. 
While we were successful at performing Cut and Run for several targets, we found 
that there was significant background signal in the no antibody control samples open sites.  
Given that the background cutting of pA-MNase in hepatocytes led to profiles that look 
remarkably similar to FOXA2 binding profiles, a FOXA2 Cut and Run reaction that did not 
work could easily be mistaken as successful.  Consequently, conclusions might be drawn 
that FOXA2 binds to promoters where it actually does not because open promoters are 
also sites of pA-MNase background signal.  These results contrast with other groups that 
observe negligible background.  We note that other groups are performing Cut and Run 
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on cell lines, while we are using native cells.  It is possible the increased background signal 
in our studies stems from a difference between cell lines and native cells, such as a 
difference in the quantity of endogenous nucleases.  Hepatocytes may be particularly 
prone to background cleavage as they contain unusually high quantities of cytoplasmic 
proteins, with 30-50 times more cytoplasm than nucleus.  While these results show Cut 
and Run to be a promising new technique, they also underline the differences between 
native tissues and cell lines, and emphasize the importance of controls. 
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VI.  Figures 
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Figure 1: Cut and Run schematic 
A) Hepatic nuclei are incubated with an antibody against a protein of interest. 
B) Then, incubate with the pA-MNase fusion protein.  The protein A portion of pA-MNase 
binds to the antibody. 
C) MNase cleavage is started by the addition of calcium cations.  Cleavage is stopped 
after a set time by the addition cation chelator.  In the stop solution is also spike-in 
DNA for sequencing normalization purposes. 
D) Nuclei are incubated on a rotator,  allowing the cut fragments of DNA to leach out of 
nuclei.  Nuclei are pelleted and DNA isolated from the supernatant. 
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Figure 2: Successful Cut and Run 
All Cut and Run samples have been filtered for unique alignments, were performed on 
the same adult female, and are shown as RPM-normalized tracks with and without no 
antibody subtraction.   
A) From top to bottom:   
No antibody control Cut and Run (black).   
H3K4me3: ENCODE adult liver ChIP, Cut and Run (Abcam 8580 GR124346-1) and 
no antibody control subtraction (brown).   
H3K27ac: ENCODE adult liver ChIP, Cut and Run (Abcam 4729 GR3187598-1) and 
no antibody control subtraction (cyan).   
FOXA2: FOXA2 hepatocyte (Iwafuchi-Doi et al., 2016) ChIP-exo (aligned by JMG), 
Cut and Run (Invitrogen 710730, Invitrogen 720061, Millipore 07-633) and no antibody 
control subtraction (green).   
Polycomb: M2 hepatocyte H3K27me3 (Grindheim et al., 2019), Cut and Run (BMI1: 
Update clone 6 05-637, CBX2: Bethyl A302-524A, EED: Santa Cruz 30812 Lot G2909) 
and no antibody control subtraction (blue).   
M2 hepatocyte RNA-seq signal from (Grindheim et al., 2019) (black). 
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Appendix D: Chromatin-associated RNA-seq, a method for isolating 
RNAs bound to chromatin 
This appendix provides a description of a collaboration between a graduate student in the 
Smale Lab, Miguel Edwards, PhD, and I that resulted in the following protocol for 
chromatin-associated RNA-seq on fresh hepatocytes isolated from 2-month-old mice.   
I.  Objective 
To isolate chromatin-associated RNA mouse hepatocytes.  Chromatin-associated RNA 
isolation has been described (Pandya-Jones and Black, 2009; Wuarin and Schibler, 1994) 
and expanded for genome-wide studies via high-throughput sequencing technologies 
(Bhatt et al., 2012).  Multiple classes of RNA are captured by chromatin-associated RNA, 
including nascent RNA and RNA which function in chromatin. 
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II.  Protocol 
Fractionation of chromatin-associated RNA 
The hepatocyte nuclei used here were isolated as described in Appendix A.  Use wide 
bore tips when handling nuclei. 
1. Resuspend the nuclei 
a. 100 μL glycerol buffer per 10E6 nuclei  
b. Incubate 2 min on ice 
c. Pellet 5 min/15,000 rpm/4°C 
d. Use a microscope and trypan blue staining to check for nuclear lysis. 
2. Transfer sup (nucleoplasmic lysate) to new tube.   
a. 10% of nucleoplasmic lysate for Western analysis 
b. 90% of nucleoplasmic lysate in TRIzol 
3.  Resuspend chromatin pellet in 25 μL PBS/10E6 nuclei  
a. 10% of chromatin lysate for Western analysis 
b. 90% of chromatin lysate in TRIzol 
 
Assessment of fractionation efficacy by Western blot 
To assess the success of fractionation, nucleoplasmic and cytoplasmic lysates were 
separated on a 12% gel and Western blotted for cytoplasmic, nucleoplasmic, and 
chromatin markers by Miguel Edwards.  Given the limited quantity of sample he normally 
works with, he blots for all three markers on the same blot without extensive work to 
achieve equal loading.  Therefore, a successful fractionation has high chromatin marker 
staining without nucleoplasmic or cytoplasmic staining. 
 
Cytoplasmic marker: α-tubulin (Calbiochem CP-06, mouse 1/1000). ~55 kDa 
Nucleoplasmic marker: α-SNRP70 (Black Lab antibody. ~ 70 kDa. 
Chromatin marker: H3 (Millipore 06-755, 1/2000).  ~17 kDa 
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From a pilot fractionation with variable concentrations of SDS, Miguel Edwards and I 
concluded determined conditions for chromatin fractions in hepatocytes (Figure 1a).  
These conditions were used on further samples and fractionation confirmed (Figure 1b). 
Library prep and sequencing 
Isolate RNA from TRIzol, deplete ribosomal RNA, and prepare libraries with Illumina’s 
TruSeq RNA Library Preparation Kit v2 with strand-specific reads.   
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III.  Figures 
A   
    
B  
  
 
Figure 1: Characterization of chromatin-associated RNA-seq samples 
A) Western blot results for pilot fractionation of nucleoplasm, chromatin, and a whole cell 
extract control. Cytoplasmic, nucleoplasmic, and chromatin markers on chromatin and 
nucleoplasmic lysates.   
B) Western blot results for fractionation of nucleoplasm, chromatin, and a whole cell 
extract control. Cytoplasmic, nucleoplasmic, and chromatin markers on chromatin and 
nucleoplasmic lysates.   
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Appendix E: qPCR primer design and testing 
This appendix provides a detailed explanation of how to design and test qPCR primers for 
reverse transcription qPCR (RTqPCR) and ChIP-qPCR.  It also provides a list of validated 
RTqPCR primer sets for useful targets to the Zaret Lab, primarily involving liver and 
pancreatic targets. 
I.  Objective 
To describe qPCR primer design best practices and provide a list of useful primers. 
II.  Background 
qPCR with a dsDNA intercalating fluorescent dye, such as the widely used SYBR Green 
assay, is widely used for both RTqPCR and ChIP-qPCR assays.  There are multiple 
considerations when designing and testing primers for these assays.  This is not an 
exhaustive description of everything that can be done when designing primers to ensure 
a robust and linearly amplifying assay, but if these practices are followed and three primer 
sets per target are tested, at least one is usually useable.  This does not take into 
consideration problems such as repeats or polyploid genomes but works well for mice and 
likely other mammalian genomes. 
1. Considerations for all qPCR primers: 
a. Linearity:  If there is twice as many amplicons in a sample, there should be 
twice as much fluorescent signal in a SYBR green assay. 
i. To design primers more likely to have linear amplification, design 
amplicons to be 80-120 bp. 
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ii. To assay for linearity, test primer sets on a 10-fold dilution series.  This 
will test a wide range of concentrations of template. 
b. Amplification of 1 amplicon:  If there is amplification of multiple products, 
then you are quantifying the quantity of all of those products together at once 
and it is not possible to separate which product the signal is coming from. 
i. To design primers that are more likely to amplify only 1 product, perform 
in silico PCR on the UCSC genome browser. 
ii. To screen for multiple products, always run a melt curve after PCR 
amplification.  Each amplicon will have a different melt temperature. 
c. Absence of primer dimer:  Some primers hybridize to themselves and the 
resulting dsDNA will cause fluorescent signal. 
i. To screen for primer dimer, run a no template control (NTC).  There 
should be no amplification in the NTC wells.  
2. Considerations for RTqPCR primers: 
a. Absence of gDNA amplification: Should not amplify genomic DNA (gDNA), 
as this will cause background if your RNA samples originally contain gDNA 
contamination.  In genes with only 1 exon, this is not always possible. 
i. To avoid gDNA amplification, design primers that span exon-exon 
junctions, which increases the amplicon length for gDNA amplicons.  
Short introns can still be amplified, so try to avoid exon-exon junctions 
with a short intron between.  
ii. To screen for gDNA amplification, test the primers against gDNA. 
III.  RTqPCR 
Reagents 
cDNA 
This cDNA should be from a tissue that should expressing the RNAs of interest. 
Power SYBR Green PCR Master Mix (Applied Biosystems 4367659) 
This mastermix contains all the necessary components for qPCR except template 
and primers.  It contains a dye that fluoresces when it is intercalated in dsDNA, 
which is how PCR amplification is detected by the qPCR machine lasers. 
10 ng/μL genomic DNA 
unsonicated gDNA for testing whether primers amplify DNA contamination. 
ApE plasmid editor software 
A free open-source software for manipulating relatively short DNA sequences, 
such as plasmids.  The latest version can be found and downloaded with a simple 
internet search. 
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Design 
1. Gene structure 
a. Look at the gene on the UCSC genome browser to see what the gene looks 
like: ie 1 or many isoforms or overlap with another gene.  This will inform which 
mRNA variant you download. 
2. Sequence download 
a. Download the mRNA sequence from the NCBI nucleotide dropdown menu.  Be 
aware there often many “variants” which is how NCBI refers to isoforms.  There 
are also partial sequences, so read the description. 
b. Copy-paste the entire NCBI entry from “LOCUS” to the “//” that occurs after the 
DNA sequence information into ApE.  Using the entire entry will allow ApE to 
automatically annotate sequence features, such as exons. 
c. Choose the exon-exon junction of interest. 
d. Copy the sequence where an amplicon is desired, plus some buffer sequence 
on either side. 
3. Primer selection 
a. Primer3 is an online tool that is available from many sites.  Use it. 
i. 80-120 bp amplicon 
ii. 58-60C melting  
1. Do all primers in this range so you can run them all on one plate 
2. This range is based on the annealing/extension preferences of 
POWER SYBR 
iii. 18-22 bp primers 
iv. Use the Primer3 setting to force inclusion of the exon-exon junction in the 
design 
4. In silico screening 
a. Use the in silico PCR tool on the UCSC genome browser to screen primers for 
i. Multiple amplicons 
ii. Amplifying gDNA (make sure to run in silico against both UCSC genes, 
which represent spliced transcripts, and the genome assembly)  
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IV. ChIP-qPCR  
Reagents 
10 ng/μL DNA from crosslinked and sonicated chromatin 
Power SYBR Green PCR Master Mix (Applied Biosystems 4367659) 
This mastermix contains all the necessary components for qPCR except template 
and primers.  It contains a dye that fluoresces when it is intercalated in dsDNA, 
which is how PCR amplification is detected by the qPCR machine lasers. 
Design 
1. Locus features 
a. Look at the gene on the UCSC genome browser to see what the feature looks 
like with respect to known datasets like DNase, histone modifications, TF 
binding, etc 
2. Sequence download 
a. Zoom into the locus where an amplicon is desired, plus some buffer sequence 
on either side. 
b. Click View → DNA 
c. Mask repeats then get DNA. 
3. Primer selection 
a. Primer3 is an online tool that is available from many sites.  Use it. 
i. 80-120 bp amplicon 
ii. 58-60C melting  
1. Do all primers in this range so you can run them all on one plate 
2. This range is based on the annealing/extension preferences of 
POWER SYBR 
iii. 18-22 bp primers 
4. In silico screening 
a. Use the in silico PCR tool on the UCSC genome browser to screen primers for 
i. Multiple amplicons 
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V.  Primer Assessment 
1. Templates 
a. NTC: No Template Control. Use water. 
b. 10-fold dilution series for RTqPCR 
i. 50 ng/uL cDNA:  Not actually 50 ng DNA by a nanodrop, but the 
equivalent of cDNA had 50 ng/μL RNA in it.  
ii. 5 ng/uL cDNA 
iii. 0.5 ng/uL cDNA 
iv. 0.05 ng/uL cDNA 
c. 10-fold dilution series for ChIP-qPCR 
i. 10 ng/uL input DNA (from crosslinked, sonicated chromatin) 
ii. 1 ng/uL input DNA 
iii. 0.1 ng/uL input DNA 
iv. 0.01 ng/uL input DNA 
d. 10 ng/μL gDNA for RTqPCR 
2. Template and Primer Mastermixes 
MM type Reagent 1X RXN 
volume 
# primer sets * 
1.15 * 2  
13.8X (RTqPCR) 
11.5X (ChIP-qPCR) 
Template 
MM 
2X Power SYBR 
MM 
4   
Template 1   
Primer MM 2X Power SYBR 
MM 
1  13.8 or 11.5  
20 μM primer mix 3.9  53.9 or 44.9 
H2O 0.1  1.38 or 1.15 
a. The mastermixes were designed to both add up to 5 μL, which is a volume 
most 100 μL max volume repeat pipettors can do 20 times, making plate 
loading rapid and precise. 
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3. Plate loading 
a. The first 12 columns and rows A-F of a 384 well plate shown below 
  1,2 3,4 5,6 7,8 9,10 11,12 
A 10-fold dilution series 
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B 10-fold dilution series 
C 10-fold dilution series 
D 10-fold dilution series 
E NTC template 
F gDNA template (RTqPCR 
only) 
4. Thermal cycling with melt curve (per manufacturer’s protocol) 
a. 95C 10 minutes: hot start 
b. 40 cycles 
i. 95C 15 seconds: denature 
ii. 60C 45 seconds: anneal and extend 
c. Melt curve 
i. 95C 15 seconds 
ii. 60C 15 seconds 
iii. 95C 15 seconds 
5. Analysis 
a. Check the amplification plots (Cycle versus RN) (Figure 1A) 
i. Sometime the program choses a cutoff (green horizontal line) at the 
extremes of the y-axis, where the signal is noise or affected by limited 
primers or nucleotides.  A cutoff in the middle of the amplification plot is 
desired. 
b. Screen for gDNA amplification (for RTqPCR primers) 
i. Select the gDNA wells and then check the melt curve.  This should not 
have signal.  The Ct in the table should be undetermined, though  35 Ct 
is acceptable because 35 cycles is the max used in real experimental 
conditions. 
c. Screen for primer dimer 
i. Select the NTC wells and then check the melt curve for amplification.  
This should not have signal.  The Ct in the table should be undetermined, 
though  35 Ct is acceptable because 35 cycles is the max used in real 
experimental conditions.   
d.  Screen for multiple amplicons (Figure 1B) 
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i. Select all templated samples and check the melt curve.  There should be 
one peak.  Multiple peaks reflect the different melting temperatures of 
different amplicons.   
e. Screen for linearity (Figure 1C) 
i. With a 10-fold template dilution series and PCR doubling amplicons 
every cycle, 3.32-fold more signal is expected for every 10-fold increase 
in template.  An ideal slope would therefore by 3.32, but 3.1 to 3.5 are 
acceptable. 
ii. Note the range of Cts that correspond to linear implication.  Some primer 
sets work well from, for example, Ct 20-30, but are no longer linear at 
higher Ct.  The Ct range where primers work is not exact, since the 
fluorescence cutoff (green horizontal line in Figure 1A) varies between 
plates. 
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VI.  Figures 
 
Figure 1: Assessing primer efficacy 
Data as presented by Applied Biosystems’ SDS software. 
A) Amplification plot of a 10-fold dilution series. 
B) Melt curves, also known as dissociation curves.  Note on left an example where there 
is only 1 melt curve, indicating that there was only 1 amplicon.  Note on the right, 
multiple amplicons, possibly from amplification of pseudogenes, multiple splice 
variants, or amplification of gDNA. 
C) Standard curve plot.  Note to the right (pink arrow) the slope.  The slope may be -/+ 
3.3, depending on the plate setup.  In the graph, points off the line may indicate non-
linearity at extreme Ct and can be omitted, which will cause re-calculation of the slope, 
but the linear Ct range should be noted and not considered in future experiments.  
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VII.  Verified mus musculus RTqPCR primers 
gDNA= amplifies gDNA 
Target Forward  Reverse  Comment 
Alb TTTCCAGGGGTGTGTTTCGC ACTGGGAAAAGGCAATCAGGA  
Alb CACCATTTGAAAGGCCAGAGG TGGGGCATAGAAATAAGGATGTC  
Ezh2 GCTCAAGAGGTTCAGAAGAGC CTGTATCCTCCGCTGCTTCC Exon 2-3 
Ezh2 CTCATTGCGCGGGACTAGG GCATTCAGGGTCTTTAACGGG Exon 3-4 
Ezh2 CCTCTGTCTCACGTGTGGAG GACGGTGCCAGCAGTAAGT Exon 15-16 
Ezh2 TTACTGCTGGCACCGTCTG TCTGTCTGCTTCATCCTGAGA Exon 16-17 
Ezh2 GGATGAAGCAGACAGAAGAGGA CTTTCGGGTTGCATCCACCA Exon 17-18 
Ezh2 GACCACAGGATAGGCATCTTTG CCCACATACTTCAGGGCATCA Exon 19-20 
Tifa CCTATCCCCAGGCTTCCA CCACAGCTAGATCAGGACTCC  
Tifa GGAGTCCTGATCTAGCTGTGG CAAGTGACCGTCTCCTCTGT  
Ntrk2 var 2 TTGACCCGGAGAACATCACG GGTTTCTCAGCCCCACGTAA  
Ntrk2 var 2 CTCATTGCAAACCAGAAAAGGC GCCACAAACTTTAAGCCGGA  
Ntrk2 var 2 GCAGCGACGTCATCCTACA ACCTGAGGCTTGCTTTCCAA  
Prdm16 GAGAGAGATTCCGCGAGCC AGGTCCGGGTCAGGTTCATA  
Prdm16 TGCATGTGAAAGAAGGTGCC TCACACTCATCACAGCGGAA gDNA 
Cbfa2t3 CCATCCTGATCCCCGAGAGC ATTCTTCTGCCCACTCGCGT  
Entpd2 AGCACTCCACTCTACCTGGGA GGTACCGTGTGAGCGTCTGT  
Fstl1 GCTCCCACCTTCGCCTCTAA GCCAGCCATCGTTTCCACAT  
Fstl1 TTTGTGGAGCTGGCAGGGAA TGCCATTACTGCCACACACA  
Cbx6 TGGGAGCCAGAGGAGAACAT TCTTCTTGGGCCCATACAGCT  
Ngf TGCCAAGGACGCAGCTTTCT TCTGCCTGTACGCCGATCAA gDNA  
Ngf CAGTGAGGTGCATAGCGTAATGT GCTATCTGTGTACGGTTCTGCC gDNA 
Wnt4 AACCGGCGCTGGAACTGTTC ACCTGCTGAAGAGATGGCGT  
Igf2bp3 TCGGTCCCTAAACGGCAGAG CACAGCTCTCCACCACTCCA  
Fgfr1 var 3 CGGGAGTAAGATCGGGCCAG CCTCCATTTCCTTGTCGGTGG  
Rgma CAATACACCTGTGCTGCCGG TCTGGTCCACACACTCTTGGA  
Tulp3 TGCCTTTGACGATGAGACCCT CAAGGCGCTTCTTTCTCTGCT  
Tnfsf12 TTGCAGCCCATTATGAGGTTCA GGTCTCTTCCCAGCCACTCA  
Cdkn2a CCGACGGGCATAGCTTCAG GCTGAGGCCGGATTTAGCTC  
Krt19 CCCTCCCGAGATTACAACCA GGCGAGCATTGTCAATCTGT  
Krt19 CCACCTACCTTGCTCGGATT ACTTCGGTCTTGCTTATCTGGA  
Krt19 ACCACTACTTTAAGACCATCGAG GCGAGCATTGTCAATCTGTAGG  
Hes1 CCAAGCTAGAGAAGGCAGAC GGTATTTCCCCAACACGCTC  
Hes1 GAAGCACCTCCGGAACCT GTCACCTCGTTCATGCACTC  
Col1a1 GTTCAGCTTTGTGGACCTCC TTCAGGGATGTCTTCTTGGC  
Foxa3 GTGGAGCTACTACCCGGAG TGAGTGGGTTCAAGGTCATG  
Cebpa CAAGAGCCGAGATAAAGCCA CAGGCGGTCATTGTCACTG gDNA 
Onecut1 TGGAAGTGGCTGCAGGAG CGTGTTCTTGCTCTTTCCGT  
Onecut2 CAGGATGTGGAAGTGGCTG CTGCGAGTTGTTCCTGTCTT  
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Sox9 AGACCAGTACCCGCATCTG AAGGGTCTCTTCTCGCTCTC gDNA 
Sox9 ATTCCTCCTCCGGCATGAG GATCAACTTTGCCAGCTTGC gDNA 
Sox9 ACTCCCCACATTCCTCCTC GTTTTGGGAGTGGTGGGTG gDNA 
Hnf4a 
var 7/8/9 
TCCTTATGACACGTCCCCATCT GAGGCTCCGTAGTGTTTGCC embryonic liver 
Hnf4a 
var 1/2/3 
GGCAATGACACGTCCCCATC CACAGATGGCGCACAGGG adult liver 
Hnf1b AGAGAGCTGCCCTGTACACT AGAGCTCTGGACTGTCTGGT  
Foxa1 TGGCTCCAGGATGTTAGGGA ACAGGGACAGAGGAGTAGGC  
Sox4 TGGAAGCTGCTCAAGGACAG GCCGGTACTTGTAGTCAGGG gDNA 
Gfap CTTTGCACAGGACCTCGGCA ACGCAGCCAGGTTGTTCTCT  
Acta2 GGAGAAGCCCAGCCAGTCG CCAGAGCCATTGTCGCACAC  
Des GTGGAGCGTGACAACCTGAT TCGGAAGGCAGCCAAGTTGT  
Pecam1 
var1 
AGGATTCAGCTGAGGTGGGC TGGATGCTGTTGATGGTGAAGG  
 
 
